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 Introduction 
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Burden of renal disease  
There has been a notable increase in the incidence and prevalence of patients 
undergoing renal replacement therapy (RRT) in Western countries in recent 
years.1-5 RRT encompasses dialysis and renal transplantation. In Germany, 
more than 80,000 people currently receive RRT,6 while more than 15,000 
patients require RRT in the Netherlands, where the proportion of transplant 
patients is continuously increasing and represents almost 60% of all patients 
in this population.7 End stage renal disease (ESRD) can be defined by either 
the need for renal transplantation or long-term dialysis.8 It is associated with 
declined quality of life, as patients have to come in to see their doctor on a 
regular basis, up to three times a week for dialysis or for additional blood tests 
associated with either dialysis or renal transplantation. ESRD is a final 
outcome of a gradual decline of renal function due to various reasons, such as 
diabetes or hypertension. ESRD is not only a huge burden from the patients’ 
perspective, but also for healthcare systems, with a proportion of the national 
expenditures devoted to ESRD in European countries ranging from 0.7% in 
the UK to 1.8% in Belgium.9,10 From a health care perspective, the costs of 
ESRD treatment amount to €42,000 per patient per year in the 
Netherlands,9,11,12 and up to €45,000 in Germany,13 respectively.  
The prevention of ESRD is therefore not only important from patient and 
medical perspective, but also from an economic viewpoint. There are various 
reasons for renal insufficiency, among those diabetes, vascular nephropathy 
and different forms of inflammatory kidney diseases (nephritides).14,15 
Diabetes is considered the most common cause for ESRD in most Western 
countries, accounting for about 40% of all ESRD cases.6,16,17 In addition, the 
prevalence of especially type 2 diabetes and its secondary complications is 
expected to rise due to an aging population and a growing obesity rate.18-21 As 
a logical consequence, higher costs for diabetes treatment itself and 
especially for treatment of secondary complications (such as nephropathy, 
retinopathy or neuropathy) will challenge healthcare systems in the future.   
Looking at this patient population in terms of quality of life, a cross-sectional 
study showed that diabetes is associated with a decrease in quality of life. 
Here, adult diabetic patients (n=292) with a disease duration of at least one 
year and a mean age of 62 years (range 21 – 85) were interviewed using the 
time tradeoff (TTO) method.22 Arnesen et al.23 investigated quality of life in 
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ESRD patients, while Hoerger et al.24 did a survey on patients with advanced 
renal insufficiency using the time tradeoff (TTO) method in 65 patients, and 
they both demonstrated a significant loss of utility in these states of disease.  
Renal disease, i.e. nephropathy, leads to a gradual decline of the renal 
function and is initially characterized by the presence of protein in the urine, 
which is called micro- or macroalbuminuria, depending on the total amount. 
Creatinine is a lab marker representative for the renal function. A rise in the 
creatinine level indicates a decline of the renal function and can therefore 
provide evidence of advanced renal insufficiency. Angiotensin-converting 
enzyme (ACE) inhibitors, which are drugs initially approved for hypertension 
or heart failure treatment, slow down the progression of diabetic 
nephropathy independent of elevated blood pressure.25,26 Angiotensin II 
receptor blockers (ARBs) have similar effects on renal outcomes,25-27 but are 
more expensive. Both drug classes were also proven effective in delaying the 
onset of ESRD in non-diabetic nephropathy patients.28-30  
Health technology assessment (HTA) and economic 
evaluation 
Health technology assessment (HTA) provides a broad perspective on the 
evaluation of new or existing health technologies that in principle can cover 
every activity in healthcare that is patient orientated. HTA can be seen as a 
multi-disciplinary field of policy analysis that studies the medical, social, 
ethical, as well as the economic implications of the development, diffusion 
and use of health technology.31 From the assessment of individual patient 
interventions (such as a specific drug), to disease management and 
population based care programmes, the purpose of HTA is to provide 
decision makers with the information they need.  
With respect to HTA, technology assessment is not limited to new drugs, 
screening or diagnostic activities in healthcare, but it also includes evaluation 
of the organization of care and its infrastructure. For instance, HTA can be 
seen as a bridge between scientific evidence and policy decision-making.32 
HTA and cost-effectiveness analyses are becoming more and more important 
as healthcare costs are increasing in Western countries and resources are 
scarce. This means that healthcare must compete financially with other 
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sectors, such as education, housing and national defense. In addition, there 
are new and more expensive interventions, creating a tension between 
clinical treatment possibilities and scarce financial resources. As a result, the 
demand for evidence based on economic evaluation is increasing, e.g. for 
legislation regarding the reimbursement of pharmaceuticals and other 
interventions (e.g. NICE), and cost information is being demanded by research 
funding organizations. 
It would be impossible for a society to funnel the majority of its resources 
towards healthcare and to finance all treatment options that provide some 
benefit without experiencing significant and unacceptable sacrifices in other 
important social sectors. Societies have to set priorities when deciding what 
gets subsidized.  
 
One focus of HTA is on performing economic evaluation; it is only one part, 
but is a significant part, of HTA. Economic evaluation can be seen as the 
“comparative analysis of alternative courses of action in terms of both their 
costs and consequences”.33 The basic goals of an economic evaluation are to 
compare the costs with the consequences of the alternatives that are 
considered, in order to help decision makers to efficiently allocate scarce 
resources. According to Drummond et al.,33 there are basically four types of 
full economic evaluations: cost-minimization analysis, cost-effectiveness 
analysis, cost-utility analysis and cost-benefit analysis. A cost-minimization 
analysis (CMA) compares alternative strategies where all relevant outcomes 
are equal (i.e. equal patient quality of life). A cost-effectiveness analysis (CEA) 
compares alternatives and measures (in natural units) the primary objectives 
of an intervention (e.g. life-years saved). A cost-utility analysis (CUA) compares 
alternatives similar to a CEA, but uses a more generic outcome. Hence, a cost-
benefit analysis (CBA) compares alternatives by using monetary outcomes 
(e.g. euros).  
In a CEA, for example, the incremental effectiveness of an intervention is 
quantified and compared with its incremental costs (Figure 1.1).  
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Figure 1.1 Economic evaluation (CEA). 
 
 
The results of an economic evaluation are often presented in an aggregated 
way, using an incremental cost-effectiveness ratio (ICER). This ICER represents 
how much it will cost to improve one point on an outcome scale. The ICER is 
calculated as follows:  
 
ICER = (CA – CB) / (EA– EB), 
where CA is the total cost of group A, CB is the total cost of the comparator 
group, EA is the effect at follow-up for group A and EB is the effect at follow-up 
for the comparator group.  
Be aware that the numerator, the C, includes the resources saved by the 
intervention or the comparator. So C stands for costs minus savings in both 
groups. In a CEA, the main endpoint used in the denominator of the ICER can 
be any ordinal measure, i.e. any morbidity and mortality outcome. In a CUA, 
utilities or QALYs are used in the denominator.34 
Basically, there are two approaches to performing an economic evaluation 
study: a trial-based economic evaluation study, and a model-based economic 
evaluation study. A trial-based economic evaluation study is mostly piggy-
backed onto an ongoing trial, in which input (costs) and output (effects) are 
measured and valued. In a model-based economic evaluation, data from a 
wide range of sources (RCTs, observational studies, trial-based economic 
evaluations, etc.) are synthesized using an economic model. These two 
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methods of economic analysis are seen as complementary,32 and each has its 
own advantages and disadvantages.35-37  
A model-based approach can be interesting when accounting for scenarios 
where the natural history of a disease lasts for years, meaning it covers a 
period of time which is much longer than a clinical trial could cover in a real 
life setting. The progression of renal disease is a good example of a medical 
condition which might develop over decades. 
Hence, looking at cost-effectiveness of ACE inhibitors in renal disease, we 
opted for a model-based approach to account for the long timeframe and 
disease duration. Modelling studies often use Markov models. A Markov 
model is an iterative process where patients are assumed to stay in one cycle 
(i.e. a defined health state) for a certain amount of time and then make a 
transition to another cycle.38 Those models are useful when a decision 
problem involves risk that is continuous over time, when the timing of events 
is important and when important events may happen more than once. 
Different clinical strategies and time-points for starting ACE inhibitor therapy 
were compared, and the models were constructed with the best available 
evidence regarding input parameters such as preference weights, transition 
probabilities, costs, etc. The outcomes were measured by means of costs per 
quality adjusted life year (QALY).  
To calculate QALYs, preference weights, among other data, are needed. In 
health economics, the assessment of quality of life plays a major role, as 
outcomes are not only assessed in terms of enhanced survival (i.e. additional 
years to life), but also enhanced quality of life (QoL). In detail, health-related 
QoL analyses measure the impact of treatments on the physical, social and 
emotional aspects of life from the patients’ perspective. There are many 
techniques available to assess QoL, e.g. by using questionnaires such as the 
EQ-5D39 or the SF-36.40 
Besides the questionnaires mentioned above, there are other methods to 
assess the QoL, among those the time trade-off (TTO) method. The TTO is the 
most commonly used method to elicit quality-of-life weights for QALYs.41,42 
The TTO technique determines the proportion of remaining life years in poor 
health that patients are willing to give up or trade in exchange for perfect 
health. Based on patient responses, utility scores are calculated. The TTO 
method is essentially relevant to our analyses and is further investigated in 
this thesis, as there is still a debate if costs for consumption and leisure 
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activities should be included in the ICER. Those utility measures in economic 
evaluations are becoming more and more important given the fact that 
decision makers are asked to optimize the allocation of scarce healthcare 
resources across disease areas and patient groups.43 
Conducting an economic evaluation, whether it is a trial-based or a model-
based one, is not without precariousness. Hence, a large number of guidelines 
exist that set parameters regarding how to perform a good and valid 
economic evaluation.36,44-49 Nevertheless, even following a guideline does not 
prevent various types of bias, as guidelines show what to do but not exactly 
how to do it and in which way. Investigating how to minimize bias in trial- and 
model-based economic evaluation would be very worthwhile for both 
researchers and policymakers. 
Objectives of the thesis 
This thesis has two different aims: first to assess ACE inhibitors and ARBs in 
renal disease, i.e. nephropathy, in various patient populations and second to 
contribute to the clarification of methodological aspects in terms of bias and 
quality of life as measured using the TTO method.  
These aims can be further divided into three objectives:  
1. To assess whether costs for consumption and leisure activities need to be 
considered in the incremental cost-effectiveness ratio (ICER) in cost-
effectiveness analyses. (Part Ia – methodological aspects) 
2. To review evidence on bias types in trial-based as well as model-based 
economic evaluations (Part Ib – methodological aspects)  
3. To assess the cost-effectiveness of ACE inhibitors and angiotensin II 
receptor blockers in diabetic as well as non-diabetic renal disease in 
different countries  (Part II – economic evaluation studies) 
Outline of the thesis  
Figure 1.2 gives an overview of the outline. The first part, which is covered in 
Chapters 2 to 4, focuses on methodological aspects. Chapter 2 deals with the 
consideration of the costs of consumption and leisure time activities when 
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using the quality-adjusted life year as a measure of health outcome from a 
societal perspective in cost-effectiveness analysis. The purpose of this study 
was to investigate whether the effects of ill health on consumptive activities 
are spontaneously considered in a health state valuation exercise and how 
much this matters. Our survey included patients with inflammatory bowel 
disease in Germany (n=104). Patients were randomly provided or not 
provided with explicit instructions regarding the consideration of 
consumption and leisure effects in a time trade-off (TTO) exercise. The 
decision against performing a study on diabetic patients, or even patients 
with renal insufficiency, was made because a population of young patients 
with relatively high disease burden was needed to answer our research 
question. This neither accounts for the diabetic nor for the renal disease 
population covered in the economic evaluation studies (Chapters 5 to 7). The 
main focus of Chapter 2 is not on the disease itself, but on how patients 
consider loss of consumption and leisure activities due to a chronic disease 
when being confronted with a TTO exercise, which is the method of assessing 
quality of life applied in the economic evaluation studies. 
Chapter 3 focuses on bias forms in trial-based economic evaluations. This 
chapter gives an overview of the risks of bias in trial-based economic 
evaluations. Key sources for bias are identified and strategies are shown for 
how key sources for bias can be revealed and overcome (i.e. what bias-
reducing strategies might be employed) in future trial-based economic 
evaluations. The biases identified in Chapter 3 do also account for model-
based studies. Hence, Chapter 4 focuses on specific bias forms in model-based 
economic evaluation. It is obvious that in model-based economic evaluation 
some other types of bias may occur apart from the bias types presented and 
discussed in Chapter 3. We aim to report on specific bias forms related to 
model-based economic evaluation, to illustrate potential problems and to 
show how those biases might influence the results of economic evaluations. 
These model-specific biases are related to structural assumptions, the model 
type, time horizon or data selection, etc. Finally, a checklist on bias in 
economic evaluation (ECOBIAS checklist) is presented, merging results from 
Chapters 3 and 4.  
The next three chapters, Chapters 5 to 7, cover modelling studies on the cost-
effectiveness of ACE inhibitors in renal disease. Chapter 5 assesses the cost-
effectiveness of ACE inhibitors and angiotensin II receptor blockers in newly 
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diagnosed type 2 diabetes patients in Germany. A sample of newly diagnosed 
type 2 diabetic patients was chosen and a Markov model was constructed, 
simulating the progression through all stages of albuminuria, up to ESRD and 
finally death. Here, a calculation of ESRD costs for the German setting was also 
performed. Chapter 6 focuses on the Dutch setting and the prevention of 
diabetic nephropathy. In the Netherlands, not only costs but also quality of 
life parameters differ from the German setting. Furthermore, treatment 
regiments are quite different. For example, a higher percentage of patients 
with ESRD receive a renal transplantation, while in Germany a higher 
percentage receives dialysis. Chapter 7 deals with the cost-effectiveness of 
ACE inhibitors in non-diabetic advanced renal disease in the Netherlands. 
Although diabetes is the most common cause for ESRD in the Western world, 
there a many other possible causes as mentioned above. There is a debate on 
whether patients, especially those with advanced renal disease, should be 
treated with ACE inhibitors, as this is not without the risk of side effects. 
Hence, these patients are likely to be underexplored, at least in terms of cost-
effectiveness studies. So, we built a lifetime-model, which was used by 
patients with non-diabetic advanced renal disease that followed to ESRD and 
finally death; one group was treated with ACE inhibitors and the other group 
was not.  
All models are based on a Markov model, and various sensitivity analyses, 
univariate as well as multivariate, were performed. Finally, Chapter 8 discusses 
the research findings presented in the previous chapters with respect to their 
implications for practice, future research and policy-making.  
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Figure 1.2 Outline of the thesis 
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Abstract 
Objective 
There has been a debate on whether cost-effectiveness analysis should consider the cost of 
consumption and leisure time activities when using the quality-adjusted life year as a measure 
of health outcome under a societal perspective. The purpose of this study was to investigate 
whether the effects of ill health on consumptive activities are spontaneously considered in a 
health state valuation exercise and how much this matters. 
 
Methods 
The survey enrolled patients with inflammatory bowel disease in Germany (n=104). Patients 
were randomized to explicit and no explicit instruction for the consideration of consumption 
and leisure effects in a time trade-off (TTO) exercise. 
 
Results 
Explicit instruction to consider non-health-related utility in TTO exercises did not influence TTO 
scores. However, spontaneous consideration of non-health-related utility in patients without 
explicit instruction (60% of respondents) led to significantly lower TTO scores. 
 
Conclusions  
Results suggest an inclusion of consumption costs in the numerator of the cost-effectiveness 
ratio, at least for those respondents who spontaneously consider non-health-related utility 
from treatment. Results also suggest that exercises eliciting health valuations from the general 
public may include a description of the impact of disease on consumptive activities. Given the 
importance of this question for the conduct of cost-effectiveness analysis in health care, 
confirmation in additional studies that are conducted outside Germany and consider other 
health-state valuation techniques and diseases is recommended. 
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Introduction 
There has been a debate on whether cost-effectiveness analysis should 
include health-related costs in added life years that are unrelated to the 
disease or intervention in question. Several authors have argued in favor of 
this inclusion.1-5 A perhaps even more controversial debate has been around 
the question whether cost-effectiveness analysis should consider the cost of 
consumption and leisure time activities when using the quality-adjusted life 
year (QALY) as a measure of health outcome under a societal perspective. For 
example, Meltzer1 argues that consumption costs and earnings during added 
years of life should be included in cost–utility analyses. Yet, Nyman2 suggests 
otherwise based on the argument that none of the existing direct or indirect 
utility measures explicitly recognizes variations in consumption or foregone 
leisure. The underlying principle is that costs should be excluded from cost–
utility analyses if they represent resources that produce utility that is not 
being measured in the denominator of the cost–utility ratio. 
For life-extending treatments, however, handling of the cost of consumption 
and leisure time activities seems less controversial. As satisfying primary 
needs such as food, shelter, and clothing contributes to the additional survival 
time and the associated utility, the costs associated with these resources 
should also be included in cost–utility analyses, according to Nyman’s 
principle.3,6 For a similar notion see Liu et al. (2012, p. 494).7 
For quality-of-life enhancing interventions some empirical studies have been 
conducted on how much the effects of ill health on leisure time matter in 
health state valuations. In the following we describe some of the most recent 
empirical evidence on leisure time effects. Krol et al. conducted a survey on 
222 people of the general public to assess the incorporation of leisure in time 
trade-off (TTO) exercises.8 They found that 88% of the respondents 
spontaneously included the effects of ill health on leisure time. They also 
showed that respondents including leisure time gave significantly lower TTO 
values to one out of 3 health states. The authors conclude that it may be 
necessary to explicitly instruct respondents to include the effects of ill health 
on leisure time. Additional research on the effects of ill health on leisure time 
was conducted using a visual analogue scale (VAS) among non-patients.9-11 
To the best of our knowledge, for the effects of ill health on consumptive 
activities no such empirical evidence has been gathered so far. Therefore, the 
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purpose of our study was to conduct an empirical survey on whether the 
effects of ill health on consumptive activities are spontaneously considered in 
a health state valuation exercise and how much this matters. To this end, 
participants were randomized to explicit and no explicit instruction for the 
consideration of consumption and leisure effects. The investigation thus 
aimed at providing insight into the question whether cost-effectiveness 
analysis should consider the cost of consumption and leisure time activities in 
the numerator of the cost-effectiveness ratio. 
As a health-state valuation technique we used the TTO questionnaire. The 
TTO is the most commonly used method to elicit quality-of-life weights for 
QALYs. Also, it is the most commonly used technique in EQ-5D valuation 
studies.12  
In contrast to the above-mentioned studies, we recruited actual patients and 
not representatives of the general population because only patients have the 
necessary experience to judge how disease affects consumption and leisure 
time activities. We note that arguments have been brought forward to justify 
the valuation of health states by community members, for example, the 
popular argument that community members should have a say in resource 
allocation.13 The question of whose preference assessment should count 
when calculating QALYs for the purpose of economic evaluations is intensely 
debated in the health economics literature.13-17 Yet, regardless of one’s 
position in this debate, our study is also relevant for the elicitation of 
population preferences. That is, if patients considered non-health-related 
disutility from disease to be a significant factor in the valuation of health 
states, then exercises eliciting health valuations from the general public may 
also include a description of the impact of disease on consumptive activities. 
We enrolled patients with inflammatory bowel disease (IBDs) because they 
are relatively young and therefore perhaps more aware of forgone 
consumption and leisure opportunities in life. 
IBDs are chronic diseases of the gastrointestinal tract. IBD is a generic term for 
Crohn’s Disease (CD) and Ulcerative Colitis (UC). It is most prevalent in 
Europe.18 IBDs are characterized by episodes of remission and relapses,19,20 
mostly associated with intestinal symptoms, which include bloody stools, 
abdominal pain and diarrhea, as well as extra-intestinal symptoms, ie, weight 
loss, fatigue, and joint-pain. These factors all lead to a decrease of patient’s 
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well-being and ability to work and also affect a patient’s leisure-time and 
consumption activities.21-23 
Methods 
The survey was conducted between March 2012 and February 2013. Patients 
were recruited at two German university hospital outpatient clinics 
specialized in IBD treatment, where patients come in either on a regular basis 
for routine follow-up visits or show up in case or worsening of the disease, i.e., 
a flare or any sort of complication. Thus, patients could be identified in 
advance to assure that they do meet the inclusion criteria. No patient refused 
to participate in the study. 
Patients were eligible if they were between 18 und 45 years of age and had a 
memorable disease flare within the last two years of at least moderate activity, 
measured either by the Crohn’s Disease Activity Index (CDAI) (>220) or the 
Mayo Score for UC patients (>6). After signing the informed consent patients 
were randomized into two groups (A and B). Randomization was computer-
generated, with allocation concealment by opaque sequentially numbered 
sealed envelopes.  
Patients in both groups were individually instructed to fill out a questionnaire 
while a physician or nurse was available for questions. In both questionnaires 
respondents were first asked some background questions about age, gender, 
profession, family status, disease duration, time from last flare, Beck 
Depression Inventory (BDI) score (an instrument for measuring the severity of 
depression), and disease activity indices. 
Patients in group A were then confronted with the TTO question first. 
Respondents were asked how many years (out of 10) in the given health state 
with possible flares and complications they would be willing to give up in 
order to be in full health. Patients were informed to trade off months or weeks 
as well. Afterwards, patients were asked if consequences of complete healing 
on their life circumstances had been considered. If yes, patients were 
instructed to write down their thoughts.  
Patients in group B were asked upfront what they would do differently 
regarding leisure-time and consumption activities as well as family and job in 
case they would become healthy. The TTO question as described above was 
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asked afterwards with the instruction to explicitly consider changes 
concerning leisure-time and consumption activities as well as family and job.  
In order to adjust TTO scores for imbalances in participant characteristics, we 
performed a multiple regression analysis using Stata 12 (StataCorp LP, College 
Station, TX, USA). Independent variables were the version of the 
questionnaire, age, gender, profession, family status, disease duration, time 
from last flare, BDI score, and disease activity indices. Gender, profession and 
family status were coded as categorical variables. To avoid overfitting we used 
a simple dichotomy for profession and family status. We considered p<0.05 to 
be statistically significant. Details of the statistical approach are shown in the 
appendix. 
Results 
A total of 104 patients participated in the study. See Table 2.1 for 
characteristics of study participants. Except for one data item concerning age 
and three data items concerning consequences of complete healing on life 
circumstances, questionnaires were filled out completely. 
Figure 2.1 estimates the probability density functions of TTO scores by the 
Kernel method. It shows that both groups have a similar distribution of TTO 
scores. The two-sample Kolmogorov-Smirnov test for equality of distribution 
functions showed no difference (p=1.000). The null hypothesis of meeting the 
Tobit model assumptions was not rejected. Table 2.2 and 2.3 show the results 
of the Tobit and the marginal Tobit model using TTO score as a dependent 
variable. Explicit instruction to consider consumption and leisure effects did 
not have a significant impact on the TTO score, as shown by the first rows of 
Tables 2.2 and 2.3. Table 2.4 shows corrected Tobit model coefficients using 
the formula suggested by Pullenayegum et al.24 However, among patients 
who were not explicitly instructed to consider consumption and leisure 
effects (group A) consideration of consumption and leisure effects (60% of 
respondents in group A) significantly reduced the TTO score in both the Tobit 
and the marginal Tobit model (p=0.037 and p=0.033, respectively). The 
corrected Tobit model coefficient for consideration of consumption and 
leisure effects using the formula suggested by Pullenayegum et al. was 0.26, 
meaning that consideration of consumption and leisure effects reduced the 
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TTO score by 0.26 (the unadjusted difference was 0.14).24 According to the 
qualitative statements by respondents, this disutility was not driven by 
changes in expected earnings. 
Furthermore, in all models BDI score and age had a significant impact on the 
TTO score. That is, a higher depression score and lower age were associated 
with a lower TTO score. 
 
Table 2.1 Characteristics of study participants (n=104). 
 Group A 
(no explicit 
instruction) 
Group B 
(explicit instruction)
P value for 
difference of 
means 
Total number 50 54  
Male (%) 50 52 0.840 
Mean age 27 29 0.191 
Family status (%)   
   single 70 70 
   married 24 24 
   divorced   4   4 
   separated   2   2 
1.000 
Profession (%)   
   employed 74 74 
   not job seeking   7 10 
   unemployed   4   6 
   student  9 10 
   retired   6   0 
0.705 
BDI score      9.5 13  0.029 
Mean duration of disease (month) 35 36 0.854 
Mean time from last flare (weeks) 50 54 0.825 
p values marked in bold are significant at a 0.05 level. BDI = Beck Depression Inventory 
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Figure 2.1 Probability density functions of time trade-off (TTO) scores estimated by the Kernel 
method. Comparison groups were explicit and no explicit instruction to consider 
changes in leisure-time and consumption activities. 
 
Table 2.2 Results of the Tobit model analyzing the relationship between time trade-off score 
and individual variables. 
 
Coefficient Standard 
error 
t p>t 95% CI 
(lower 
bound) 
95% CI 
(upper 
bound) 
Version*   0.036 0.082   0.43 0.665 -0.128   0.200 
CDAI score (current) -0.001 0.001 -1.29 0.199 -0.002   0.000 
CDAI score (last flare) -0.001 0.001 -0.63 0.532 -0.002   0.001 
Mayo Score (current) -0.023 0.027 -0.85 0.395 -0.078   0.031 
Mayo Score (last flare) -0.011 0.024 -0.44 0.658 -0.058   0.037 
BDI score -0.017 0.004 -3.81 0.000 -0.025 -0.008 
Age   0.016 0.007   2.17 0.033   0.001   0.031 
Gender   0.048 0.078   0.62 0.539 -0.107   0.204 
Family status   0.080 0.097   0.83 0.409 -0.112   0.272 
Profession -0.103 0.100 -1.03 0.305 -0.302   0.096 
Duration of disease -0.004 0.008 -0.51 0.611 -0.020   0.012 
Time from last flare   0.001 0.001   0.89 0.375 -0.001   0.003 
Constant   0.604 0.328 1.84 0.068 -0.046   1.255 
P values marked in bold are significant at a 0.05 level. *Dummy variable where 1 = no explicit 
instruction for the consideration of consumption and leisure effects; 0 if otherwise; 
CI = confidence interval; CDAI = Crohn’s Disease Activity Index; BDI = Beck Depression Inventory. 
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Table 2.3 Results of the marginal effects Tobit model analyzing the relationship between 
time trade-off score and individual variables 
 
Coefficient Standard 
error 
z p>z 95% CI 
(lower 
bound) 
95% CI 
(upper 
bound) 
Version* 0.032 0.074 0.430 0.666 -0.112 0.176 
CDAI score (current) -0.001 0.001 -1.290 0.197 -0.002 0.000 
CDAI score (last flare) 0.000 0.001 -0.630 0.531 -0.002 0.001 
Mayo Score (current) -0.021 0.024 -0.850 0.394 -0.069 0.027 
Mayo Score (last flare) -0.009 0.021 -0.440 0.658 -0.051 0.032 
BDI score -0.015 0.004 -3.700 0.000 -0.023 -0.007 
Age 0.014 0.007 2.210 0.027 0.002 0.027 
Gender 0.043 0.069 0.620 0.536 -0.093 0.178 
Family status 0.070 0.083 0.850 0.398 -0.093 0.234 
Profession -0.093 0.091 -1.020 0.307 -0.270 0.085 
Duration of disease -0.004 0.007 -0.510 0.607 -0.017 0.010 
Time from last flare 0.001 0.001 0.910 0.365 -0.001 0.002 
P values marked in bold are significant at a 0.05 level. *Dummy variable where 1 = no explicit 
instruction for the consideration of consumption and leisure effects; 0 if otherwise; 
CI = confidence interval; BDI = Beck Depression Inventory; CDAI = Crohn’s Disease Activity Index. 
 
 
Table 2.4 Corrected Tobit model coefficients. 
 Coefficient 
Version*   0.030 
CDAI score (current) -0.001 
CDAI score (last flare)   0.000 
Mayo Score (current) -0.020 
Mayo Score (last flare) -0.009 
BDI score -0.014 
Age   0.014 
Gender   0.040 
Family status   0.066 
Profession -0.090 
Duration of disease -0.003 
Time from last flare   0.001 
* Dummy variable where 1 = no explicit instruction for the consideration of consumption and 
leisure effects; 0 if otherwise; BDI = Beck Depression Inventory; CDAI = Crohn’s Disease Activity 
Index. 
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Discussion 
Explicit instruction to consider non-health-related utility in TTO exercises did 
not influence TTO scores. However, spontaneous consideration of non-health-
related utility in the group without explicit instruction (60% of respondents of 
this group) led to significantly lower TTO scores. Hence, the first finding could 
be explained by spontaneous consideration of non-health-related utility even 
without explicit instruction (thus offsetting the effect of explicit instruction). 
Spontaneous consideration of non-health-related utility thus leads to a utility 
gain from treatment compared to no spontaneous consideration. This is 
consistent with the notion that health gains can increase the marginal utility 
of consumption. In turn, this would justify an inclusion of consumption costs 
in the numerator of the ICER not only for life extending but also for quality-of-
life enhancing interventions, at least for those respondents who 
spontaneously consider non-health-related utility from treatment. Results also 
suggest that exercises eliciting health valuations from the general public for 
the purpose of conducting economic evaluations from a societal perspective 
may include a description of the impact of disease on consumptive and 
leisure activities. 
An alternative approach not considered in this paper would be to instruct 
patients to exclude non-health-related utility. However, this approach was 
indirectly considered as it is equivalent to the situation of no explicit 
instruction and no spontaneous consideration of non-health-related utility. 
One strength of our study is that we randomized patients to the two groups, 
thus controlling for omitted variable bias. Still, we would like to point out 
several limitations. First, results are based on a single chronic disease group. 
Therefore, it is not known whether results are transferable to other diseases. 
On the other hand, mixing patients with different diseases in one study would 
have introduced other problems, e.g., the question whether results from such 
a study would hold for every disease. Second, our sample purposely included 
relatively young patients and while we adjusted for age in our analysis, 
another sample with more elderly patients may provide a different result. 
Third, our sample size may have lacked the power to detect additional 
significant associations. Finally, results may not be transferable from country 
to country. 
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Given the importance of this question for the conduct of cost-effectiveness 
analysis in health care, confirmation in additional studies that are conducted 
outside Germany and consider other health-state valuation techniques and 
diseases is recommended. Future research may also include elderly patients. 
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Appendix – Statistical Approach 
Many measures of preferences have the property that a proportion of the 
population achieves the upper bound of 1.24 Therefore, the utility distribution 
will be non-normal and linearity of utility–covariate associations will be 
questionable.24 The Tobit model provides a consistent and efficient alternative 
for estimating such data with a bounded nature.25 Yet, the Tobit model is 
sensitive to the assumptions of normality and homoscedasticity of residuals. 
Both heteroscedasticity and non-normality therefore cause inconsistency in 
the Tobit estimator. 
The Tobit model assumes that there is a latent (i.e., unobservable) variable 
that can extend below zero and above 1 (i.e., there is no bounding at zero and 
1) but has been observed subject to censoring at zero and 1.24 Because of the 
latent variable extending below zero, the simple Tobit model does not allow 
interpreting the effect of independent variables on the dependent variable. 
The marginal effects Tobit model is required to estimate the coefficients and 
is conditional upon the latent variable being at or above zero. To this end, the 
constant is dropped.26 
When preference weights are assumed to be bounded at 1, meaning that 
preference weights cannot exceed 1, a formula to calculate corrected 
coefficients for the Tobit model has been recently published.24 We note that 
there is a debate about whether preference weights are, in fact, bounded at 
1.24,27 It has been argued that the definition of full health (ie, a preference 
weight of 1) depends on the type of preference-based questionnaire used and 
therefore leaves the possibility of scores above 1 open.27 
In order to check for bias in the Tobit estimator we tested the hypothesis of 
homoscedasticity and normality of residuals. To this end, we performed the 
conditional moment (CM) test.28,29 
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Abstract 
Objective 
The objectives of this article are first to give an overview of the risks of bias in trial-
based economic evaluations and, second, to identify how key sources for bias can be 
revealed and overcome (i.e. what bias-reducing strategies might be employed) in 
future trial-based economic evaluations in the field of health psychology. 
 
Design 
Narrative review discussing sources of bias in trial-based economic evaluations and 
bias-reducing strategies. 
 
Results 
We identified 11 biases and assigned them to a particular trial phase. A distinction is 
made between pre-trial biases, biases during the trial and biases that are relevant 
after the actual trial. All potential forms of bias are discussed in detail and strategies 
are shown to detect and overcome these biases. 
 
Conclusion 
In order to avoid bias in trial-based economic evaluations, one has to be aware of all 
the possible forms of bias. All stakeholders have to examine trial-based economic 
evaluations in a rigorous and stringent manner. This article can be helpful in this 
examination as it gives an overview of the possible biases which researchers should 
take into account. 
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Introduction 
In the current economic climate, it is of crucial importance to prove that 
innovative health behaviour change interventions are not only effective, but 
also cost-effective. Economic evaluation studies compare the costs and 
outcomes of an innovative health behaviour change intervention with a 
control intervention, mostly care as usual.  
Basically, there are two approaches to performing an economic evaluation 
study: a trial-based economic evaluation study, and a model-based economic 
evaluation study. A trial-based economic evaluation study is mostly piggy-
backed onto a behavioural/educational trial. In general this means that a 
resource-use measure (most often a cost questionnaire; for a repository see 
www.DIRUM.org) and a quality of life instrument (most often the EuroQol 
questionnaire1 or the Short-Form 2 are included in the prospective 
behavioural/educational trial design, in order to calculate the cost-
effectiveness of the health behaviour change intervention. In a model-based 
economic evaluation, data from a wide range of sources (behavioural/ 
educational trials, observational studies, trial-based economic evaluations, 
etc.) are synthesized using an economic model. These two methods of 
economic analysis are seen as complementary3 and each has its own 
advantages and disadvantages.4-6 
As this special issue for Psychology & Health focuses on the risk of bias in 
randomized controlled trials (RCTs) of health behaviour change 
interventions,7 this article will focus on trial-based economic evaluations. A 
major strength of trial-based economic evaluations is that the data are 
collected alongside an already existing behavioural/educational trial, making 
it feasible to do an economic evaluation without investing a lot of additional 
research funding. Furthermore, both costs and outcomes are collected in the 
same population, making a head-to-head comparison more viable. The 
discipline of trial-based economic evaluation has a strong tradition in 
epidemiology, where the RCT is regarded as the gold standard.8 Although 
evidence from RCTs is very powerful, it is often said that the RCT design has 
limitations when it comes to the generalisability of economic evaluations, 9,10 
especially when looking at behavioural/educational interventions. In these 
public health interventions, costs and benefits are very broad,10 and the 
context and setting are of critical importance, due to variation and 
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uncertainty in diagnosis and treatment.9 As a result, relying solely on evidence 
from RCTs can mean that de facto cost-efficacy rather than cost-effectiveness 
studies are produced, see Evers 2007.9 In addition to trial-based and model-
based economic evaluations, qualitative methods of evaluation may help to 
address some of these limitations. 
In addition to the choices which researchers have to make when designing a 
behavioural/educational trial, a number of choices have to be made by the 
economic evaluators: i.e. the perspective of the study, the comparator, the 
costs included, the outcomes measured, the valuation methods used, and the 
threshold used. There is evidence, that based on the choices of the economic 
evaluator, certain biases are induced which might influence the cost-
effectiveness of the health behaviour change intervention.  
A bias or a systematic error occurs when there is a difference between the true 
value (in the population) and the observed value (in the study) from any cause 
other than sampling variability.11 In other words, a bias is an effect which 
deprives a statistical result of representativeness by systematically distorting 
it, as distinct from a random error which may distort on any one occasion but 
balances out on the average.12 A bias can be unintentional or intentional and 
can have either substantial or little impact.  
In our personal experience, we have often noticed that, although evaluators 
are often aware of the current methods of trial-based economic evaluations, 
awareness of biases induced by these methods is, in our opinion, limited. To 
date, no study has given an explicit overview of additional biases identified in 
trial-based economic evaluations and the way these biases can be reduced. 
However, several studies have highlighted the importance of rigid 
methodology in trial-based economic evaluations, by highlighting 
methodological challenges,3 assessing methodological quality,13-16 or by 
developing guidelines for economic evaluation, see Pharmacoeconomic 
Guidelines Around The World at ispor.org/peguidelines or Ramsey et al..5 As far 
as we know, the study of Eble17 is the only study explicitly looking at the risk of 
bias in trial-based economic evaluations. However, Ebles’ study is limited to 
bias that the medical literature already has identified, and doesn’t focus on 
the additional bias induced by performing an economic evaluation within a 
trial. 
The objectives of this article are first to give an overview of the risks of bias in 
trial-based economic evaluation and, second, to identify how the key sources 
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for bias can be revealed and overcome (i.e., what bias-reducing strategies 
might be employed) in future trial-based economic evaluation in the field of 
health psychology. The article does not provide novel methodological 
approaches in the field of trial-based economic evaluations, but highlights 
sources of potential biases, as well as some bias-reducing strategies.  
As not all readers of Psychology & Health might have knowledge of economic 
evaluations, this article will start with a small paragraph on how health 
behaviour change interventions can become cost-effective. 
How does a health behaviour change intervention become cost-
effective?  
Whether an intervention ultimately becomes cost-effective depends on a 
number of choices made by the economic evaluator. In a trial-based 
economic evaluation, a behavioural or educational intervention is compared 
with one or more interventions, mostly care as usual. During the follow-up 
period, called ‘time horizon’ in economic evaluation, the costs are measured 
continuously. This means that all the relevant cost items of the 
behavioural/educational intervention as well as of the comparator are 
assessed during the total follow-up period of the trial.  
At the end of the trial the difference in costs between the 
behavioural/educational intervention and the comparator are related to the 
differences in effects. The results of an economic evaluation are often 
presented in an aggregated way, i.e. an incremental cost-effectiveness ratio 
(ICER). This ICER represents how much it will cost to improve one point on an 
outcome scale (for instance, a psychological measure or quality-adjusted life 
years (QALYs). The ICER is calculated as follows: ICER = (Ci – Cc) / (Ei – Ec), where 
Ci is the annual total cost of the behavioural/educational intervention group, 
Cc is the annual total cost of the comparator group, Ei is the effect at follow-up 
for the behavioural/educational intervention group and Ec is the effect at 
follow-up for the comparator group.  
Be aware that the numerator, the C, includes the resources saved by the 
behavioural/educational intervention or the comparator. So C stands for costs 
minus savings in both groups. In a cost-effectiveness analysis (CEA) the main 
endpoint used in the denominator of the ICER can be any ordinal 
(psychological) measure, i.e. any morbidity and mortality outcome; 
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psychological outcome; physical, social, and mental functioning; nutritional 
status, etc. In most cases, the primary outcome of behavioural/educational 
trial is chosen to be the denominator of the ICER of the cost-effectiveness 
analysis. In a cost-utility analysis (CUA), utilities or quality-adjusted life years 
(QALYs) are used in the denominator. A utility is a preference or a value 
attached to health in which 0 represents death and 1 represents full health. 
Utilities can be derived using questionnaires such as the EQ-5D,1 or the SF-12 
or SF-36.2 To exemplify, the EuroQol is a self-administered questionnaire, 
containing 5 dimensions of health-related quality of life, i.e. mobility, self-care, 
daily activities, pain/discomfort and depression/anxiety. Each dimension can 
be rated at three levels (or five levels): ranging from no problems to major 
problems. The 5 dimensions can be summed into a health state. Utility values 
can be calculated for these health states, using preferences elicited from a 
general population, the so-called valuation sets; these are available for the 
EuroQol18 and Short-Form.19 The QALY is based on the number of years of life 
that would be added by the behavioural/education intervention corrected for 
their utilities.  
The height of ICER is thus defined by the difference in costs and the 
differences in effects between the behavioural/educational intervention and 
the comparator. If the ICER, the costs per QALY, is below a certain threshold, 
the health behaviour change intervention is regarded as cost-effective. Each 
jurisdiction has its own threshold, which varies between €12,000 and €80,000 
per QALY20,21 depending upon the disease burden. 
A behavioural/educational intervention is thus not cost-effective if: 1) the 
costs of the behavioural/educational intervention are too high in relation to 
the comparator, 2) the effects of the behavioural/educational intervention are 
too low in relation to the comparator, or 3) the ICER is unfavourable in relation 
to the threshold of the jurisdiction.  
Academic disagreement between economic evaluators, as well as creative 
ways of influencing ICER, may lead to methodological uncertainty. 
Consequently, several countries have developed guidelines on how to 
perform an economic evaluation study, especially for pharmaceuticals.5,22 In 
addition, as mentioned before, a number of choices have to be made at every 
stage of the process of an economic evaluation, and these might lead to 
uncertainty. As a consequence each trial-based economic evaluation study 
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should include a sensitivity analysis to address any items about which the 
evaluator is uncertain.23 
Design 
This article,which looks at common biases in economic evaluation, is based on 
a scoping review complemented with experiences of the authors. For the 
scoping review, a literature search was performed in July 2013 using PubMed 
(search terms (Costs and Cost Analysis [MeSH Terms] cost-effective and cost-
effectiveness, based on and bias)24,25 and the NHS Economic Evaluation 
Database (search term bias in “any field” in NHS EED, retrievable via 
www.crd.york.ac.uk). The NHS EED focuses primarily on the economic 
evaluation of health care interventions, for which each week extensive 
literature searches are undertaken to identify relevant economic evaluations. 
It is known that combining PubMed and NHS EED is an optimal search 
strategy for economic evaluations.24,25 Furthermore, additional information 
was found by citation tracking and own knowledge. For inclusion, the paper 
had to deal explicitly with any kind of bias (in the aim or research question), 
which could occur when performing a trial-based economic evaluation. The 
selection process was performed by the first author. 
Biases can occur in several phases within the trial (a classification scheme for 
this was developed by Pannucci26: i.e. I, in the pre-trial phase, during the 
planning of the trial and study design; II, during the trial itself, in the data 
collection and analysis, and III, after the trial, in the publication phase of the 
economic evaluation study. As shown in Table 3.1, the results of this scoping 
review are placed in this classification overview. 
Results 
The search strategy resulted in 2,370 hits in PubMed and 1,860 hits in NHS 
EED. However, only 12 articles were relevant. The most common reason for 
exclusion was that bias was mentioned as part of a cost-effectiveness model, 
rather than bias being the subject under investigation. 
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Table 3.1 Tips for avoiding different types of bias in trial-based economic evaluation. 
Type of bias (i) Influence of the bias (ii) Recommendation/ 
Bias reducing strategies (iii) 
I Pre-trial bias   
Narrow perspective 
bias 
Omission of relevant costs and 
outcomes 
State perspective explicitly; societal is 
preferred, justification of narrower 
perspective  
Inefficient 
comparator bias 
Overestimation of costs and 
outcomes 
3-armed trial, including best alternative as 
comparator, as well as care as usual, and 
describe all comparators sufficiently 
Cost measurement 
omission bias 
Overestimaton of the 
incremental costs 
Explicitly identify items relevant to 
disease and intervention studied 
Intermittent data 
collection bias 
Under- or overestimation of 
costs 
Continuous measurement of resource use 
II Bias during trial   
Invalid valuation 
bias 
Under- or overestimation of 
costs 
Use reference prices, or present price 
calculation in detailed manner 
Ordinal ICER bias 
 
Double-counting 
bias 
Uninformative ICER 
 
Under- or overestimation of 
costs and effects 
Use cardinal scales for the outcomes 
measurement in a CEA 
Consider explicitly if variables are not 
double counted; items included in the 
effect side should be included in the costs 
and vice versa 
Inappropriate 
discounting bias 
 
 
ICER varying from cost-
effective to not being cost-
effective 
If possible use rates from a guideline or 
from national statistics; furthermore 
various discount models/rates should be 
used, including 0% (sensitivity bias) 
Limited sensitivity 
analysis bias 
Level of certainty surrounding 
the ICER is wrongly regarded 
as low 
Make a list of the variables for which 
uncertainty is assumed. Test the 
uncertainty regarding these variables by 
means of a sensitivity analysis based on 
alternative assumption. Overall sensitivity 
analysis will include sampling uncertainty, 
methodological uncertainty (such as 
discount rate, study perspective), and 
subgroup analysis 
III Bias after trial   
Sponsor bias Favourable ICER of sponsored 
studies 
Sponsorship disclosure, stringent 
guidelines, study protocol, rigorous 
review  
Reporting and 
dissemination bias 
Tendency to underreport non-
significant findings in journals 
versus monographs 
Monographs publicly available and trial-
based economic evaluation listed in trial 
registers 
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As mentioned earlier, until now, no study has given an explicit overview of 
biases in trial-based economic evaluations. However, we have identified a 
number of publications, either tutorials (such as Ramsey et al., 2005)5 or 
articles which highlight one or more methodological issues in trial-based 
economic evaluation (such as Bell et al.27; M. Drummond & Sculpher, 20053; 
Matthews, Dumville, Hewitt, & Torgerson, 201128), which are included in this 
scoping review. In particular, the publication of Drummond et al.3 gives a 
good overview of the common methodological flaws in trial-based economic 
evaluations. Based on the search results, citation tracking, and extensive 
experience of the research group in conducting cost-effectiveness studies, an 
overview is made of the potential biases and how these biases can be 
detected and overcome (see also Figure 3.1). A total of 11 potential biases 
were identified (see Table 3.1) of which four were related to pre-trial, five to 
bias during trial and two to bias after the trial. Each of them is described 
separately below. For each bias, we first explained and defined the type of 
bias (under i), illustrated the influence of bias (ii), and described bias-reducing 
strategies (iii). An overview of these points (i, ii and iii) is given in Table 3.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1  
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Major Sources of Bias in Trial-based economic evaluation
 Narrow perspective bias
 Inefficient comparator bias
 Cost-measurement omission bias
 Intermittent data collection bias
 Invalid valuation bias
 Ordinal ICER bias
 Double-counting bias
 Inappropriate discounting bias
 Limited-sensitivity analysis bias
 Sponsor bias
 Reporting/dissemination bias
Pre-trial bias
Bias during trial
Bias after trial
Trial Progression
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I Pre-trial bias 
Narrow perspective bias 
In general, textbooks and guidelines state that economic evaluators have to 
be explicit about the perspective which is taken in the analysis.29 The 
perspective is the viewpoint from which the trial-based economic evaluation 
is performed and it will have particular influence on the range of costs 
included in the analysis. In general, a societal perspective is seen as optimal 
and superior,30 and is recommended by most (pharmacoeconomic) 
guidelines. In a societal perspective, all costs and outcomes are considered 
important, regardless of who pays the costs and will have the effects. The 
remaining minority of guidelines recommend performing economic 
evaluations from the perspective of the payer or of the healthcare sector;31 
this can be more suitable in certain limited cases.  
The narrow perspective bias can be defined (i) as using a restricted 
perspective, which will lead to omissions of important costs and outcomes, as 
these costs and outcomes are regarded as irrelevant from a narrower 
perspective. This will lead to the inefficient allocation of resources in the short 
term as well as over the long run (ii).  
The bias-reducing strategy in this case (iii) is quite straightforward. Economic 
evaluators should be explicit about the perspective, which is used for the trial-
based economic evaluation, and the societal perspective is preferred.30,31 In 
addition, within a broader societal perspective, it is possible to differentiate 
the perspective into narrower perspectives (such as the payer and the health 
care sector perspectives) in order to address specific policy issues.30 Other 
narrower perspectives will include only certain components. If economic 
evaluators use a more narrow perspective, the evaluators should provide 
justification as to why this narrower perspective is valid. A recent systematic 
review looking at economic evaluations of behaviour change interventions 
revealed that this is not common practice;32this review showed that the 
perspective of the analysis was explicitly stated by only 57% of the studies. 
Moreover, trial-based economic evaluations often state that a broader 
(societal) perspective is taken, while a review of the study reveals that in 
reality sometimes a more limited perspective has been used. 
Although using the societal perspective is advised, we would like to comment 
that it is not completely without drawbacks. An issue is that, when 
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considering healthcare planning, there is a strong debate on whether the 
societal perspective is the most informative in comparison with, for instance, 
the healthcare perspective. Often costs outside the healthcare sector, such as 
labour, educational and judicial costs, are not of interest to health care 
planners.  However, a societal perspective, which includes a disaggregated 
description of types of costs, could improve the use of economic evaluations 
in healthcare planning. However,  use of  the societal perspective in economic 
evaluation might lead to a greater likelihood of other biases, such as double 
counting (see double counting bias) and increased uncertainty (see limited 
sensitivity analysis bias).  
Inefficient comparator bias 
The selection of appropriate comparators for the intervention studied is 
critical for any trial-based economic evaluation.33 If, in the case of inefficient 
comparator bias (i), a less effective treatment option is used as a comparator, 
the possible gains for both costs and outcomes might be overestimated, 
leading to biased cost-effectiveness estimates. Therefore, the choice of 
comparator is critical when evaluating a behavioural or educational 
intervention for a trial-based economic evaluation. 
At first glance the choice of a comparator in a trial-based economic evaluation 
seems to be no different from the choice of comparator for any other analytic 
design. However, guidelines for economic evaluations often state that care-
as-usual should be used as the most relevant comparator (see 
www.ispor.org/peguidelines/index.asp). The motivation for using care-as-
usual as a comparator is that economic evaluations serve to inform 
policymakers about the consequences of implementing a (behavioural or 
educational) intervention into their healthcare system. For policymakers 
facing this decision, care as usual is the best comparator possible for revealing 
the opportunity costs and outcomes when implementing a new treatment in 
comparison with prevailing practice. The problem is that care as usual is often 
not defined.34,35 and this comparator can differ from country to country. 
Furthermore, care as usual is a very diverse and often collective term for all 
the different interventions with which control subjects are confronted during 
the trial. Therefore, the care as usual comparator is unlikely to be the ‘best’ 
alternative and thus not the most cost-effective alternative intervention 
currently available.  
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As care-as-usual is somewhat vague it is likely to provoke comparator issues  
(ii) in a trial-based economic evaluation. This is illustrated by the review of Hill 
et al,36 looking at submission for reimbursement of pharmaceuticals in 
Australia, which revealed that in 6% of the economic evaluation studies, 
uncertainty about the choice of the comparator or an inappropriate 
comparator is an issue.  
To avoid inefficient comparator bias (iii), a three-armed trial in which the 
behavioural or educational intervention is compared with care as usual and 
the best alternative might be an option. In any case, the behavioural or 
educational intervention, the comparator,(s), including usual care should be 
described in detail; i.e. the authors should tell who did what to whom, where, 
and how often.3 This will enable the reader to relate the information on costs 
and outcomes of behavioural or educational intervention to the comparators.  
Cost measurement omission bias  
Within a trial-based economic evaluation looking at behavioural and 
educational interventions, it is crucial to identify and measure all relevant 
resource use, looking at the disease and at the intervention studied. Even if 
the societal perspective is chosen, this does not necessarily mean that all 
important costs and outcomes are included. The adaptation of the societal 
perspective raises the biggest measurement challenges, and as a result it may 
be tempting to omit items for consideration.  
As mentioned by others,3 one way of biasing a trial-based economic 
evaluation would be the cost measurement omission bias (i), i.e. leaving out  
measurement items that might count against the behavioural or educational 
intervention. This might lead to overestimation of the cost differences 
between the intervention and the comparator (ii).  
In choosing items for a resource-use measure (RUM) - often a diary or 
questionnaire - it is important to focus on the dominant cost drivers, and on 
those cost drivers that will be different between the intervention and the 
comparator. Accordingly, items included in the RUM need to be sensitive to 
the needs of the group studied and sensitive to the intervention under 
consideration. The RUM should highlight benefits and savings which are 
ultimately valued in monetary terms. This implies that an RUM looking at, for 
instance, ‘free heroin under medical supervision to people heavily addicted to 
the drug’ might include other items (including criminal and judicial costs), 
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than an RUM looking at ‘self-management for people with stroke’ which 
might include items such as the costs of informal care. Within that process it is 
advised, for standardisation, to base the items of the RUM on earlier resource 
use measurement instruments rather than developing specific items over and 
over. The Database of Instruments for Resource Use Measurement (DIRUM) 
(www.dirum.org) can be very helpful in establishing shared resource use 
measures and methods.37 Using an available RUM has several advantages; first 
of all, it is less costly and it will lead to consistency across studies.38 But even 
the most appropriate existing questionnaire may not represent the best way 
to capture the key cost drivers for any given study. As a result, each existing 
instrument has to be adapted or extended with new items. The process of 
developing valid and reliable items for an RUM encompasses a lot of steps in 
planning, development, and piloting, and might well take a lot of time.38 Due 
to time constraints, existing RUMs are often used without any adaptation 
when looking at behavioural and educational interventions in trial-based 
economic evaluation; this might in the end bias the results of the study. 
Accordingly, a strategy for overcoming cost measurement omission bias (iii) is 
to identify explicitly those items which are relevant for the disease and 
intervention studied. In order to get a grip on the big items when looking at 
resource use, information can be gathered from cost-of-illness studies, 
qualitative interviews with stakeholders, earlier economic evaluations in the 
same field, or from existing RUMs. In addition, several authors39,40 have made 
taxonomies of possible costs and benefits inside and outside the healthcare 
sector; these might be informative when identifying relevant items for the 
resource use measurement. 
Intermittent data collection bias 
Once a valid RUM is constructed, it is important that there is insight into all 
resource use (costs) during the entire follow-up period of the trial-based 
economic evaluation. From a societal perspective, all relevant resource use, 
formal and informal, reimbursed and not-reimbursed, has to be included in an 
RUM. Accordingly, the RUM has to include healthcare sector costs, patient and 
family costs, and costs in other sectors.29 Because there are no institutional 
records tracking information on the type, frequency, and magnitude of 
resource use, data must be obtained through self-reporting RUMs, such as 
questionnaires and diaries. In comparison with questionnaires, diaries have 
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been reported to provide information prospectively over a period of time, 
resulting in minimum recall error.41 
Whatever methods are chosen, the resource use has to be known 
continuously, meaning that insight has to be gained into the utilization of 
resources every day during the study period,42 as not doing this will lead to a 
intermittent data collection bias (i). Earlier studies41,43 revealed that the 
intermittent collection of data – for at least 3 months during a 1 year period - 
might provide good estimates of annual costs. However, overall little is known 
about the patterns in which resource use occurs during the follow-up period 
of a trial, and as a result limited evidence is available about exactly when - 
which three months of the year - the resource use should be collected. For 
instance, intermittent data collection could be performed during the first, 
middle, and last months of a year, during periods with supposedly higher 
costs, or randomly.42 When data are collected intermittently, total annual 
costs have to be estimated based on the obtained data. Several imputation 
techniques are available for this. A study of Hendriks et al.42 compared several 
intermittent data collection patterns combined with several imputation 
techniques with data collected continuously from a trial-based economic 
evaluation. The study revealed that the amount of bias for random source 
measurement combined with individual mean imputation - in which the sum 
of the observations available is multiplied to obtain annual costs - leads to the 
smallest bias (0.4%), whereas other data collection patterns and imputation 
techniques could lead to a bias of up to 20% (ii). Overall the choice for 
intermittent data collection instead of continuous data collection is often 
based on practical considerations, such as relieving the burden on 
participants of the trial. As shown by the study of Hendriks,42 this choice might 
lead to an unintentional bias. Intentional bias might be induced if in a trial-
based economic evaluation, data collection patterns are chosen in such a way 
that they are in favour of one of the comparators.  
Although there is some evidence that intermittent data collection patterns 
with imputation might be valid,42 this evidence is based on only one trial on 
fall prevention for elderly people. As we have concerns regarding the 
generalisability of these results to other settings, we would like to advise (iii) 
measuring resource use data continuously in a trial-based economic 
evaluation in order to reduce the data collection bias. 
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II Bias during trial 
Invalid valuation bias  
In the valuation step, all the resource use (such as contacts with GPs, 
consultations with psychologists, and days in hospital), which is measured by 
the RUM, are translated into monetary values (Euros e.g.). For the valuation in 
economic evaluation studies, the resources used should be valued at their 
opportunity costs, i.e. the value of their best alternative use.44 As the 
healthcare market is not fully competitive, it is in general very difficult to use 
opportunity costs. To resemble these costs, cost prices are calculated 
optimally using a bottom-up approach, which is a very detailed method of 
costs calculation covering the full costs of the resources used. Overall tariffs or 
charges are not seen as a valid approximation of these costs.45 Tariffs can be 
used only if there is a clear indication that a tariff represents a reasonable 
approximation of the actual costs. As calculating the costs bottom-up is 
labour intensive alternative sources for cost prices, such as unit costs which 
are published annually, costs of individual facilities, or combined estimates of 
different reference setting, are used as well as tariffs.  
In the case of an invalid valuation bias (i), unit prices are not estimated 
correctly, leading to either an under- or overestimation of the costs (ii). The 
amount of a cost price of a certain resource use, for instance a consultation 
with a clinical psychologist, depends on a number of factors. Jacobs et al.46 
addressed issues of bias in cost valuation, and illustrated that the height of 
the cost price depends on the scale on which the clinical psychologist is 
working (scale bias), the case-mix (case-mix bias), the sites selected for the 
trial (site selection bias) and the methodology used (methods bias). 
Accordingly, calculating bottom-up cost prices can be biased and is very time 
consuming. Comparability between studies can be at stake due to differences 
in the methodologies used by the economic evaluator.  
A special issue of cost valuation, which might be inducing biases, is the fact 
that profit making organisations, like the pharmaceutical industry, have to set 
a price for their drugs. Knowing that if the ICER, the costs per QALY, is below a 
certain threshold, the drug is regarded as cost-effective, might lead to price 
inflating mechanisms. In this situation the final price of a drug is set at such a 
level that this price is the maximum price acceptable for the decision maker 
(so that the final ICER is below the threshold), and at a minimum price 
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acceptable to the company (the highest price possible for an ICER being 
below the threshold).  
To overcome the invalid valuation bias (iii), for every aspect of trial-based 
economic evaluation, country-specific data (cost prices and utility values) 
have to be used as much as possible, and cost prices should relate to one 
recent reference price year. Accordingly, to overcome systematic errors in the 
price valuation, a number of countries, including among others Australia, 
Canada and the Netherlands, have established guidelines with recommended 
unit costs. A reference price is an average unit cost estimated on the basis of 
large, diverse populations; the average unit cost estimate can be used directly 
to value resource utilization.47 Reference prices reduce the likelihood that 
biases will occur and increase the comparability of economic evaluations 
within one country. Furthermore, if the cost price of a particular resource use, 
such as the intervention studied, is based on own cost valuation, this 
calculation should be presented in a detailed and transparent manner.  
Ordinal ICER bias 
A crucial part of an economic evaluation is the incremental analysis of costs 
and outcomes of the behavioural/educational intervention versus the 
comparator, such as in an ICER. An issue that is highlighted in almost every 
systematic review of trial-based economic evaluations, also in field of public 
health,32 is that, without any motivation, this incremental analysis is often 
missing.  
As mentioned earlier, the ICER reflects how much it will cost to improve one 
point on a certain outcome scale. For resource allocation decisions, cardinal 
(interval or ratio) scales are necessary. In cardinal scales, the difference 
between two points is quantifiable and interpretable. In addition, it is 
assumed that the difference between two points has the same meaning 
throughout the whole range of the measurement scale. 
It is known that nominal scales are unsuitable for use in an ICER, and will thus 
induce a ordinal ICER bias (i).48,49 If the ICER is calculated based on nominal 
scales, in many cases the ICER may be misleading for resource allocation, as 
these scales do not allow for applying fundamental algebraic operations (ii). 
As a result, the ICER calculated using ordinal scales is not informative.48 
The easiest way to circumvent an ordinal ICER bias (iii) is to avoid using 
ordinal scales when calculating an ICER. This means that in designing the trial 
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the economic evaluator should already be aware of this bias when choosing 
primary outcome measures for the cost-effectiveness study. In addition, 
economic evaluators should be aware that using previously mentioned 
thresholds to decide if a health behaviour change intervention is cost-
effective or not is meaningful only if the outcomes used are QALYs, as to our 
knowledge the current threshold defines only how much a society is willing to 
pay for a QALY, but does not necessarily apply to other parameters. 
Double-counting bias 
Double-counting bias (i), is an error that can occur in economic evaluation, 
whereby a parameter is counted more than once. It occurs in cost-utility 
analyses, when consequences of a treatment get incorporated on the cost 
side (numerator) as well as in the estimation of quality weights, i.e. QALY 
(denominator). In addition, double counting may also occur when social 
security benefits and other transfer costs are valued monetarily, in additional 
to valuing, for instance, productivity losses monetarily. 
As already noted above, a societal perspective is recommended. Accordingly, 
all relevant costs and outcomes should be included in the ICER. In other 
words, benefits which are excluded in the QALY estimation need to be 
included in the costs. As it is not always clear what has to be included in the 
QALY estimation, two problems can arise (ii). First, a cost or benefit item can 
get lost and not be included in the analysis and second, cost and benefit may 
be included in the QALYs as well as in the costs. Double-counting in general is 
an important issue, which is discussed in detail elsewhere.50 The extent to 
which double-counting becomes relevant depends on a number of factors, 
such as the healthcare system, reimbursement procedures and sick-leave 
payment. Looking at changes in productivity and healthcare costs, it’s 
obvious that patients might incorporate the QALY assessment in their 
responses. Being aware of this issue (iii) might lead to a clear strategy to 
overcome or at least minimize this bias. Furthermore, a good phrasing of the 
assessment questions is crucial,  for instance by stating explicitly what 
assumptions the patient should make when completing a questionnaire or 
diary.50 
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Inappropriate discounting bias 
In behavioural and educational trials the follow-up period of respondents is 
often longer than one year. In general, regarding time preference, people 
prefer to have positive outcomes right now (for instance health gains) and 
negative outcomes, like costs, later in time. This is especially the case for 
preventive activities, such as lifestyle programs which aim to avoid diseases 
later in life. Due to the fact that people want to pay their costs as late as 
possible, and to enjoy their benefits as soon as possible, discounting is 
necessary in trial-based economic evaluation studies. Discounting is rather 
technical;51 several rates (varying between 1.5% for effects to 6% for costs) 
and models are suggested.  
Several authors have shown that the ICER, i.e. the final results of a trial-based 
economic evaluation, is very sensitive to the discount model and the discount 
rate used, thus inducing an inappropriate discounting bias (i).52,53 
Consequently, discounting can have a strong influence on cost-effectiveness 
ratios (ii) for setting priority, especially in preventive interventions. As a result, 
the conclusions of a trial-based economic evaluation study could change from 
a behavioural/educational intervention being cost-effective to not being cost-
effective, just by changing the discount rates.  
As there is no unique correct way for dealing with discounting, variation in 
practice is defensible.44 However, as there is no agreement over the models 
and rates used for discounting, this might introduce biases in which economic 
evaluators choose the most favourable discount rate. To overcome the use of 
a possibly inappropriate discount rate (iii), we suggest presenting several 
scenarios of the results, using various discount models and rates as a kind of 
sensitivity analysis. This sensitivity analysis should include undiscounted 
results (0%); this is also suggested by Hillman and Kim54 as a scenario, and if 
available, the discount models or rates that are suggested by the country-
specific guidelines should be used. 
Limited sensitivity analysis bias 
The limited sensitivity analysis refers to the fact that the trial-based economic 
evaluation does not apportion uncertainty according to different sources (i). 
Uncertainty in trial-based economic evaluation might come from several 
sources; the methodology, sampling variation, extrapolation, 
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generalizability.23 Moreover, evaluators in trial-based economic evaluation 
can be uncertain about the calculation of one specific parameter. 
Methodological uncertainty derives from the situation that different 
techniques can be used to value costs and utilities. As there is no gold 
standard, several countries advise performing their trial-based economic 
evaluation alongside a reference case. A reference case is a standard set of 
methodological practices that an economic evaluator would seek to follow in 
an economic evaluation study. Often, even in a randomised trial, the evaluator 
might have doubts about the group selected or there might be outliers in one 
of the arms of the trial. This sampling variation will result in uncertainty 
around the ICER. In order to test for sampling uncertainty, statistical 
techniques such as bootstrapping can be used. Another source of uncertainty 
arises in the situation when a researcher would like to extrapolate the results 
of a trial-based economic evaluation beyond the time of the trial. Modelling 
techniques can be used for this. Finally, sensitivity analysis can be used to test 
whether the results of a trial-based economic evaluation still hold if the results 
are generalised to another setting or if one parameter is changed. In 
sensitivity analysis, the robustness of a trial-based economic evaluation is 
assessed by examining the changes in results of the analysis when key 
variables are varied over a specific range. 
The bias (ii) induced from having no or a limited sensitivity analysis is that the 
level of certainty surrounding the ICER is wrongly regarded as low. Economic 
evaluators (iii) should make a list of the variables for which uncertainty is 
assumed. Evaluators should use a reference case and test the uncertainty 
regarding this variable by means of alternative assumptions. This will include 
analysing the effects of sampling uncertainty, the impact of methodological 
assumptions (such as discount rate, study perspective), and subgroup 
analysis. 
III Bias after trial 
Sponsor bias 
The most discussed bias in research is probably the sponsor bias.55 It is often 
mentioned that profit-making organisations (first of all the pharmaceutical 
industry) have been considering economic evaluations to be a marketing 
device instead of academic exercises (M. Drummond, 199156; Hillman et al., 
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1991)57, and thus are more likely to induce bias (i). Accordingly, a number of 
studies (ii) (Azimi & Welch, 199858; Baker, Johnsrud, Crismon, Rosenheck, & 
Woods, 200359; Bell et al., 200627; Bero & Rennie, 199660; Friedberg, Saffran, 
Stinson, Nelson, & Bennett, 199961; Hill et al., 200036; Hillman et al., 199157; 
John-Baptiste & Bell, 201062; Lexchin, Bero, Djulbegovic, & Clark, 200363; 
Miners, Garau, Fidan, & Fischer, 2005)64 have been focusing on the fact that 
profit-making organisations are more likely to report favourable results from 
trial-based economic evaluation studies. The studies’ overall conclusion is that 
ICERs submitted by profit-making organisations are significantly favourable in 
comparison with submissions performed by non-profit-making organisations. 
Studies sponsored by the industry were more than twice as likely to report 
favourable ICERs.27. One of the explanations for this difference might be the 
lower methodological quality of studies submitted by the industry.27,36,63 An 
alternative explanation might be a publication bias,61,63 and the phase (timing) 
in which these economic evaluation studies are performed. Regarding 
publication, there seems to be a bias in profit-making organisations towards 
“positive” results.61 Furthermore, it can be argued that profit-making 
organisations are more likely to be involved in research in the early stage of 
the dissemination of an intervention, as the study population in this phase is 
more selective towards people for whom the intervention is optimally 
intended. Accordingly, early trial-based economic evaluations are more likely 
to yield positive outcomes.61 Notwithstanding the presence of a sponsorship 
bias, the reality is that the industry is still one of the major funding bodies for 
trial-based economic evaluation,65 especially for pharmaceuticals.  
As a result, solutions (iii) have to be sought to overcome this bias. Of course, 
the sources of sponsorship should be fully disclosed at all times. The idea 
behind this is that disclosure will place sufficient pressure on economic 
evaluators to be sure that their research and subsequent publication is as 
unbiased as possible.66 However, disclosure of the financial conflict of interest 
cannot eliminate all biases. In the long run, maintenance of good 
methodological standards is of major importance. This implies that there are 
stringent guidelines on how to perform trial-based economic evaluation, and 
that the study protocol (including the analysis) should be published 
beforehand. Finally, rigorous independent assessment and review of the 
studies might also be ways of limiting this bias.57,67  
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Reporting/dissemination bias  
Within the field of economic evaluation there seems to be a specific form for 
reporting bias (i), in addition to the publication bias, which is known. 
Economic evaluations are often published both in a monograph produced for 
the funders, and in a corresponding professional journal. A review study by 
Matthews et al.28 revealed (ii) that there is a tendency to underreport non-
significant outcomes in journal publications as opposed to monographs, with 
the consequence that significant statistical findings tend to be disseminated 
more widely.  
To avoid the possibility of a reporting/dissemination bias (iii) the monographs 
should be included in decision-making processes.28 Furthermore, the 
monographs should be available publicly and (trial-based) economic 
evaluations should be listed in trial registers. 
Conclusion 
This article attempts to identify biases, which may occur before, during, and 
after a trial-based economic evaluation. It is important for various 
stakeholders to be aware of these biases as trial-based economic evaluations 
are being used increasingly in reimbursement decisions. Understanding 
biases also allows readers to review trial-based economic evaluations critically 
and independently. To gain insight into the potential biases of a study, a 
transparent and detailed description of trial-based economic evaluation is 
necessary.15 Journals can encourage greater transparency by requiring 
authors to provide appendices with details to be published on the web in 
order to overcome space limitations.62  
As we have shown, there are several ways of influencing the final results of 
trial-based economic evaluation with respect to biases. To our current 
knowledge, this is the first scoping review giving an overview of possible 
biases in trial-based economic evaluations. A review of the literature revealed 
that there are several types of systematic errors, which can influence the final 
results of trial-based economic evaluation. Overall, the number of studies 
dealing with biases in trial-based economic evaluation is limited, and the 
evidence included in this scoping review thus comes from only a few articles. 
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Accordingly, additional research is needed to identify (additional) biases, and 
to reveal appropriate strategies for addressing the risk of bias. 
It is important to understand that different bias types can be related to each 
other and that the elimination of one can introduce another. For instance, 
using the societal perspective (in order to reduce the limited perspective bias) 
might induce double counting (double counting bias) and uncertainty 
(limited sensitivity analysis bias). Accordingly, different stakeholders have to 
be aware of all types of biases to make an informed decision. 
During a trial-based economic evaluation, evaluators have to decide among 
several choices. Several checklists29,68 have been designed to scrutinize the 
quality of a study. There is a thin line between limited methodological quality 
and biases. In this article, we have classified factors as a bias if it is likely that 
any manipulation will lead to a difference between the true value in the 
population and the observed value in the trial-based economic evaluation. As 
a consequence, we have limited ourselves to true biases, although evidence 
showed that studies with a high score on quality were also less likely to report 
favourable ICER.27  
This article is not a systematic review as such, but in writing this article we 
have tried to retrieve as much information as possible about biases in trial-
based economic evaluations. This scoping review is based on a limited search 
in PubMed and the NHS EED only, which might have led us to miss some 
relevant publications, although it is generally accepted that using this search 
practice is an optimal search strategy for retrieving economic evaluations.24,25 
Furthermore, this article, due to the scope of this special issue of Psychology & 
Health, focuses only on trial-based economic evaluations. In general, all the 
biases discussed in Table 3.1 also hold for model-based economic evaluation 
studies.69 In a model-based economic evaluation there are a number of 
additional potential biases which are relevant;3 however, identifying these 
biases goes  beyond the scope of this article. 
Like Cainet al.70, we believe that everyone is a little bit biased, including 
economic evaluators. As noted earlier, a number of guidelines have been 
developed for trial-based economic evaluations. However, these guidelines 
and the solutions suggested in Table 3.1 are not enough to overcome all 
biases. Economic evaluators, like any other researchers, will have to rationalize 
the choices they have made during every phase of the study.71 In order to 
avoid biases in trial-based economic evaluations, researchers, readers, 
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reviewers, editors, decision-makers etc. have to be aware of the possible 
biases and all stakeholders have to examine trial-based economic evaluations 
in a rigorous and stringent manner. This article can be helpful in this 
examination as it provides an overview of the possible biases, which 
researchers should take into account. 
Chapter 3 
62 
References 
1. The EuroQol Group. EuroQol--a new facility for the measurement of health-related quality 
of life. Health Policy 1990;16:199-208.  
2. Brazier JE, Harper R, Jones NM, O'Cathain A, Thomas KJ, Usherwood T, Westlake L. 
Validating the SF-36 health survey questionnaire: new outcome measure for primary care. 
BMJ 1992;305:160-164.  
3. Drummond M, Sculpher M. Common methodological flaws in economic evaluations. 
Medical Care 2005;43(7 Suppl):5-14.  
4. Brennan A, Akehurst R. Modelling in health economic evaluation. What is its place? What 
is its value? PharmacoEconomics 2000;17:445-459.  
5. Ramsey S, Willke R, Briggs A, Brown R, Buxton M, Chawla A, Cook J, Glick H, Liljas B, Petitti 
D, Reed S. Good research practices for cost-effectiveness analysis alongside clinical trials: 
the ISPOR RCT-CEA Task Force report. Value Health 2005;8:521-533. 
6. Sculpher MJ, Claxton K, Drummond M, McCabe C. Whither trial-based economic 
evaluation for health care decision making? Health economics 2006;15:677-687.  
7. Bruijn De M XXX Editorial 
8. Williams A. Cochrane Lecture. All cost effective treatments should be free ... or, how Archie 
Cochrane changed my life! J Epidemiol Community Health 1997;51:116-120.  
9. Evers S, Salvador-Carulla L, Halsteinli V, McDaid D, Group, The Mheen. Implementing 
mental health economic evaluation evidence: Building a bridge between theory and 
practice. Journal of Mental Health 2007;16:223-241.  
10. Weatherly H, Drummond M, Claxton K, Cookson R, Ferguson B, Godfrey C, Rice N, Sculpher 
M, Sowden A. Methods for assessing the cost-effectiveness of public health interventions: 
key challenges and recommendations. Health Policy 2009;93:85-92. 
11. Brown GW. On Small-Sample Estimation. The Annals of Mathematical Statistics, 
1947;18:582–5.  
12. The International Statistical Institute edited by Yadolah Dodge. The Oxford Dictionary of 
Statistical Terms: Oxford University Press 2003. 
13. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savovic J, Schulz KF, 
Weeks L, Sterne JA; Cochrane Bias Methods Group; Cochrane Statistical Methods Group. 
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 
2011;343, d5928.  
14. Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 
5.1.0 [updated March 2011]. . The Cochrane Collaboration, Available from www.cochrane-
handbook.org  
15. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, 
Briggs AH, Mauskopf J, Loder E; ISPOR Health Economic Evaluation Publication Guidelines-
CHEERS Good Reporting Practices Task Force. Consolidated Health Economic Evaluation 
Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health 
Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value 
Health 2013;16:231-250.  
 Risk of bias in trial-based economic evaluations 
63 
16. Walker DG, Wilson RF, Sharma R, Bridges J, Niessen L, Bass EB, Frick K. Best Practices for 
Conducting Economic Evaluations in Health Care: A Systematic Review of Quality 
Assessment Tools. Methods Research Report. (Prepared by Johns Hopkins University 
Evidence-based Practice Center under contract No. 290-2007-10061-I.) AHRQ Publication 
No. 12(13)-EHC132-EF. Rockville, MD: Agency for Healthcare Research and Quality. 
October 2012.www.effectivehealthcare.ahrq.gov/reports/final.cfm.  
17. Eble A, Boone P, Elbourne D. Risk and Evidence of Bias in  Randomized Controlled Trials in 
Economics. CEP Discussion Paper No 1240 September 2013 http://cep.lse.ac.uk/pubs/ 
download/dp1240.pdf. In L. S. o. Economics (Ed.), Centre for Economic Performance. 
18. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095-1108.  
19. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health 
from the SF-36. J Health Econ 2002;21:271-292.  
20. Eichler HG, Kong SX, Gerth WC, Mavros P, Jonsson B. Use of cost-effectiveness analysis in 
health-care resource allocation decision-making: how are cost-effectiveness thresholds 
expected to emerge? Value Health, 2004;7:518-528.  
21. Raad voor de Volksgezondheid en Zorg. Bijlage 3 Prioriteren op basis van gegevens bij het 
rapport Zinnige en duurzame zorg. Zoetermeer: Raad voor de Volksgezondheid en Zorg. 
2006. 
22. Tarn TYH, Dix Smith M. Pharmacoeconomic guidelines around the world. . ISPOR 
Connections 2004;10:5–15.  
23. Briggs A, Sculpher M, Buxton M. Uncertainty in the economic evaluation of health care 
technologies: the role of sensitivity analysis. Health Econ 1994;3:95-104.  
24. Alton V, Eckerlund I, Norlund A. Health economic evaluations: how to find them. Int J 
Technol Assess Health Care 2006;22:512-517.  
25. Sassi F, Archard L, McDaid D. Searching literature databases for health care economic 
evaluations: how systematic can we afford to be? Med Care 2002;40:387-394.  
26. Pannucci CJ, Wilkins EG. Identifying and Avoiding Bias in Research. Plastic and 
Reconstructive Surgery 2010;126:619-625. 
27. Bell CM, Urbach DR, Ray JG, Bayoumi A, Rosen AB, Greenberg D, Neumann PJ. Bias in 
published cost effectiveness studies: systematic review. BMJ 2006;332:699-703.  
28. Matthews GA, Dumville JC, Hewitt CE, Torgerson DJ. Retrospective cohort study 
highlighted outcome reporting bias in UK publicly funded trials. J Clin Epidemiol 
2011;64:1317-1324.  
29. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the 
Economic Evaluation of Health Care Programmes, third edition. New York: Oxford 
University Press Inc 2005. 
30. Jonsson B. Ten arguments for a societal perspective in the economic evaluation of medical 
innovations. Eur J Health Econ 2009;10:357-359.  
31. Knies S, Severens JL, Ament AJ,, Evers SM. (2010). The transferability of valuing lost 
productivity across jurisdictions. differences between national pharmacoeconomic 
guidelines. Value Health 2010;13:519-527.  
32. Alayli-Goebbels AF, Evers SM, Alexeeva D, Ament AJ, de Vries NK, Tilly JC, Severens JL. 
(2013). A review of economic evaluations of behavior change interventions: setting an 
agenda for research methods and practice. J Public Health (Oxf) 2014;36:336-344  
Chapter 3 
64 
33. Berger ML. Design of Prospective Cost-Effectiveness Clinical Trials: The Critical Role of the 
Comparator Group. Drug Information Journal, 1995;29:1415-1420.  
34. Ayling K, Brierley S, Johnson B, Heller S, Eiser C. (2015). How standard is standard care? 
Exploring control group outcomes in behaviour change interventions for young people 
with type 1 diabetes. Psychol Health, 2015;30:85–103. 
35. Bishop FL, Fenge-Davies AL, Kirby S, Geraghty AW. Context effects and behaviour change 
techniques in randomized trials: A systematic review using the example of trials to 
increase adherence to physical activity in musculoskeletal pain. Psychol Health 
2015;30,104–121.  
36. Hill SR, Mitchell AS, Henry D. Problems with the interpretation of pharmacoeconomic 
analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme. JAMA 
2000;283:2116-2121.  
37. Ridyard CH, Hughes DA, Team, Dirum. Development of a database of instruments for 
resource-use measurement: purpose, feasibility, and design. Value Health 2012;15: 
650-655. 
38. Thorn JC, Coast J, Cohen D, Hollingworth W, Knapp M, Noble SM, Ridyard C, Wordsworth 
S, Hughes D. Resource-use measurement based on patient recall: issues and challenges for 
economic evaluation. Appl Health Econ Health Policy 2013;11:155-161.  
39. Drost R, Paulus A, Ruwaard D, Evers S. Inter-Sectoral Costs and Benefits of Mental Health 
Prevention: Towards a New Classification Scheme. J Ment Health Policy Econ 2013;16: 
179-186.  
40. Luce BR, Elixhauser A. Estimating costs in the economic evaluation of medical 
technologies. Int J Technol Assess Health Care 1990;6:57-75.  
41. Goossens ME, Rutten-van Molken MP, Vlaeyen JW, van der Linden SM. The cost diary: a 
method to measure direct and indirect costs in cost-effectiveness research. J Clin 
Epidemiol 2000;53:688-695.  
42. Hendriks MR, Al MJ, Bleijlevens MH, van Haastregt JC, Crebolder HF, van Eijk JT, Evers SM. 
(2013). Continuous versus Intermittent Data Collection of Health Care Utilization. Med 
Decis Making 2013;33:998-1008.  
43. Lamoureux EL, Chou SL, Larizza MF, Keeffe JE. The reliability of data collection periods of 
personal costs associated with vision impairment. Ophthalmic Epidemiol 2006;13:121-126.  
44. Drummond MF, McGuire A. Economic evaluation in health care : merging theory with 
practice. Oxford ; New York: Oxford University Press 2010. 
45. Finkler SA. The distinction between cost and charges. Ann Intern Med 1982;96:102-109.  
46. Jacobs P, Baladi JF. Biases in cost measurement for economic evaluation studies in health 
care. Health Econ 1996;5:525-529.  
47. Tan SS, Bouwmans CA, Rutten FF, Hakkaart-van Roijen L. Update of the Dutch Manual for 
Costing in Economic Evaluations. Int J Technol Assess Health Care 2012;28:152-158.  
48. Ament A, Evers S, Baltussen R. The usefulness of ratios for allocation decisions: the case of 
stroke. Cerebrovasc Dis 2000;10:283-288. 
49. Karlsson G, Johannesson M. The decision rules of cost-effectiveness analysis. 
Pharmacoeconomics 1996;9:113-120.  
50. Johannesson M. Avoiding double-counting in pharmacoeconomic studies. Pharmaco-
economics 1997;11:385-388.  
 Risk of bias in trial-based economic evaluations 
65 
51. Brouwer WB, Niessen LW, Postma MJ, Rutten FF. Need for differential discounting of costs 
and health effects in cost effectiveness analyses. BMJ 2005;331:446-448.  
52. Bonneux L, Birnie E. The discount rate in the economic evaluation of prevention: a 
thought experiment. J Epidemiol Community Health 2001;55:123-125.  
53. Katz DA, Welch HG. Discounting in cost-effectiveness analysis of healthcare programmes. 
Pharmacoeconomics 1993;3:276-285.  
54. Hillman AL, Kim MS. Economic decision making in healthcare. A standard approach to 
discounting health outcomes. Pharmacoeconomics 1995;7:198-205.  
55. Detsky AS. (2006). Sources of bias for authors of clinical practice guidelines. CMAJ 
2006;175:1033-1035.  
56. Drummond M. Economic evaluation of Pharamaceuticals: Science or marketing? 
Discussion paper 91. York: Centre for Health Economics, Health Economics Consortoum. 
1991. 
57. Hillman AL, Eisenberg JM, Pauly MV, Bloom BS, Glick H, Kinosian B, Schwartz JS. Avoiding 
bias in the conduct and reporting of cost-effectiveness research sponsored by 
pharmaceutical companies. N Engl J Med 1991;324:1362-1365.  
58. Azimi NA, Welch HG. (1998). The effectiveness of cost-effectiveness analysis in containing 
costs. J Gen Intern Med 1998;13;664-669.  
59. Baker CB, Johnsrud MT, Crismon ML, Rosenheck RA, Woods SW. (2003). Quantitative 
analysis of sponsorship bias in economic studies of antidepressants. Br J Psychiatry 
2003;83:498-506.  
60. Bero LA, Rennie D. Influences on the quality of published drug studies. Int J Technol 
Assess Health Care 1996;12:209-237.  
61. Friedberg M, Saffran B, Stinson TJ, Nelson W, Bennett CL. Evaluation of conflict of interest 
in economic analyses of new drugs used in oncology. JAMA 1999;282;1453-1457.  
62. John-Baptiste A, Bell C. Industry sponsored bias in cost effectiveness analyses. BMJ 
2010;341:c5350. 
63. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and 
research outcome and quality: systematic review. BMJ 2003;326:1167-1170.  
64. Miners AH, Garau M, Fidan D, Fischer AJ. Comparing estimates of cost effectiveness 
submitted to the National Institute for Clinical Excellence (NICE) by different organisations: 
retrospective study. BMJ 2005;330:65. 
65. Barnes R, Heaton A. Panel 6: addressing questions of bias, credibility, and quality in health 
economic evaluations. Value in health : the journal of the International Society for 
Pharmacoeconomics and Outcomes Research 1999;2:99-102 
66. Palumbo FB, Barnes R, Deverka P, McGhan W, Mullany L, Wertheimer A. ISPOR Code of 
Ethics for Researchers background article--report of the ISPOR Task Force on Code of 
Ethics for Researchers. Value in health : the journal of the International Society for 
Pharmacoeconomics and Outcomes Research 2004;7:111-117.  
67. Rennie D, Luft HS. Pharmacoeconomic analyses: making them transparent, making them 
credible. JAMA 2000;283:2158-2160.  
68. Evers S, Goossens M, de Vet H, van Tulder M, Ament A. Criteria list for assessment of 
methodological quality of economic evaluations: Consensus on Health Economic Criteria. 
Int J Technol Assess Health Care 2005;21:240-245.  
Chapter 3 
66 
69. Garattini L, Koleva D, Casadei G. Modeling in pharmacoeconomic studies: funding sources 
and outcomes. Int J Technol Assess Health Care, 2010;26:330-333. 
70. Cain DM, Detsky AS. Everyone's a little bit biased (even physicians). JAMA 2008;299: 
2893-2895. 
71. Cain DM, Loewenstein G, Moore DA. (2005). The dirt on coming clean: Perverse effects of 
disclosing conflicts of interest. Journal of Legal Studies 2005;34:1-25.  
 
 
 
67 
Chapter 4 
 
Risk of bias in model-based economic  
evaluations: The ECOBIAS checklist 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adarkwah CC 
Van Gils PF 
Hiligsmann M 
Evers SMAA 
Submitted to Expert Rev Pharmacoecon Outcomes Res 
Chapter 4 
68 
Abstract 
Background  
Economic evaluations are becoming increasingly important in helping policymakers to 
efficiently allocate scarce resources. Several biases can occur when performing economic 
evaluations. It is therefore important for policymakers to be able to assess potential biases and 
for researchers to minimize them. Earlier research revealed which biases exist in trial-based 
economic evaluations. 
 
Objectives  
This article aims first to identify biases that are specifically related to model-based economic 
evaluations and to illustrate their potential impact on economic outcomes using examples 
from the literature. Second, the article aims to present a checklist for assessing the risk of biases 
in economic evaluations (the ECOBIAS checklist), which can be used for trial- and model-based 
studies. 
 
Methods 
Several possible sources of bias in model-based economic evaluations were identified using the 
Philips guideline for good practices in modelling economic studies as a structuring framework. 
Biases were identified and illustrated using evidence from previously published model-based 
economic evaluation studies. Examples of biases were found through a scoping review, 
scrutinization of systematic reviews that used the Philips guideline, working-group meetings 
and discussions with the lowlands Health Economics Study Group (lolaHESG). By combining 
biases that can occur in trial-based with those that can occur in model-based studies, which 
were identified in a previous article by the author group, a checklist for assessing biases in 
economic evaluations was developed (ECOBIAS). 
 
Results 
Eleven additional model-specific biases were identified and classified by structure, data and 
consistency of the model. These biases are related to structural assumptions, model type, time 
horizon, data selection (such as treatment effects), assessment of uncertainty and internal 
validation. The impact of these biases could be massive, changing the outcomes from being 
highly cost-effective to not being cost-effective at all. The ECOBIAS checklist aims to help 
researchers identify biases and includes a total of 22 biases, of which eleven are specific for 
modelling economic studies. 
 
Conclusion 
In this study, we identified several biases that are related to model-based economic evaluations 
and developed the ECOBIAS checklist for identifying biases in economic evaluations. We hope 
that our results and the ECOBIAS checklist will help to reduce biases in future economic 
evaluations and will increase faith in model-based economic evaluations in particular. 
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Introduction 
Economic evaluations are becoming increasingly important in providing 
policymakers with information for reimbursement decisions. However, in 
many cases, a significant difference is notable between study results and real-
life observations. This can be due to confounding and many other factors. In 
this context, bias might play an important role. 
There are basically two analytical frameworks used to perform economic 
evaluations: model-based and trial-based. In a model-based economic 
evaluation, data from a wide range of sources (randomized-controlled trials 
(RCTs), meta-analyses, observational studies) are combined using a 
mathematical model to represent the complexity of a healthcare process. 
Several studies and guidelines have already highlighted the importance of 
strong methodology by developing guidelines for model-based economic 
evaluations.1-7 Those guidelines provide information on the different steps for 
conducting a model-based economic evaluation. Overall, these guidelines 
instruct researchers on what to do, but not exactly on how to deal with 
specific biases. Some guidelines provide a checklist that includes several 
criteria that are assumed to reflect aspects of quality (,8-10 while others do 
not.11-13 The checklists provided are either based on a number of items that 
are given the same weight9,10,14 or are based on a quantitative grading system 
(Chiou et al., 2003).8  
Other guidelines focus on specific methodological aspects. Eddy et al. focused 
on transparency and validation.15 They evaluated methods and recommended 
best practices to make models more transparent and to validate them. Briggs 
et al. developed a guideline for examining and reporting uncertainty 
surrounding an outcome.16 In Caro et al. (2014), a questionnaire to assess 
relevance and credibility was developed.17 All of the abovementioned 
concepts should be critically considered by modelling researchers. However, 
none of these studies focused specifically on biases in economic evaluations. 
In the current article, biases are addressed. The Cochrane Handbook18 defines 
bias as “... a systematic error, or deviation from the truth, in results or 
inferences”.19 Bias can lead to over- or underestimation of the true 
intervention effect and is different from imprecision in the estimated 
treatment effect, which implies random rather than systematic error.20 A bias 
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can be unintentional or intentional and can have either substantial or 
insubstantial impact.  
In other fields, such as epidemiology and health psychology, explicit attention 
has been paid to common sources of bias and strategies for reducing the risk 
of bias. This has resulted in widely-used instruments for assessing the risk of 
bias, such as the Cochrane risk of bias tool for randomized controlled trials.19 
Awareness of potential biases is also extremely important in the field of 
economic evaluation for both researchers and policymakers. Researchers 
should be aware of the forms of bias so they can reduce or at least minimize 
them, while policymakers should be aware of potential bias so they can 
accurately assess economic evaluations.  
Several biases related to trial-based economic evaluation have already been 
identified and discussed previously.21 As model-based economic evaluation 
involves other methods, it also faces other challenges. Specific biases that 
could occur in modelling studies need to be identified when using and 
reviewing model-based studies. 
This study aims to identify additional key biases that could occur in model-
based economic evaluations and to illustrate their potential impact on cost-
effectiveness results using examples from the literature. As part of this study, 
a checklist was also developed, called the Bias in Economic Evaluation 
(ECOBIAS) checklist, which provides a full overview of the biases that could 
occur in model-based and trial-based economic evaluations. The ECOBIAS 
checklist can be used to consistently examine any bias in an economic 
evaluation. Researchers can use it in planning, performing and analysing an 
economic evaluation. 
Methods 
The first step was to identify relevant biases in model-based economic 
evaluations. For this identification step, we combined several strategies 
including: (a) a scoping review to identify any biases, (b) an analysis of earlier 
systematic reviews and (c) input from experts to find additional biases. For the 
scoping review (a), a literature search was performed in March 2015 using 
PubMed (search terms: Costs and Cost Analysis [MeSH Terms] cost-effective 
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and cost-effectiveness, based on,22,23 bias, and model-based economic 
evaluation).  
As we had the idea that systematic reviews (b) looking at model-based 
economic evaluation might reveal some additional biases, we also performed 
a literature review, searching for earlier systematic reviews focussing on 
model-based economic evaluations. To identify relevant model-based studies, 
a literature search was performed in April 2015, primarily focussing on reviews 
using the Philips guideline,24 which is a comprehensive assessment tool that is 
recommended by the Cochrane Handbook for Systematic Reviews of 
Interventions for assessing the methodological quality of model-based 
economic evaluations.18,25 We identified these systematic reviews using 
PubMed (search terms: philips[All Fields] AND ("checklist"[MeSH Terms] OR 
"checklist"[All Fields])). All articles were checked for valuable information on 
bias.  
The findings were complemented with knowledge from the author group and 
input from external experts (c). Regular meetings of the author group were 
held, and two external experts were consulted for the identification and 
illustration of biases. The findings were also presented and intensively 
discussed during the lowlands Health Economics Study Group (lolaHESG) 
Annual Meeting (May 2015) to reveal additional biases.   
A second step in the strategy was to classify all the biases that were identified 
in step 1 into a logical framework. In this step, we classified biases into three 
different sections (i.e. structure, data and consistency) and related sub-
sections, following the Philips guideline.24 
Third, for every bias identified in published model-based economic evaluation 
studies, we first described the overall recommendations of the Philips 
guideline, defined the bias thereafter and then illustrated the influence of the 
bias using one or two examples.  
As a final step, the ECOBIAS checklist for bias in economic evaluation was 
developed, which gives an overview of biases in trial-based and model-based 
economic evaluations. Here, the results of the current paper were merged 
with the results of our previous article.21 The ECOBIAS checklist encompasses 
a common part for model- and trial-based economic evaluations and a model-
specific part. Part A of the checklist incorporates eleven biases that occur in 
both types of economic evaluation, which were identified and discussed in a 
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previous article by the author group,21 whereas Part B covers eleven model-
specific aspects of biases presented in the following section. 
Results 
Model-specific biases 
In total, 38 studies were identified that cited the Philips guideline, and among 
those were twelve reviews. Eleven model-specific biases (Table 4.1) were 
identified, which are presented in detail in the following sections. The results 
section is structured according to the items of the Philips guideline to allow 
for a good overview. The following types of bias were identified: 
 
Table 4.1       Mode-specific biases in economic evaluation. 
 
 
A. Bias related to structure  
A 1. Structural assumptions bias  
Overall recommendation of the guideline: It is of great importance that the 
structure of a model is consistent with a coherent theory of the condition that 
is being investigated.6,24 For instance, treatment pathways should carefully 
reflect the underlying nature and process of the disease, which is emphasized 
 Type of bias 
I Bias related to structure 
 Structural assumptions bias 
 No treatment comparator bias 
 Wrong model bias  
 Limited time horizon bias 
II Bias related to data 
 Bias related to data identification 
 Bias related to baseline data 
 Bias related to treatment effects 
 Bias related to quality-of-life weights (utilities) 
 Non-transparent data incorporation bias 
 Limited scope bias 
III Bias related to consistency 
 Bias related to internal consistency 
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separately in the Philips guideline. In addition, all structural assumptions 
should be transparent and well justified, and the presentation should be 
tailored to policymakers’ needs. The cycle length chosen should also be 
dictated by the natural history of disease.  
Definition of the bias: Structural assumption bias exists if the model 
structure is not consistent with a coherent theory of the condition that is 
being investigated. If the issues mentioned above are not critically 
considered, structural assumptions bias is likely to occur.  
Illustration of potential bias: The structural assumptions bias is very well 
illustrated in the paper of Hoogendoorn et al..26 Here, seven cost-effectiveness 
models on COPD were compared using the same input parameters. The 
results of four hypothetical interventions were checked against each other 
and the models were in this way cross-validated by running the same 
treatment scenarios. There was a high variability of structural assumptions, 
such as the number of COPD severity states, the possibility of backward 
transition and the inclusion of exacerbation-related mortality. The ICER 
significantly differs according to the model used, ranging from €17,000 per 
QALY to €47,000 per QALY, depending on the model. Those differences could 
only be explained by structural uncertainty in the models.  
A 2. No treatment comparator bias  
Overall recommendation of the guideline: In line with the 
recommendation, there should be a clear definition of all options that are 
evaluated. The model should reflect all options relating to the decision 
problem and therefore should also reflect current practice.24  
Definition of the bias: Hence, in a sound economic evaluation, you are 
comparing the intervention under investigation with care as usual. In a 
model-based economic evaluation study, you can, as opposed to a trial-based 
economic evaluation, induce the comparison of nobody receiving any 
alternative intervention, which is unlikely in practice. This will lead to the no 
treatment bias (i.e. an overestimation of the cost-effectiveness of the 
intervention studied) by comparing it with an unrealistic alternative (i.e. that 
the comparator receives no treatment). 
Illustration of potential bias: In a systematic review of cost-effectiveness 
analyses of drugs in osteoporosis published between 2008 and 2013, it was 
shown that relatively few economic evaluations included all potential relevant 
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interventions in their analysis.27 Although there has been an increased use of 
active comparators, some articles are still only comparing a drug treatment 
versus no treatment, which could lead to a more favourable cost-effective 
result.  
A 3. Wrong model bias  
Overall recommendation of the guideline: The decision problem should 
dictate the appropriate model. In addition, the choices made with regard to 
causal relationships within the model also need to be considered carefully.24 
Definition of the bias: For instance, different model types have different 
justifications and indications. For certain decision problems (i.e. more simple 
scenarios that occur over a short time period), decision trees can be more 
appropriate than Markov models, while the latter can be more suitable for 
other problems, especially when a decision problem involves risk that is 
continuous over time, when the timing of events is important, and when 
important events may happen more than once. Neglecting this might lead to 
bias. 
Illustration of potential bias: Although it is difficult to find a completely 
wrong model in the literature, the paper of Simpson et al. clearly shows that 
the choice of the right model makes a difference.28 The article presents a 
comparison of Markov model and discrete-event simulation (DES) techniques 
in HIV modelling. Making use of published data as model input, both 
approaches were compared regarding the clinical outcomes at five-year and 
lifetime cost-effectiveness estimates. It was shown that the DES model 
predicted more detailed outcomes and had better long-term predictive 
validity than the Markov model. So the authors concluded that the DES model 
is better than the Markov model in isolating long-term implications of small 
but important differences in crucial input data. In another article, Karnon and 
Brown29 reviewed decision trees, Markov models and DES, taking breast 
cancer as an illustrative example. They discussed pros and cons and 
concluded that the choice of the right model depends on a number of factors, 
which need to be critically considered before choosing the model type for an 
economic evaluation. 
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A 4. Limited time horizon bias  
Overall recommendation of the guideline: According to Philips et al.,24 the 
time horizon in the optimal case should cover a lifetime to make sure not to 
miss important events. In all other cases, justification for shorter time horizons 
should be stated appropriately. It is furthermore important to distinguish 
between the time horizon of the model, the duration of treatment and the 
duration of treatment effects. 
Overall, the time horizon should be long enough to capture all relevant costs 
and outcomes relating to the disease and the duration of treatment and 
treatment effects.   
Definition of the bias: Bias might occur where the choice of the time horizon 
is not appropriate (too short) for the decision problem or choosing a more 
limited time horizon (less than a lifetime horizon) is not justified 
appropriately. The bias which is induced is that not capturing relevant events 
(in terms of costs and effects) beyond the study’s time horizon may have a 
significant impact on the final results of the study.  
Illustration of potential bias: The paper of Vijgen et al. illustrated how time 
horizons affect the ICER and can potentially lead to bias.30 This paper 
determined the cost-effectiveness of a Dutch school-based smoking 
education program. The ICER of the school-based smoking education 
program compared with current practice was highly dependent on the time 
horizon (25 years: €231,500 per QALY gained, 50 years: €29,300 per QALY 
gained and 75 years: €18,500 per QALY gained). So if the time horizon is not 
long enough, the ICERs are rather unfavorable. This is because the major 
health benefits are to be found beyond a time horizon of 25 years.  
B. Bias related to the data 
B 1. Data identification  
Overall recommendation of the guideline: Researchers should make the 
methods used to identify data transparent, and those methods should be in 
line with the model’s objectives.24 There needs to be a justification for any 
choices that are made about specific data inputs, and data identification itself 
should be done in a systematic way. In addition, particular attention has to be 
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paid to data identification of those parameters to which the results of the 
model are extremely sensitive.  
Data identification refers to the sources where data that are implemented into 
a model come from. Literature suggests that data should come from high-
quality and well-designed studies.31,32 Rules for assessing the quality of input 
data have been suggested.32 
Definition of the bias: The identification might induce bias in several ways. 
Model-based economic evaluation normally combines data from different 
sources and integrates them into one model. The advantage is that data from 
different sources can be obtained and used. For example, models often use a 
combination of local observational data (i.e. registries) to reflect local 
treatment patterns and experimental data (from RCTs).  
Bias can be induced if the data used for the model are not an adequate 
choice. This issue needs to be considered critically. So the question is whether 
the input data come from large meta-analysis or RCTs or only small trials, 
which might be of lower quality. Another bias can be induced if researchers 
only rely on a sole source of information. This could be data from only one 
RCT where important comparators or events might not even be considered. 
We are aware of the fact that meta-analysis or RCTs are not available in any 
case, but the justification of data sources needs to be transparent and stated 
clearly, especially when relying only on data from a single trial.  
Illustration of potential bias: In a recent systematic review of economic 
evaluations, Hiligsmann et al.27 use the CHEERS checklist to assess the quality 
of reporting of 39 economic evaluations. The authors showed that the 
methods used for the identification and synthesis of clinical effectiveness data 
is often not reported. Although poor reporting does not necessarily lead to 
poor quality and results bias, high-quality and transparent data identification 
is needed. 
Next to that, adherence to interventions has been shown to have a substantial 
impact on the ICER.33 When assumptions about the willingness to participate 
in a screening program are too optimistic, for example, it may lead to 
conclusions that are too optimistic, while with assumptions that are more 
realistic, the conclusions about the cost-effectiveness would be less favorable. 
Taking the case of colorectal cancer screening as an example, an economic 
evaluation showed that a decrease in adherence from 100% to the more 
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realistic figure of 30% resulted in a doubling of the ICER, from €21,000 to 
€42,000.34  
Especially when the implementation of large public health interventions is 
considered, it is necessary to have accurate information about adherence. The 
relevance of this can be illustrated using the case of chlamydia screening in 
the Netherlands.35 The results from a relatively small trial to determine 
Chlamydia trachomatis prevalence organized by the Municipal Public Health 
Services showed a participation rate of 41%.35 However, a large pilot 
implementation project showed an adherence of only 16% after the first 
invitation, which declined to 9.5% after the third invitation.36  
Following this limited participation of the target group in the intervention, 
cost-effectiveness could no longer be demonstrated. This example underlines 
the importance of using real-life data for important parameters, especially for 
the effectiveness of cost-effectiveness models. Other examples that illustrate 
the economic impact of non-adherence are available in the literature.37 
B 2. Bias related to pre-model data analysis  
a. Bias related to baseline data 
Overall recommendation of the guideline: The guideline suggests that the 
methodology of data analysis should be described adequately and that the 
methodology should be based on justifiable statistical and epidemiological 
methods.24 This should be done with regard to baseline data, treatment 
effects and quality-of-life weights. Regarding baseline data, probabilities, for 
example, should be based on natural history data derived from 
epidemiological or observational studies. Transformation of rates into 
transition probabilities needs to be done accurately. Furthermore, not 
applying a half-cycle correction on all transitions in a state transition model 
(costs as well as outcomes) needs to be justified.  
Definition of the bias: Looking at the definition, it becomes clear that 
inducing a bias with regard to baseline data is not unlikely. Although it is hard 
to find a concrete example here, you could imagine that there might be over- 
or underestimation of certain risks, costs or benefits with regard to a certain 
intervention, which could lead to overestimating (or underestimating) the 
cost-effectiveness of an intervention. 
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b. Bias related to treatment effects 
Overall recommendation of the guideline: The guideline suggests that 
relative treatment effects derived from trial data should be synthesised using 
appropriate meta-analytic techniques.24 The methods and assumptions that 
are used to extrapolate short-term results to final outcomes should be 
documented and justified, along with alternative assumptions regarding 
extrapolation, which should be explored through sensitivity analysis. 
Assumptions regarding the continuing effect of treatment once treatment is 
complete should be documented and justified. If evidence regarding the 
long-term effect of treatment is lacking, alternative assumptions should be 
explored through sensitivity analysis.24 
Definition of the bias: If assumptions about treatment effects are not 
realistic and not justified adequately, bias is likely to occur. Other scenarios 
besides the base case need to be shown in order to demonstrate the impact 
on the ICER.  
Illustration of potential bias: Treatment effects can be both, over- and 
underestimated. In van Baal et al.38, the cost-effectiveness of a low-calorie diet 
intervention and a combination of both a low-calorie diet and Orlistat 
treatment over a one-year period were compared to no treatment at all. The 
sensitivity analysis performed (Table 4.4 in the paper) shows that the 
assumptions about weight loss maintenance in the long run dramatically 
influence the ICER. In detail, the base case weight loss maintenance was 23%. 
Assuming 100% maintenance after one year, ICERs decrease significantly, 
from €58,800 to €24,100 in the combination group. 
Furthermore, the assumptions about treatment effects after stopping 
treatment are a potential source of bias. The article of Caulin et al.39 shows the 
impact of the effects of stopping treatment on the ICER, taking osteoporosis 
as an example. The ICER was shown to substantially differ when changing the 
assumption about the effect of therapy after stopping it.  
c. Bias related to quality-of-life weights (utilities) 
Overall recommendation of the guideline: The utilities incorporated into a 
model should be appropriate for the specified decision problem.24 Utilities 
should be assessed using adequate methods and should be derived from the 
selected population in a formal way. 
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Definition of the bias: Hence, it is important to have a correct and 
transparent description of the derivation and incorporation of utility values.40 
QALYs are often the main and preferred outcome in decision models. Utility 
values need to be consistently used within a model and derived in the target 
population using established methods. Even if the utility weights were 
derived by the same method (e.g. time trade-off or standard gamble, multi-
attribute utilities scores), consistency needs to be assured in order to avoid 
bias. 
Illustration of potential bias: Unruh et al.41 assessed the health-related 
quality of life (HRQOL) in hemo-dialysis patients, comparing self-administered 
and interviewer-administered surveys. The Kidney Disease Quality of Life–
Long Form questionnaire (KDQOL-LF) was used as a measurement tool. The 
authors demonstrated that patients in the interviewer-administered group 
had higher scores on scales that measured role-physical, role-emotional and 
effects of kidney disease. They concluded that dialysis studies that restrict 
HRQOL measurement to patients who are able to complete surveys without 
assistance (i.e. the self-administered group) will not accurately represent the 
health of the overall hemo-dialysis population. 
B 3. Bias related to data incorporation  
Overall recommendation of the guideline: All data that are incorporated 
into the model should be described, and the sources of data should be 
reported in detail.24 All in all, the process of data incorporation should be 
transparent, and authors need to state clearly if data are considered as point 
estimates or as distributions.  
Definition of the bias: Not having a clear and transparent way of data 
incorporation might induce bias. For example, the methods used in a 
particular study should be stated in such a way that the study could be 
replicated. As previously mentioned, non-transparent data incorporation does 
not necessarily lead to poor quality and result in bias, but at least hinders the 
assessment of bias.  
Illustration of potential bias: Hiligsmann et al.27 reported that quality of 
reporting of recent economic evaluations is still largely insufficient for several 
articles. Several items were partially or not at all reported in most articles. 
Poorly reported items included methods used for the identification and 
synthesis of clinical effectiveness data, the description of the population and 
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methods used to value preference-based outcomes, the reporting of the 
dates of the estimated resource quantities and unit costs.  
B 4. Bias related to the assessment of uncertainty  
Limited scope bias 
Overall recommendation of the guideline: Regarding the assessment of 
uncertainty, the four principles of uncertainty, i.e. methodological, structural, 
heterogeneity and parameter, need to be considered.24 
Definition of the bias: Event though the standards of certain model-based 
economic evaluations can be quite high, studies can still lack in some parts of 
uncertainty. The Philips guideline distinguishes between the different types of 
uncertainty mentioned above, and there is a large variation in the models 
published. This starts with models that do no analysis at all and also includes 
models that do not look at all four types of uncertainty in particular (e.g. 
missing one type). We feel that, in many cases, not all possible and reasonable 
scenarios could be presented. Probabilistic sensitivity analyses are not always 
reported. Furthermore, the presentation of a best-case and worst-case 
scenario is often missing.  
C. Bias related to consistency 
C 1. Bias related to internal consistency 
Overall recommendation of the guideline: According to the guideline, 
there should be evidence that internal consistency of the model, in terms of 
its mathematical logic, has been evaluated.24 
Definition of the bias: Internal consistency seems to be underreported, 
which hinders an adequate assessment of bias. 
Illustration of potential bias: In a systematic review of model-based 
economic evaluations of diagnostic and therapeutic strategies for lower 
extremity artery disease using the Philips guideline, Vaidya et al.42 pointed out 
that internal consistency was not addressed in any of the sixteen identified 
studies. Next to that, in another study that used the Philips guideline, none of 
the four studies investigated addressed internal consistency.43  
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The ECOBIAS checklist 
The ECOBIAS checklist, which aims to help researchers identify bias, includes a 
total of 22 biases (Part A + Part B), of which eleven are specific for modelling 
economic studies (Part B).  
Two of the biases identified here (“no treatment comparator bias” and 
“limited scope bias”) have some overlap with biases mentioned in Part A; this 
overlap is indicated in Table 4.2. Authors can note if a bias is relevant to the 
actual study and describe in detail how the bias was dealt with, explaining 
rationale and strategy.   
 
Table 4.2 The ECOBIAS checklist for bias in economic evaluation. 
 
 
 
Type of bias Issues addressed 
(questions to consider) 
Relevant to 
study 
Yes/ No / Partly / 
Unclear / NA 
How did you deal 
with this bias? 
(description of 
strategy and 
rationale) 
PART A. Overall checklist for bias in economic evaluation 
 Narrow perspective 
bias 
Was a societal perspective adopted? If 
not, has a different perspective been 
justified? 
  
 Inefficient 
comparator bias* 
Was the best alternative chosen as a 
comparator? Was current practice chosen 
as a comparator? Have all comparators 
been described in sufficient detail?  
  
 Cost measurement 
omission bias 
Were all costs relevant to the disease and 
intervention identified and considered? 
  
 Intermittent data 
collection bias 
Was the resource use measured 
continuously? 
  
 Invalid valuation 
bias 
Is the price calculation presented in a 
detailed manner? Have reference prices 
been used? 
  
 Ordinal ICER bias Have cardinal scales for the outcomes 
measure in a CEA been used? 
  
 Double-counting 
bias 
Have the variables been adequately 
checked for double-counting? 
  
 Inappropriate 
discounting bias 
Have discounting rates from guidelines 
been applied?  
  
 Limited sensitivity 
analysis bias§ 
Have the four principles of uncertainty 
(methodological, structural, 
heterogeneity, parameter) been 
considered in sufficient detail? 
  
 Sponsor bias Have sponsorships been disclosed? Is the 
study protocol freely accessible? 
  
 Reporting and 
dissemination bias 
Has the study / trial been listed in a trial 
register? Have all results been reported 
according tot he study protocol? 
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Table 4.2 (continued) 
 
 
 
Type of bias Issues addressed 
(questions to consider) 
Relevant to 
study 
Yes/ No / Partly / 
Unclear / NA 
How did you deal 
with this bias? 
(description of 
strategy and 
rationale) 
PART B. Model-specific aspects of bias in economic evaluation 
I Bias related to structure   
 Structural 
assumptions bias 
Is the model structure in line with 
coherent theory? Do treatment pathways 
reflect the nature of disease? 
  
 No treatment 
comparator bias* 
Is there an adequate comparator, i.e. care 
as usual? 
  
 Wrong model bias Is the model chosen adequate regarding 
the decision problem? 
  
 Limited time horizon 
bias 
Was a lifetime horizon chosen? Were 
shorter time horizons adequately 
justified? 
  
II Bias related to data   
 Bias related to data 
identification 
Are the methods of data identification 
transparent? Are all choices justified 
adequately? Do the input parameters 
come from high-quality and well-
designed studies? 
  
 Bias related to 
baseline data 
Are probabilities, for example based on 
natural history data? Is transformation of 
rates into transition probabilities done 
accurately? 
  
 Bias related to 
treatment effects 
 
 
 
 
Are relative treatment effects synthesized 
using appropriate meta-analytic 
techniques? Are extrapolations 
documented and well justified? Are 
alternative assumptions explored 
regarding extrapolation? 
  
 Bias related to 
quality-of-life 
weights (utilities) 
Are the utilities incorporated appropriate 
for the specific decision problem? 
  
 Non-transparent 
data incorporation 
bias 
 
Is the process of data incorporation 
transparent? Are all data and their 
sources described in details? 
  
 Limited scope bias§ Have the four principles of uncertainty 
(methodological, structural, 
heterogeneity, parameter uncertainty) 
been considered? 
  
III Bias related to consistency   
 Bias related to 
internal consistency 
Has internal consistency in terms of its 
mathematical logic been evaluated? 
  
* These biases are overlapping regarding their content. § These biases are overlapping regarding their 
content. 
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The ECOBIAS checklist 
The ECOBIAS checklist, which aims to help researchers identify bias includes a 
total of 22 biases (Part A + Part B), of which eleven are specific for modelling 
economic studies (Part B).  
Two of the biases identified here (“no treatment comparator bias” and 
“limited scope bias”) have some overlap with biases mentioned in Part A, this 
overlap is indicated in Table 4.2. Authors can note if a bias is relevant to the 
actual study and describe in detail how the bias was dealt with, explaining 
rationale and strategy. 
Discussion 
This study identified several additional biases related to model-based 
economic evaluation and showed that the impact of these biases could be 
massive, changing the outcomes from being highly cost-effective to not 
being cost-effective at all. The majority of the biases discussed in this paper 
might, however, be unintentional. The aim of the paper was not to criticize 
researchers, but rather to raise awareness of biases in economic evaluation. As 
research in the field of economic evaluation is developing, an unintentional 
bias today might be an intentional bias ten years from now, also due to the 
fact that one is able to test and correct for this.15,44 Looking at the specific 
issues mentioned in the results, it becomes apparent that overcoming some 
biases is possible, at least to some extent.  
In order to be able to identify biases, being transparent in reporting is 
extremely important.45 Hence, when looking at models, policymakers are 
often insecure because there is a high deficit in understanding of what 
researchers exactly do.46 Open access to input data, assumptions, data 
identification and model structure, for example, should be facilitated by 
researchers,47 as is already standard in some other fields of research, such as 
computational neuroscience. Open access to the model itself should be 
provided in an optimal way. Using the ECOBIAS checklist would facilitate this 
process. 
Our findings suggest that a wide range of alternative research results should 
be presented in model-based economic evaluation. This means that more 
results should be presented in different scenarios and also that sensitivity 
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analyses should be extended to strengthen results that will form the basis for 
decisions regarding reimbursements.  
The ECOBIAS checklist presented in Table 4.2 can be useful both for 
researchers and for those who use and monitor the results of model-based 
economic evaluations, such as reviewers and policymakers. The checklist can 
be used to check if the work is performed systematically looking at bias and to 
demonstrate that the risk of bias is dealt with in an adequate way. To allow for 
more transparency, the completed checklist should be made available to 
reviewers and audiences, for example as an online appendix with the 
supplementary material. Furthermore, policymakers are enabled to check for 
biases and make more valid assessments of economic evaluations. 
The ECOBIAS checklist can be seen as a complementary tool next to the 
guidelines and checklists mentioned previously.1-17 The establishment of an 
ISPOR task force on bias or a consensus panel meeting could be the next steps 
forward.  
Still, the current research on bias in economic evaluation has some limitations. 
We cannot present a complete overview of all possible biases in economic 
evaluations, also because unawareness of bias is an issue. The reader should 
first be aware that this study focused on specific biases in model-based 
economic evaluation, which are important and should be critically 
considered. In a previous study,21 an overview of biases in trial-based 
economic evaluation was provided. Many of those biases also apply to model-
based economic evaluation and were not discussed again in this article but 
were included in the ECOBIAS checklist (Table 4.2). Second, we highlighted 
biases and elucidated the impact on the final results of the economic 
evaluation. Our aim was not to describe strategies for overcoming those 
biases. Further research is therefore needed to look explicitly at possible ways 
to manage biases in more detail. Third, we decided on the Philips guideline as 
a starting point. We are aware that there are many other approaches that 
could be used, such as focus groups or other guidelines. Fourth, our checklist 
is most likely not exhaustive. We are open to any additional feedback, which 
can be sent to the first author. Although ECOBIAS already covers a large 
number of items, further research beyond the scope of our article is needed to 
establish all bias-related items relevant to economic evaluation studies. In this 
further research, we might also learn from other fields that already have a 
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longstanding tradition of looking at bias, such as environmental research, 
health psychology and epidemiology.  
Notwithstanding these limitations, we think that this article, combined with 
earlier work, gives a good overview of the potential biases in economic 
evaluation, although further research is needed. We recommend that editors 
and reviewers consistently use a checklist, such as the ECOBIAS checklist 
presented in Table 4.2. To ensure more transparency, the completed checklist 
could be made compulsory with submission and could afterwards be made 
available to the community online with supplementary material.  
 
Expert commentary 
Although there is some overlap between biases in trial- and model-based 
economic evaluation, this research identified several biases specific for 
modelling studies. Being aware of these biases could help researchers to 
minimize them, and the ECOBIAS checklist could also help decision makers to 
assess economic evaluations.  
This would contribute to bridging the gap between researchers and 
policymakers and would most likely increase faith in model-based economic 
evaluations in particular. 
Five-year view 
We expect that minimizing biases in model-based economic evaluation will 
become increasingly important. This is first because modelling studies are 
becoming more popular due to several advantages they have over trial-based 
evaluations.48 Second, output of health economic models is increasingly 
needed in order to provide policymakers with reliable information to allocate 
the scarce resources in healthcare systems. More awareness about bias needs 
to be raised, and further research should therefore be done in order to 
continuously improve and further develop the checklist. 
To sum up, we expect that a correct handling of biases will be a crucial 
indicator for quality in and acceptance of model-based economic evaluation 
in future health economic research. 
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Key issues 
 Several studies have highlighted the importance of strong methodology 
by developing guidelines for model-based economic evaluations.  
 Bias can lead to over- or underestimation of the true intervention effect 
and is different from imprecision in the estimated treatment effect, which 
implies random rather than systematic error  
 Eleven key biases that could occur in model-based economic evaluations 
were identified and their potential impact on cost-effectiveness results 
was illustrated using examples from the literature.   
 Bringing the results from the previous and present article together, a 
comprehensive checklist on bias in economic evaluation (ECOBIAS 
checklist) is presented 
 The ECOBIAS checklist can be used by researchers to document the 
quality of their work and can thereby increase the acceptance of 
economic evaluations. 
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Abstract 
Objective 
Type 2 diabetes is the main cause of end-stage renal disease (ESRD) in Europe and the 
USA. Angiotensin-converting enzyme (ACE) inhibitors slow down the progression of 
renal disease and therefore provide a renal-protective effect. The aim of this study 
was to assess the most cost-effective time to start an ACE inhibitor (or an angiotensin 
II receptor blocker (ARB) in the event of cough) in patients with type 2 diabetes in 
Germany.  
 
Methods 
Three strategies were compared: treating all patients at the time of diagnosing type 2 
diabetes, screening for microalbuminuria, and screening for macroalbuminuria. A 
lifetime Markov decision model with simulated 50-year-old patients with newly 
diagnosed diabetes mellitus was developed using published data on costs and health 
outcomes and simulating the progression of renal disease. A statutory health 
insurance (SHI) perspective was adopted.  
 
Results  
In the base-case analysis, the treat-all strategy is associated with the lowest costs and 
highest benefit and therefore dominates screening both for macroalbuminuria and 
microalbuminuria. A multivariate sensitivity analysis shows that the probability of 
savings is 89%.  
 
Conclusions  
Patients with type 2 diabetes should receive an ACE inhibitor immediately after 
diagnosis if they do not have contraindications. The potential for cost savings would 
be even larger if the prevention of cardiovascular events were considered. 
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Introduction 
Type 2 diabetes is the main cause of end-stage renal disease (ESRD) in 
Germany and the United States.1,2 Diabetic nephropathy leads to a gradual 
decline of the renal function and is initially characterized by micro- or 
macroalbuminuria. Diabetic nephropathy may progress to ESRD. In Germany, 
the cost of ESRD treatment is about €40 000 per patient year.2-6 Hence, 
prevention of ESRD is also important from an economic viewpoint. 
 
ACE inhibitors slow down the progression of diabetic nephropathy 
independent of an elevated blood pressure.7,8 ARBs have similar effects on 
renal outcomes in diabetic patients,9 but are more expensive. Evidence 
suggests that the only major clinical difference between these classes of 
drugs is a higher risk of dry cough associated with ACE inhibitors.10 
 
Several clinical practice guidelines recommend starting ACE inhibitor therapy 
in diabetic patients with (micro)albuminuria.11,12 However, physician 
compliance in Germany is rather low.13,14 Cost-effectiveness models 
conducted in the United States by Golan et al.15 and Rosen et al.16 suggest that 
the best starting point is immediately after diagnosis of diabetes. However, 
results may not be transferable to the German setting, particularly due to 
differences in prices. Furthermore, the model by Golan et al.15 was criticized 
for presenting limited evidence on the transitions between the different renal 
disease stages17 (this criticism equally applies to Rosen et al.16). Moreover, 
both models do not consider that 9.9% of patients develop cough as a side 
effect of ACE-inhibitor therapy10 and thus are eligible for more expensive ARB 
therapy as a well-tolerated alternative.10 
 
The goal of this paper was to present a cost-effectiveness model which 
determines the best time to start an ACE inhibitor in newly diagnosed 
patients with type 2 diabetes and without hypertension or heart failure in 
Germany. The analysis was conducted from the perspective of the German 
SHI, which covers approximately 90% of the German population. In our model 
we included ARBs as an alternative for patients who experience ACE-inhibitor-
induced cough. In the base case we used 50 years as the age of diagnosing 
type 2 diabetes.18,19 In contrast to Golan et al.15 and Rosen et al.16, we 
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considered broader evidence for the transition between the different renal 
disease stages, based on two Cochrane reviews.20,21 
Methods 
Overview and model design 
We conducted a cost-utility analysis and measured health outcomes in terms 
of quality-adjusted life years (QALYs). We developed a Markov model in order 
to simulate the course of a cohort of 1000 patients at the age of 50 years as it 
progresses to microalbuminuria, macroalbuminuria, ESRD, and death. A 
Markov model is an iterative process where patients are assumed to stay in 
one cycle (i.e., a defined health state) for a certain time and then make a 
transition to another cycle. Markov models are useful when a decision 
problem involves risk that is continuous over time, when the timing of events 
is important, and when important events may happen more than once. We 
chose a cycle length of one year for the health states defined by the Markov 
model because all transition probabilities gathered from the literature 
referred to a duration of at least one year (see Table 5.1). Our Markov model 
contains the following 5 health states (Figure 5.1), which represent the 
occurrence of events after model entry: 
 
1. type 2 diabetes, with normoalbuminuria (excretion < 30 mg/d) 
2. type 2 diabetes, with microalbuminuria (excretion 30-300 mg/d) 
3. type 2 diabetes, with macroalbuminuria (excretion >300 mg/d) 
4. ESRD (treated with dialysis or renal transplantation)  
5. death 
 
We assumed that diabetic nephropathy progresses without skipping any 
stage. Further, patients may transit to death at any time. During each cycle, 
patients accumulate utility (measured by QALYs) and costs. A half-cycle 
correction was applied to both costs and outcomes to allow for transition 
events occurring mid-way through each 12-month cycle.  
 
The simulation was done until the age of 100. Hence, the time horizon is 50 
years. The age of 100 was chosen as a cutting point as there are no mortality 
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data available beyond this age. Regardless, 99.4 % of patients in the 
simulation are dead at this age. 
 
Table 5.1 Data used to determine the cost-effectiveness of ACE inhibitors (ARBs) in newly 
diagnosed type 2 diabetes. 
Variable Base-case 
estimate 
Range tested Reference 
Initial disease prevalence, % 
   Normoalbuminuria 79 66.5 – 100 
   Microalbuminuria 18 0 – 27.6 
   Macroalbuminuria 3 0 – 5.9 
22 
Annual transition probabilities (without ACE inhibitors) 
   Normoalbuminuria to microalbuminuria 0.056 0.03 – 0.08 21 
   Microalbuminuria to macroalbuminuria 0.094 -0.02 – 0.20 20 
   Macroalbuminuria to ESRD 0.056 0.025 – 0.08 8 
   Normo-/micro-/macro-albuminuria to death  Age-
dependent
 6 
   ESRD to death 0.13 --- 1 
Relative risk for progression with ACE inhibitors 
   Normoalbuminuria to microalbuminuria 0.60 0.43 – 0.84 21 
   Microalbuminuria to macroalbuminuria 0.45 0.29 – 0.69 20 
   Macroalbuminuria to ESRD 0.61 0.50 – 0.75 8 
Utilities (health states) 
   Diabetes (baseline health) 0.88 0.86 – 0.90 23 
   ESRD 0.62 0.39 – 0.84 24 
   ACE inhibitor / ARB treatment  1.00 0.95 – 1.00 25 
Annual costs, € 
   Per-patient cost of diabetes compared to  
   non-diabetic population (across all ages) 
2507 --- 26; applied to all 
health states 
except for ESRD 
   ACE inhibitor (10 mg ramipril daily) 48.22 --- 27; applied to all 
health states 
except for ESRD 
   ARB (300 mg irbesartan daily) 363.25 --- 28,27; applied to 
all health states 
except for ESRD 
   Mixed drug therapy costs (10% treated  
   with ARBs) 
79.72 --- 27; applied to all 
health states 
except for ESRD 
   Creatinine and potassium testing 1.00 --- 3,29 
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Table 5.1 (continued) 
Variable Base-
case 
estimate
Range tested Reference 
Screening for microalbuminuria 6.90 --- 3; applied to patients 
with 
normoalbuminuria 
only 
Screening for macroalbuminuria 0.50 --- 3; applied to patients 
with 
microalbuminuria 
only 
ESRD 40 493 32 394 – 48 591
   Transplantation  19 958 --- 
   Dialysis 48 088 --- 
1,3-5,30 
      Home/in-center hemodialysis 41 463 --- 1,3,4 
      Continuous ambulatory peritoneal dialysis 39 627  1,4 
      Continuous cycling peritoneal dialysis 49 510 --- 1,4 
      Dialysis on partly in-patient treatment   98 282 --- 5 
      Inpatient dialysis 147 021 --- 5 
SMR 1.41 1.39 – 1.43 31 
Rate of ARB use, % 9.9 9.6 – 10.2 10 
Specificity of HPLC (microalbuminuria 
screening procedure) 
1.00 0.81 – 1.00 32 
Discount rate 0.03 0.00 – 0.07 33 
ACE = angiotensin-converting enzyme; ARB = angiotensin II receptor blocker: ESRD = end-stage 
renal disease; SMR = standardized mortality ratio; HPLC = high performance liquid 
chromatography. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 Schematic representation of the Markov decision model. 
 
 
Normoalbuminuria 
Macroalbuminuria 
ESRD 
Death 
Microalbuminuria 
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Clinical strategies 
Three starting points for ACE inhibitors were considered.15,16 In the “screen for 
microalbuminuria” strategy patients are screened for microalbuminuria once 
a year and treatment is started if the test result is positive. In the “screen for 
macroalbuminuria” strategy patients are screened for macroalbuminuria once 
a year and treatment is also started if the test result is positive. In the “treat all” 
strategy no screening is performed at all and patients start on ACE inhibitor 
therapy at the time of diagnosing type 2 diabetes. The states of albuminuria 
were defined according to the recommendations of the American diabetes 
Association.11 In addition, we considered a no-screening and no-treatment 
alternative representing the status quo. In order to find information on the 
distribution of health states at the time of diagnosis we used the following 
search strategy in PubMed (1966-2007): (newly diagnosed[All Fields]) AND 
macroalbuminuria[All Fields] AND microalbuminuria[All Fields] AND 
prevalence[All Fields] AND (albumin excretion [All Fields]) NOT (type 1 diabetes 
[All Fields]). We found two studies. One study was excluded because it was 
conducted among Pima Indians. The other one is a Finnish prospective 
observational study22 which was conducted from 1982 to 1992. In this study, 
the distribution of health states at the time of diagnosis (average age: 58 
years) was as follows: 79% normoalbuminuria, 18% microalbuminuria, and 3% 
macroalbuminuria. We tested the impact of the distribution on results in a 
sensitivity analysis. 
Transition probabilities 
In order to identify studies on the effectiveness of ACE inhibitor or ARB 
therapy on the prevention of diabetic kidney disease we searched in the 
Cochrane Database of Systematic Reviews using the search strategy 
normoalbuminuria OR microalbuminuria OR macroalbuminuria. We found two 
meta-analyses proving evidence that ACE inhibitors halt the transition from 
normo- to microalbuminuria and micro- to macroalbuminuria.20,21 These meta-
analyses pooled studies on patients with type 1 and type 2 diabetes, as 
heterogeneity did not appear to be significant. Compared to placebo, ACE 
inhibitors significantly reduced the development of microalbuminuria (six 
trials, 3840 patients: relative risk (RR) 0.60, 95% confidence interval (CI) 0.43 to 
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0.84), and the progression from microalbuminuria to macroalbuminuria 
(17 trials, 2036 patients: RR 0.45, 95% CI 0.29 to 0.69). 
 
In order to identify studies on the effectiveness of ACE inhibitors or ARBs on 
the transition from macroalbuminuria to ESRD, we checked evidence-based 
clinical practice guidelines on the prevention of diabetic nephropathy.12,34,35 
We found one randomized clinical trial8 which was rated as a well-designed 
randomized controlled trial,12,35 providing high grade evidence. In this trial 
captopril significantly reduced the development of ESRD compared to 
placebo (409 patients, RR 0.61, 95% CI 0.50 to 0.75). 
 
All input parameters including transition probabilities and the effectiveness of 
ACE inhibitor therapy are shown in Table 5.1. To determine annual transition 
probabilities we first calculated a total probability for each arm, by dividing 
the number of events (ESRD) during the trial period by the number of 
patients. Next, we determined annual transition probabilities by assuming a 
constant annual hazard rate over the study time horizon.36 A constant hazard 
rate yields an exponential survival curve. 
 
In patients with normo-, micro-, and macroalbuminuria mortality is a function 
of age and was calculated by multiplying age-specific mortality rates of the 
general population with a standardized mortality ratio for patients with 
diabetes compared to the general population.31,37 For patients with normo-, 
micro-, and macroalbuminuria we assumed that mortality is stage-
independent as there are no valid data showing that a significant difference 
exists. For ESRD patients we calculated the annual mortality rate based on 87 
151 patients in Germany,1 by dividing the annual number of decedents by the 
total number of patients. 
Preference weights 
We took preference weights of diabetic patients (Table 5.1) from a published 
cross-sectional study.38 Adult diabetic patients (n=292) with a disease 
duration of at least one year and a mean age of 62 years (range 21–85) were 
interviewed by the time tradeoff (TTO) method. We assumed that patients 
with normo-, micro-, or macroalbuminuria do not suffer from an additional 
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reduction in health-related quality of life.23 The preference weight for ESRD 
was taken from a systematic review of empirical studies in which TTO weights 
were provided by patients.24 The TTO is the most commonly used method to 
elicit quality-of-life weights for QALYs.39,40 
Costs  
Given the perspective of the German SHI, only direct costs relevant to the SHI 
were considered. Furthermore, a portion of drug expenditures needs to be 
paid out of pocket. Costs were inflated to year 2006 Euros using data on the 
consumer price index.30 Costs of ACE inhibitors, ARBs, annual screening 
procedures, and treatment for ESRD as well as health care expenditures 
related and unrelated to diabetes were taken into account. For ACE inhibitor 
therapy we used a daily dose of 10 mg of the most frequently prescribed ACE 
inhibitor, which is ramipril.41 In particular, we used the cheapest generic 
version of ramipril.27 A daily dose of 10 mg is at the high end of the 
therapeutic range.42-44. In a sensitivity analysis we applied the reference price 
of ramipril. For ARBs we applied 300 mg irbesartan daily,27 which is more 
effective in renal protection than a dose of 150 mg.28 As irbesartan is not a 
generic drug and still protected by patent, patients have to pay €37.24 per 
year out of pocket.45 In addition, we included costs for biannual monitoring of 
serum creatinine and potassium levels due to ACE inhibitor or ARB therapy.29,3 
For microalbuminuria screening we preferred a quantitative screening test 
(high performance liquid chromatography) over a semi quantitative one (e.g., 
Micral-Test®)46 because it has a higher sensitivity (100%46) and specificity 
(81-98%32) and is also recommended by a recently published health 
technology assessment report.47 In the base-case analysis we assumed a 
specificity of 100%, which is conservative because treating false positives (i.e., 
patients with normoalbuminuria) leads to cost savings. In the sensitivity 
analysis we applied a specificity of 81%.32 To screen for macroalbuminuria we 
used a dipstick test applied in a primary care physician’s office.47 For patients 
without renal failure we included age-specific health care expenditures 
unrelated to diabetes48 as well as health care expenditures related to diabetes 
as an average across all ages.26 We validated the use of average-expenditure 
data against the use of age-specific expenditures data in patients diagnosed 
at the age of 60 years (these age-specific data were not available below the 
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age of 60 years). We also assessed whether explicitly modeling the costs of 
survivors and decedents (as opposed to using average-cost data) changes the 
cost-effectiveness of ACE inhibitors. This approach accounts for the fact that 
the high costs of those who die dominate age-specific costs. Hence, when the 
last year of life is postponed, average age-specific costs fall. Age-related 
expenditure data of diabetic patients were available from a large German 
statutory health insurer (unpublished data).  
 
Annual costs of patients with ESRD were calculated as a weighted average of 
the costs of patients with different types of dialysis as well as renal 
transplantation4 and include costs unrelated to dialysis and renal 
transplantation. In detail, the following calculations were made: 
 
1. cost of dialysis = β1x1 + β2x2 + β3x3 + β4x4 + β5x5 = X, where xn = annual cost 
of dialysis treatment n = 1,2,….,5, βn = prevalence weight of the dialysis 
treatment, and β1 + β2 + β3 + β4 + β5 = 1   
2. cost of ESRD = pX + (1 - p)Y, where Y = cost of renal transplantation and p 
= proportion of ESRDs treated by dialysis treatment. 
 
Prevalence data1,5 served as weights. Data on the cost of continuous 
ambulatory peritoneal dialysis and continuous cycling peritoneal dialysis were 
obtained from an empirical survey by Nebel.4 To determine the cost of 
home/in-center hemodialysis we used the German fee schedule “Uniform 
value scale”3 to calculate costs of the dialysis itself and the survey by Nebel4 to 
determine all other expenditures for dialysis patients. Health care 
expenditures related and unrelated to diabetes were both included. See Table 
5.2 for parameters used in the analysis. 
 
Costs and benefits were discounted at an annual rate of 3%.33 
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Table 5.2 Parameters used for calculating the cost of end-stage renal disease (see cost 
section under “Methods”). 
1 = home/center hemodialysis 
2 = dialysis on inpatient treatment 
3 = dialysis on partly inpatient treatment 
4 = continuous ambulatory peritoneal dialysis (CAPD) 
5 = continuous cycling peritoneal dialysis (CCPD) 
β1 =0.861 
β2 = 0.028 
β3 = 0.064 
β4 = 0.035 
β5 = 0.012 
x1 = €41 463 
x2 = €147 021 
x3 = €98 282 
x4 = €39 627 
x5 = €49 510 
p = 0.73 
X = €48 088 
Y = €19 958 
 
Sensitivity analysis 
To address uncertainty around mean incremental costs and effectiveness, we 
conducted univariate sensitivity analyses. Whenever possible, we ran the 
analysis using the upper and lower bound of the 95% CI of the mean. For the 
annual cost of ESRD we did not have information on the 95% CI and thus 
varied costs by 20% (see Table 5.1 for uncertainty ranges).  
 
In order to assess how a simultaneous change of several variables affects the 
incremental cost-effectiveness ratio (ICER), we performed a Monte Carlo 
simulation, a type of multivariate sensitivity analysis. This technique runs a 
large number of simulations (here: 1000) by repeatedly drawing samples from 
probability distributions of input variables. Thus, it provides a probability 
distribution for the output variables, i.e., incremental costs and effectiveness. 
Probabilities and relative risks were assumed to follow a beta distribution 
Beta(α, β) because they are restricted to take on values between 0 and 1. 
Because the distribution of health states at the time of diagnosis had more 
than 2 outcomes, we assumed a Dirichlet distribution Dirichlet(α1, α2, . . ., 
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αk).38 Cost data were assumed to follow a gamma distribution Gamma(a, b) 
because they are normally distributed but restricted to take on values 
between 0 and 1. The standard deviation of probabilities and relative risks was 
calculated according to the following formula49: 
 
n
p)-p(
=σ 1  
 
Given the ambiguous interpretation of negative ICERs, we transformed ICERs 
into net monetary benefits (NMBs). We generated a cost-effectiveness 
acceptability curve based on the distribution of NMBs for each value of the 
willingness to pay per QALY gained. A cost-effectiveness acceptability curve 
allows a decision maker to consider whether a prevention strategy is cost-
effective in relation to the maximum amount a decision-maker is willing to 
pay for a QALY. At each ceiling value for the willingness to pay for a QALY, the 
cost-effectiveness acceptability curve shows the probability that treatment is 
cost-effective. 
Results 
Base-case analysis 
The base-case analysis, which applies to 50-year-old patients, shows that “no 
screening and treatment”, „screening for macroalbuminuria”, and “screening 
for microalbuminuria” are all dominated by the “treat all” strategy, which is 
associated with the lowest costs and highest benefit (Table 5.3). Treating all 
patients with ACE inhibitors at the age of 60 years also leads to savings. 
Comparing the use of average-expenditure data with age-specific 
expenditure data and separate expenditure data for survivors and decedents 
yields little difference in cost savings compared to screening for 
microalbuminuria (-€1 852, -€1 875, and -€1 982, respectively). 
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Table 5.3 Results of the base-case analysis.  
Strategy Costs (€) Undiscounted 
LYs 
Discounted 
QALYs 
ICER (€/QALY) 
No screening and treatment 151 579 25.96 14.46 Dominated 
Screening for macroalbuminuria 144 059 26.64 14.83 Dominated 
Screening for microalbuminuria 137 406 27.19 15.14 Dominated 
Treating all patients with ACEIs/ARBs 135 555 27.32 15.21 dominant 
ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin II receptor blocker; LYs = 
life years; QALY = quality-adjusted life-years; ICER = incremental cost-effectiveness ratio. 
Sensitivity analysis 
In the univariate sensitivity analysis, variables with the largest impact on 
incremental costs and effectiveness are the discount rate, the absolute risk for 
progression from micro- to macroalbuminuria without ACE inhibition as well 
as the relative risk for progression from normo- to microalbuminuria with ACE 
inhibitor therapy (Table 5.4). When assuming a low progression rate from 
micro- to macroalbuminuria without ACE inhibition, screening for 
microalbuminuria dominates the treat-all strategy. A threshold sensitivity 
analysis shows that at an annual drug cost of €309.40 (base case: €75.72) the 
breakeven point is reached. 
 
Table 5.4 Univariate sensitivity analyses: effects of varying base-case estimates on the 
incremental cost-effectiveness ratio of treating all patients with ACE inhibitors vs 
screening for microalbuminuria (reference strategy). “Lower bound” and “higher 
bound” refer to the limits of the 95% confidence interval. 
 Incremental 
costs 
Incremental 
QALYs 
Incremental cost- 
effectiveness ratio 
Initial disease prevalence: Proportion of normoalbuminuric patients, % 
   Lower bound -€1852 0.08 Dominance 
   Higher bound -€2344 0.33 Dominance 
Annual transition probabilities (without ACE inhibitors) 
from normo- to microalbuminuria 
   Lower bound - €1044 0.05 Dominance 
   Higher bound - €2309 0.10 Dominance 
from micro- to macroalbuminuria 
   Lower bound    €1253 -0.02 Dominated 
   Higher bound - €3202 0.13 Dominance 
from macroalbuminuria to ESRD 
   Lower bound - €693 0.04 Dominance 
   Higher bound - €2522 0.10 Dominance 
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Table 5.4 (continued) 
 Incremental 
costs 
Incremental 
QALYs 
Incremental cost- 
effectiveness ratio 
Relative risk for progression with ACE inhibitors 
from normo- to microalbuminuria 
   Lower bound - €3149 0.11 Dominance 
   Higher bound - €300 0.03 Dominance 
from micro- to macroalbuminuria 
   Lower bound - €1186 0.05 Dominance 
   Higher bound - €2590 0.11 Dominance 
from macroalbuminuria to ESRD 
   Lower bound - €1516 0.06 Dominance 
   Higher bound - €2231 0.09 Dominance 
Utilities (health states) 
Diabetes (baseline health) 
   Lower bound - €1852 0.07 Dominance 
   Higher bound - €1852 0.08 Dominance 
ESRD 
   Lower bound - €1852 0.10 Dominance 
   Higher bound - €1852 0.05 Dominance 
Disutility of ACE inhibitor treatment 
   Lower bound - €1852 0.04 Dominance 
   Higher bound - €1852 0.08 Dominance 
Costs 
ACE inhibitor 
   Lower bound -€1852 0.08 Dominance 
   Higher bound -€1783 0.08 Dominance 
ESRD 
   Lower bound - € 1050 0.08 Dominance 
   Higher bound - € 2643 0.08 Dominance 
SMR 
   Lower bound - €1855 0.08 Dominance 
   Higher bound - €1848 0.08 Dominance 
Rate of ARB use 
   Lower bound - € 1862 0.08 Dominance 
   Higher bound - € 1847 0.08 Dominance 
Specificity of HPLC (microalbuminuria screening procedure)  
   81% - €1549 0.06 Dominance 
Discount rate of costs and effects 
   0% - €4543 0.17 Dominance 
   3% (base case) - €1852 0.08 Dominance 
   5% - €1035 0.05 Dominance 
   7% - €582 0.03 Dominance  
QALYs = quality-adjusted life years; ACE = angiotensin-converting enzyme; ESRD = end-stage 
renal disease; SMR = standardized mortality ratio; HPLC = high performance liquid 
chromatography. 
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Changing the distribution of health states at the time of diagnosis to all 
patients being normoalbuminuric yields little difference in cost savings 
(-€2 344 vs. -€1 852) and QALYs gained (0.10 vs. 0.08). 
 
Figure 5.2 shows the cost-effectiveness acceptability curve, which considers 
uncertainty in cost-effectiveness. The probability of savings of the “treat all” 
strategy compared to screening for microalbuminuria is 89% (see also Figure 
5.3 for the scatterplot). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2 Cost-effectiveness acceptability curve. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3 Cost-effectiveness plane showing 1000 replications from a distribution of cost and 
quality-adjusted life year (QALY) differences (angiotensin-converting enzyme 
inhibitor vs microalbuminuria screening). 
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Discussion 
This modeling study shows that treating all patients with type 2 diabetes with 
ACE inhibitors (and more expensive ARBs in the event of cough) immediately 
after diagnosis is cost-effective and even reduces health care expenditures. 
Our results were robust to a variety of different assumptions of uncertainty. 
Although a significant number of newly diagnosed type 2 patients may 
receive blood pressure medications, it has not been shown that these patients 
are primarily prescribed an ACE inhibitor, which underlines the significance of 
this analysis. 
 
Our model is far from being perfect, but in modeling studies this is rarely the 
case due to constraints of resources, time, and information availability. 
Savings by treating all diabetic patients with ACE inhibitors may be even 
underestimated for several reasons. First, we did not model that ACE 
inhibitors and ARBs reduce the risk for cardiovascular events42 which leads to 
additional savings. Second, we did not consider that some patients 
discontinue ACE inhibitor therapy and thus incur no drug costs. The reason is 
that information on compliance was unavailable from the trials on ACE 
inhibitors. On the other hand, the rate of compliance is incorporated in the 
effectiveness data (thus reducing effectiveness). Third, patients may also be 
sufficiently treated by a smaller dose of ramipril than in our analysis. We used 
a dose of 10 mg, which is at the high end of the therapeutic range in studies 
investigating the effect of ACE inhibitors on renal outcomes.42-44 Forth, for 
patients who receive dialysis on an inpatient basis (2% of all patients with 
renal replacement therapy) we were not able to consider health care costs 
unrelated to dialysis due to a lack of available data. This underestimates the 
savings from preventing ESRD. Fifth, costs of dialysis treatment will likely 
continue to rise in the future, thus increasing the potential for savings by 
preventing ESRD. In the last 10 years dialysis costs have increased by 
approximately 25 percent3,4,30,50 and we expect this trend to continue due to 
stricter regulations concerning dialysis safety, technological advancement of 
dialysis machines, and better-tolerated dialysis solutions. Alleviating this 
trend may be lower prices of erythropoietin and lower reimbursement of 
physicians. Finally, we calculated annual transition rates based on trial 
duration instead of follow-up time as data concerning follow-up time were 
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unavailable for most trials. As follow-up time is generally shorter than trial 
duration this might have underestimated transition probabilities as well as 
cost savings. 
 
Further limitations of the model relate to the data sources. First, when 
calculating the weighted average cost of treating ESRD we used prevalence 
data on intermittent and automated peritoneal dialysis (IPD/APD) to weigh 
the cost of continuous cycling peritoneal dialysis (CCPD). Second, the model 
uses some epidemiological data from Western countries other than Germany. 
For example, we used a Finnish study22 as the source of the distribution of 
health states at the time of diagnosis. However, changing the initial 
distribution of health states had little impact on the results. Third, transition 
rates from macroalbuminuria to ESRD with and without ACE inhibitors were 
not available for patients with type 2 diabetes. Therefore, we used a 
randomized controlled trial in patients with type 1 diabetes as the source.8 
Fourth, the standardized mortality ratio (SMR) we applied to diabetic patients 
without ESRD31 includes patients with ESRD. Excluding these patients would 
lower the SMR, but only to a minor degree, as less than 1% of the German 
diabetic population receives renal replacement therapy.1,51 Fifth, we assumed 
that the SMR is the same for patients with normo-, micro-, and 
macroalbuminuria as there are no valid data showing that a significant 
difference exists. The slightly higher mortality ratio in microalbuminuric 
patients in the HOPE study42 was most likely the result of prior cardiovascular 
events. There is no evidence in the literature that mortality rates increase only 
on the basis of the level of albumin in the urine. Sixth, having 
microalbuminuria or macroalbuminuria might cause disutility from anxiety. 
However, standard preference measures such as the SG or the TTO method 
are not able to capture anxiety over future events as both evaluation methods 
assume a constant (!) health state over the remaining period of life. Seventh, 
the definition of hypertension was not consistent in the studies we 
incorporated in our model. Cut-off values varied between 130/80 and 160/90 
mm Hg. Finally, it is unclear whether a societal perspective leads to larger or 
smaller savings than a SHI perspective: on the one hand, ACE inhibitors and 
ARBs avoid productivity loss and copayments due to renal failure. On the 
other hand, drug copayments lead to additional costs. 
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Compared to previous cost-effectiveness models, which were conducted by 
Golan et al.15 and Rosen et al.16 based on U. S. data, we considered a much 
broader evidence base for the transition between normo- to 
microalbuminuria and micro- to macroalbuminuria. In addition, we 
considered that patients who are noncompliant with ACE inhibitors due to 
cough may receive more expensive ARBs. We did not consider that a small 
proportion of patients on ARBs (3.2%) also develop cough10 and thus may 
discontinue treatment. The reason is that noncompliance with treatment is 
already incorporated in the relative risk of treatment (thus lowering the 
relative risk), as in RCTs a certain proportion of patients discontinued 
treatment. We assumed equal effectiveness of all ACE inhibitors and ARBs, as 
meta-analyses do not suggest any independent effect of single renin-
angiotensin-system agents.52,20 Still, similar to the model by Rosen et al.16, our 
model shows that treating all newly diagnosed type 2 patients with ACE 
inhibitors saves costs. In contrast to Rosen et al., we did not consider the 
preventive effect of ACE inhibitors on cardiovascular outcomes, which would 
have increased savings. An important reason for the large savings potential in 
Germany is the low price of ramipril, which has significantly gone down 
during the last few years.27,53 ARBs are still protected by patent for a few 
additional years. Irbesartan, which we included in our study, is protected until 
March 2012. Assuming that prices of ARBs will decline after expiration of the 
patent protection would further strengthen our conclusion. 
Policy Considerations 
We recommend that all patients with type 2 diabetes covered by the SHI 
receive an ACE inhibitor at the higher end of the therapeutic dose range 
immediately after diagnosis. In case of cough, patients should be prescribed 
an ARB. This is a major step from current practice, which is not to screen for 
microalbuminuria. Finally, the transferability of the conclusion of this study to 
other countries is limited given differences in costs, clinical management, and 
epidemiology (for example, with regard to the incidence of unrelated 
diseases).  
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Abstract 
Objective 
Type 2 diabetes is the main cause of end-stage renal disease (ESRD) in Europe and the 
USA. Angiotensin-converting enzyme (ACE) inhibitors have a potential to slow down 
the progression of renal disease and therefore provide a renal-protective effect. The 
aim of our study was to assess the most cost-effective time to start an ACE inhibitor 
(or an angiotensin II receptor blocker (ARB) if coughing as a side effect occurs) in 
patients with newly diagnosed type 2 diabetes in the Netherlands. 
 
Methods 
A lifetime Markov decision model with simulated 50-year-old patients with newly 
diagnosed diabetes mellitus was developed using published data on costs and health 
outcomes and simulating the progression of renal disease. A health insurance 
perspective was adopted.  
Three strategies were compared: treating all patients at the time of diagnosing type 2 
diabetes, screening for microalbuminuria, and screening for macroalbuminuria. 
 
Results 
In the base-case analysis, the treat-all strategy is associated with the lowest costs and 
highest benefit and therefore dominates screening both for macroalbuminuria and 
microalbuminuria. A multivariate sensitivity analysis shows that the probability of 
savings is 70%. 
 
Conclusion 
In the Netherlands for patients with type 2 diabetes prescription of an ACE inhibitor 
immediately after diagnosis should be considered if they do not have 
contraindications An ARB should be considered for those patients developing a dry 
cough under ACE inhibitor therapy. The potential for cost savings would be even 
larger if the prevention of cardiovascular events were considered. 
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Introduction 
The prevalence of type 2 diabetes and its secondary complications will rise1-3 
due to ageing population and growing obesity. This type of diabetes 
represents the most common form of carbohydrate disorders affecting at 
least 5% of the population in the industrialized world.4 As a result higher costs 
for diabetes treatment in general and especially treatment of secondary 
complications will be a huge burden for health care systems. Type 2 diabetes 
is the main cause of end-stage renal disease (ESRD) in the Netherlands5 as well 
as in other European countries and the United States.6-7 Diabetic nephropathy 
leads to a gradual decline of the renal function and is initially characterized by 
micro- or macroalbuminuria. Diabetic nephropathy may progress to ESRD, 
which is defined by the need for either long-term dialysis or renal 
transplantation.8 The prevalence of patients in renal replacement therapy in 
the Netherlands doubled within the last 15 years.9 In 2010, about 15 000 
patients underwent renal-replacement therapy. In the last five years, the 
proportion of transplanted patients has been continuously increasing and 
represents about 57% of all patients requiring renal replacement therapy.9 
The costs of ESRD treatment are rather high, with a share of the national 
expenditures in European countries ranging from 0.7% in the UK to 1.8% in 
Belgium,10,11 with a share in the Netherlands of about 1.3%. In the Netherlands, 
the costs of ESRD treatment amount to €42 000 per patient per year.10,12,13 
Hence, prevention of ESRD is not only important from a medical, but also from 
an economic viewpoint. 
Angiotensin converting enzyme (ACE) inhibitors slow down the progression 
of diabetic nephropathy independent of an elevated blood pressure.14,15 
Angiotensin receptor blockers (ARBs) have similar effects on renal outcomes 
in diabetic patients16 but are more expensive, mostly due to patent 
protection. Evidence suggests that the only major clinical difference between 
these classes of drugs is a higher risk of dry cough associated with ACE 
inhibitors.17 
Several national and international clinical practice guidelines recommend 
starting ACE inhibitor therapy in diabetic patients with (micro)albuminuria.18-20 
However, physician compliance in the Netherlands as well as in many other 
European countries is rather low.21 Cost-effectiveness models conducted in 
the United States by Golan et al. (1999),22 Rosen et al. (2005)23 and in Germany 
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by Adarkwah et al. (2010)24 suggest that the best starting point for ACE 
inhibitor therapy is immediately after diagnosis of diabetes. For the 
Netherlands no data are available on the cost-effectiveness of ACE inhibitor 
therapy in diabetic patients with (micro)albuminuria. However, results of the 
non-Dutch studies may not be transferable to the Netherlands. Transferability 
of economic evaluation studies between countries is hindered by a number of 
factors such as demography, the epidemiology of the disease, availability of 
health care resources and differences in reimbursement systems between 
countries, in particularly due to variances in absolute and relative costs/prices.  
The goal of this study is to present a cost-effectiveness model, which 
determines the best time to start an ACE inhibitor in newly diagnosed 
patients with type 2 diabetes and without hypertension or heart failure in the 
Netherlands. The analysis is conducted from a health care perspective in order 
to increase comparability to other models on this topic.22-24 In our model we 
included ARBs as an alternative for patients who experience ACE-inhibitor-
induced cough. In the base case the age of 50 years was assumed as the mean 
age of diagnosing type 2 diabetes.25,26 
Methods 
Overview and model design 
Is it cost-effective to treat all newly diagnosed type 2 diabetic patients in the 
Netherlands with an ACE inhibitor to prevent renal disease? We conducted a 
cost-utility analysis and measured health outcomes in terms of quality-
adjusted life years (QALYs). We adapted a Markov decision model previously 
developed for the German setting24 and also proven applicable for non-
diabetic advanced renal disease27 in order to simulate the course of a cohort 
of 1 000 patients at the age of 50 years as it progresses to microalbuminuria, 
macroalbuminuria, ESRD, and death. A Markov model is an iterative process 
where patients are assumed to stay in one cycle (i.e., a defined health state) 
for a certain time and then make a transition to another cycle. Markov models 
are useful when a decision problem involves risk that is continuous over time, 
when the timing of events is important, and when important events may 
happen more than once. The model was built in Microsoft Excel® 2007. We 
chose a cycle length of one year for the health states defined by the Markov 
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model because all transition probabilities gathered from the literature 
referred to a duration of at least one year. All input data included in the model 
can be found in Table 6.1. Our Markov model contains the following five 
health states (Figure 6.1), which represent the occurrence of events after 
model entry: 
1. type 2 diabetes, with normoalbuminuria (excretion <30 mg/d) 
2. type 2 diabetes, with microalbuminuria (excretion 30-300 mg/d) 
3. type 2 diabetes, with macroalbuminuria (excretion >300 mg/d) 
4. ESRD (treated with dialysis or renal transplantation)  
5. Death  
 
We assumed that diabetic nephropathy progresses without skipping any 
stage. Further, patients may die at any time (stage 5). The states of 
albuminuria were defined according to the recommendations of the 
American diabetes Association.20 During each cycle, patients accumulate 
utility (measured by QALYs) and costs. A half-cycle correction will be applied 
to both costs and outcomes to allow for transition events occurring mid-way 
through each 12-month cycle.  
The simulation was done until the age of 99. Hence, the time horizon is 50 
years. The age of 99 was chosen as a cutting point as there are no mortality 
data available beyond this age. Regardless, more than 99% of patients in the 
simulation are dead at this age. 
 
Table 6.1 Data used to determine the cost-effectiveness of ACE inhibitors and ARBs in newly diagnosed 
type 2 diabetes. 
Variable Base-case 
estimate 
Range tested* Reference 
Initial disease prevalence, % 
   Normoalbuminuria 79 66.5 – 100 
   Microalbuminuria 18       0 – 27.6 
   Macroalbuminuria   3     0 – 5.9 
[28] 
Annual transition probabilities (without ACE inhibitors) 
   Normoalbuminuria to microalbuminuria 0.056   0.03 – 0.08 [29] 
   Microalbuminuria to macroalbuminuria 0.094 -0.02 – 0.20 [30] 
   Macroalbuminuria to ESRD 0.056 0.025 – 0.08 [15] 
   Normo-/micro-/macro-albuminuria to  
   death 
Age-
dependent 
--- [35] 
   ESRD to death 0.09 --- [9] 
Relative risk for progression with ACE inhibitors 
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Table 6.1 (continued) 
Variable Base-case 
estimate 
Range tested* Reference 
   Normoalbuminuria to microalbuminuria 0.60 0.43 – 0.84 [29] 
   Microalbuminuria to macroalbuminuria 0.45 0.29 – 0.69 [30] 
   Macroalbuminuria to ESRD 0.61 0.50 – 0.75 [15] 
Utilities (health states) 
   Diabetes (baseline health) 0.88 0.86 – 0.90 [38] 
   ESRD 0.62 0.39 – 0.84 [39] 
   ACE inhibitor / ARB treatment 1.00 0.95 – 1.00 [63] 
Annual costs, € 
   General health care expenditures 3.310,23 - 
23.626,23 
(age-
dependent) 
--- [43,44,55] 
   Per-patient cost of diabetes compared to 
   non-diabetic population  
547 --- [43,44,55] applied to all health 
states except for ESRD 
   ACE inhibitor (20mg enalapril daily) 6.96 --- [46] applied to all health 
states except for ESRD 
   ARB (300mg irbesartan daily) 298.68 --- [46,47] applied to all health 
states except for ESRD 
   Mixed drug therapy costs (9.9% treated  
   with ARBs) 
62.70 62.70 – 83.78 [46] applied to all health 
states except for ESRD 
   Screening for microalbuminuria 7.00 --- [58,59] applied to patients 
with normoalbuminuria only 
   Screening for macroalbuminuria 1.12 --- [58,59] applied to patients 
with microalbuminuria only 
   ESRD 42 110 33 688 – 50 532
   Transplantation 14 387 --- 
      Dialysis 79 112 --- 
 
[9,13] 
 
           Home/in-center hemodialysis 83 217 --- 
           Continuous ambulatory peritoneal  
           dialysis 
54 067 --- 
          Continuous cycling peritoneal dialysis 69 546 --- 
 
 
[9,13] 
   SMR 1.41 1.39 – 1.43 [1] 
   Rate of ARB use, % 9.9 9.6 – 10.2 [17] 
   Specificity of HPLC (microalbuminuria  
   screening procedure) 
1.00 0.81 – 1.00 [53] 
   Discount rate of costs 0.04 0.00 – 0.10 [44,54,55];  
   Discount rate of benefits 0.015 0.00 – 0.10 [44,54,55];  
ACE = angiotensin-converting enzyme; ARB = angiotensin II receptor blocker; ESRD = end-stage renal 
disease; HPLC = high performance liquid chromatography; SMR = standardized mortality ratio 
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Figure 6.1 Schematic representation of the Markov decision model. 
 
Clinical strategies 
Three starting points for ACE inhibitors were considered.3,22 In the “screen for 
microalbuminuria” strategy patients are screened for microalbuminuria once 
a year and treatment is started if the test result is positive. In the “screen for 
macroalbuminuria” strategy patients are screened for macroalbuminuria once 
a year and treatment is also started if the test result is positive. In the “treat all” 
strategy no screening is performed at all and patients start on ACE inhibitor 
therapy at the time of diagnosing type 2 diabetes. In addition, the analysis 
performed included the ARB option for the entire patient population in all 
three strategies reflecting a more expensive treatment. To find information on 
the distribution of health states at the time of diagnosis, we used the 
following search strategy in the PubMed database (date: February 08, 2011): 
(newly diagnosed[All Fields]) AND macroalbuminuria[All Fields] AND 
microalbuminuria[All Fields] AND prevalence[All Fields] AND (albumin excretion 
[All Fields]) NOT (type 1 diabetes [All Fields]). We obtained 2 hits. Thereof one 
study was excluded because it was conducted among Pima Indians. The other 
one is a Finnish prospective observational study,28 which was conducted from 
1982 to 1992. In this study, the distribution of health states at the time of 
diagnosis (average age: 58 years) was as follows: 79% normoalbuminuria, 18% 
microalbuminuria, and 3% macroalbuminuria. We tested the impact of the 
initial distribution on results in a sensitivity analysis. 
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Transition probabilities 
In order to identify studies on the effectiveness of ACE inhibitor or ARB 
therapy on the prevention of diabetic kidney disease we searched in the 
Cochrane Database of Systematic Reviews using the search strategy 
normoalbuminuria OR microalbuminuria OR macroalbuminuria. We found two 
meta-analyses proving evidence that ACE inhibitors halt the transition from 
normo- to microalbuminuria and micro- to macroalbuminuria.29,30 These meta-
analyses pooled studies on patients with type 1 and type 2 diabetes, as 
heterogeneity did not appear to an issue. Compared to placebo, ACE 
inhibitors significantly reduced the development of microalbuminuria (six 
trials, 3 840 patients: relative risk (RR) 0.60, 95% confidence interval (CI) 0.43 to 
0.84), and the progression from microalbuminuria to macroalbuminuria (17 
trials, 2 036 patients: RR 0.45, 95% CI 0.29 to 0.69). 
In order to identify studies on the effectiveness of ACE inhibitors or ARBs on 
the transition from macroalbuminuria to ESRD, evidence-based clinical 
practice guidelines were checked on the prevention of diabetic 
nephropathy.19,31-33 One randomized clinical trial15 was identified that was 
rated as well-designed randomized controlled trial (RCT)19,33 providing high-
grade evidence. In this trial captopril significantly reduced the development 
of ESRD compared to placebo (409 patients, RR 0.61, 95% CI 0.50 to 0.75). 
To determine annual transition probabilities we first calculated a total 
probability for each arm, by dividing the number of events (ESRD) during the 
trial period by the number of patients. Next, we determined annual transition 
probabilities by assuming a constant annual hazard rate over the study time 
horizon.34 A constant hazard rate yields an exponential survival curve. 
In patients with normo-, micro-, and macroalbuminuria mortality is a function 
of age and was calculated by multiplying age-specific mortality rates of the 
Dutch general population35 with a standardized mortality ratio for patients 
with diabetes compared to the general population.1,36 For patients with 
normo-, micro-, and macroalbuminuria we assumed that mortality is stage-
independent as there are no valid data showing that a significant difference 
exists. For patients with ESRD, we calculated the annual mortality rate based 
on 13 905 patients in the Netherlands,9 by dividing the annual number of 
decedents by the total number of patients. While the annual number of 
decedents treated with dialysis could be derived from the website, the 
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number of decedents with a transplant was obtained by personal 
communication (A. Hemke, Dutch End-Stage Renal Disease Registry, March 
17, 2011).  
Preference weights 
We included preference weights of diabetic patients (Table 6.1) from a 
published cross-sectional study.37 Adult diabetic patients (n=292) with a 
disease duration of at least one year and a mean age of 62 years (range 21-85) 
were interviewed by the time trade-off (TTO) method. We assumed that 
patients with normo-, micro-, or macroalbuminuria do not suffer from an 
additional reduction in health-related quality of life.38 There is no convincing 
evidence in the literature that confirms a utility decrease merely due to 
albuminuria. The preference weight for ESRD was taken from a systematic 
review of empirical studies in which TTO weights were provided by patients.39 
The TTO is the most commonly used method to elicit quality-of-life weights 
for QALYs.40,41 The TTO technique determines the proportion of remaining life 
years in poor health patients are willing to give up or trade in exchange for 
perfect health. Based on patient responses utility scores are calculated. Utility 
measures in economic evaluations are becoming increasingly important 
given the fact that decision makers are asked to optimize the allocation of 
scarce health care resources across disease areas and patient groups.42 Values 
are similar to EQ-5D scores (baseline value 0.61) reported by de Wit et al. 
(1998).13 
Costs  
As stated, the analysis is conducted from the health care perspective. Hence, 
only direct costs and direct health effects – defined as life years gained – were 
considered. Costs were inflated to year 2010 euros using data on the 
consumer price index.43 Costs of ACE inhibitors, ARBs, annual screening 
procedures, and treatment for ESRD as well as health care expenditures 
related and unrelated to diabetes were taken into account. The 
recommendations of the Dutch guidelines for pharmacoeconomic research 
were followed.44 For ACE inhibitor therapy the most frequently prescribed ACE 
inhibitor in the Netherlands, enalapril,45 was taken into consideration. In the 
base case, the cheapest generic of enalapril 10 mg daily was used, whereas 
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the most expensive one was applied in the sensitivity analysis [46]. For ARBs 
we considered a dose of 300 mg irbesartan daily,46 which is more effective in 
renal protection than a dose of 150 mg.47 The costs of enalapril and irbesartan 
treatment were based on 2011 Dutch prices and include 6% value-added tax 
as well as a 3-monthly pharmacists’ prescription fee of €7.50.48 As 
recommended by a published health technology assessment (HTA) report49 
and a national clinical chemistry report,50 a quantitative screening test for 
microalbuminuria (high performance liquid chromatography or 
immunoturbidimetrie) was preferred over a semi quantitative one (e.g., 
Micral-Test®),51,52 because it demonstrates higher sensitivity (100%)52 and 
specificity (81-98%).53 Bakker et al.51 clearly state that a simple dipstick test is 
not sufficient to detect microalbuminuria at an early stage. In the base-case 
analysis we assumed a specificity of 100% which is conservative because 
treating false positives (i.e., patients with normoalbuminuria) leads to cost 
savings. In the sensitivity analysis we applied a specificity of 81%. To screen 
for macroalbuminuria we used a dipstick test applied in a general 
practitioner’s office recommended by the Dutch Kidney Check Campaign.31,49 
The annual costs of patients with ESRD were calculated as a weighted average 
of the costs of different types of dialysis as well as renal transplantation based 
on a Dutch study13 and prevalence data available from the national register.9  
 
In detail, the following calculations were made (see Table 6.2 in the appendix 
for details): 
 
1. cost of dialysis = β1x1 + β2x2 + β3x3 = X, where xn = annual cost of dialysis 
treatment n=1,2,3; βn = prevalence weight of the dialysis treatment, and β1 
+ β2 + β3 = 1   
2. cost of ESRD = pX + (1-p)Y, where Y = cost of renal transplantation and p = 
proportion of ESRD treated by dialysis treatment. 
 
A transplant survival of 10 years was assumed and a distinction made 
between the first year of transplantation and the years following. Costs were 
inflated to 2010 Dutch prices. 
Health care expenditures related and unrelated to diabetes were both 
included. Costs were discounted at an annual rate of 4% whereas benefits 
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were discounted at an annual rate of 1.5% in accordance with the CVZ 
recommendations.44,54,55 
 
Table 6.2 Parameters used for calculating the cost of end-stage renal 
disease (see cost section under “Methods”). 
variable meaning 
1 home/center hemodialysis 
2 continuous ambulatory peritoneal dialysis (CAPD) 
3 continuous cycling peritoneal dialysis (CCPD 
β1 0.82 
β2 0.106 
β3 0.074 
x1 € 83 217 
x2 € 54 067 
x3 € 69 546 
p 0.43 
X € 79 112 
Y € 14 387 
 
Sensitivity analyses 
To address uncertainty around mean incremental costs and effectiveness, 
univariate sensitivity analyses were conducted. Whenever possible, we run 
the analysis using the upper and lower bound of the 95% CI of the mean.  
In order to assess how a simultaneous change of several variables affects the 
incremental cost-effectiveness ratio (ICER), we performed a Monte Carlo 
simulation, a type of multivariate sensitivity analysis. This technique runs a 
large number of simulations (here: 1 000) by repeatedly drawing samples 
from probability distributions of input variables. Thus, it provides a probability 
distribution for the output variables, i.e., incremental costs and effectiveness. 
Probabilities and relative risks were assumed to follow a beta distribution 
Beta(α, β) because they are restricted to take on values between 0 and 1. 
Because the distribution of health states at the time of diagnosis had more 
than 2 outcomes, we assumed a Dirichlet distribution Dirichlet (α1, α2, . . ., 
αk).37 Cost data were assumed to follow a gamma distribution Gamma(a, b) 
because they are normally distributed but restricted to take on values 
between 0 and 1. The standard deviation of probabilities and relative risks was 
calculated according to the following formula56: 
Chapter 6 
126 
 
n
p)-p(
=σ 1  
Given the ambiguous interpretation of negative ICERs, we transformed ICERs 
into net monetary benefits (NMBs). We generated a cost-effectiveness 
acceptability curve based on the distribution of NMBs for each value of the 
willingness to pay per QALY gained. A cost-effectiveness acceptability curve 
allows a decision maker to consider whether a prevention strategy is cost-
effective in relation to the maximum amount a decision-maker is willing to 
pay for a QALY. At each ceiling value for the willingness to pay for a QALY, the 
cost-effectiveness acceptability curve shows the probability that treatment is 
cost-effective. The input data for the model are summarized in Table 6.1. 
Results 
Base-case analysis 
The base-case analysis, which applies to 50-year-old patients, shows that “no 
screening and treatment”, “screening for macroalbuminuria”, and “screening 
for micro-albuminuria” are all dominated by the “treat all” strategy, which is 
associated with the lowest costs and highest benefit (Table 6.3). Again, the 
“treat all” strategy implies that all patients are treated with an ACE inhibitor 
(or an ARB in the event of cough).  
 
Table 6.3 Results of the base-case analysis, based on mean estimates of input variables. 
Strategy Costs (€) Undiscounted LYs Discounted QALYs ICER (€/QALY) 
Screening for macroalbuminuria 110 777 28.52 19.15 Dominated 
Screening for microalbuminuria 101 140 28.88 19.54 dominated 
Treating all patients with ACEIs/ARBs 98 421 28.94 19.63 dominant 
ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin II receptor blocker; LYs = life years; 
QALY = quality-adjusted life-years; ICER = incremental cost-effectiveness ratio 
Sensitivity analysis 
In the univariate sensitivity analysis, variables with the largest impact on 
incremental costs and effectiveness are the absolute risk for progression from 
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micro- to macroalbuminuria without ACE inhibition as well as the relative risk 
for progression from normo- to microalbuminuria with ACE inhibitor therapy 
and the discount rate (see Table 6.4 for details). When assuming a low 
progression rate from micro- to macroalbuminuria without ACE inhibition, 
screening for microalbuminuria dominates the “treat all” strategy. A threshold 
sensitivity analysis shows that at an annual drug cost of €426.70 (base case: 
€62.70) the breakeven point is reached. The probability of savings is 70%. 
 
Table 6.4 Univariate sensitivity analyses: effects of varying base-case estimates on the incremental cost-
effectiveness ratio of treating all patients with ACE inhibitors vs screening for 
microalbuminuria (reference strategy). “Lower bound” and “higher bound” refer to the limits 
of the 95% confidence interval. 
 Incremental costs Incremental 
QALYs 
Incremental cost- 
effectiveness ratio 
Initial disease prevalence: Proportion of normoalbuminuric patients, % 
   Lower bound - 2 289 0.080 - 28 647 
   Higher bound - 3 442 0.120 - 28 647 
Annual transition probabilities (without ACE inhibitors) 
from normo- to microalbuminuria 
   Lower bound -1 712 0.062 - 27 659 
   Higher bound - 3 348 0.123 - 27 214 
from micro- to macroalbuminuria 
   Lower bound 1 238 -0.22 - 57 155 
   Higher bound - 4 604 0.166 - 27 736 
from macroalbuminuria to ESRD 
   Lower bound - 1 202 0.047 - 25 823 
   Higher bound - 3 625 0.126 - 28 661 
Relative risk for progression with ACE inhibitors 
from normo- to microalbuminuria 
   Lower bound - 4 352 0.141 - 30 831 
   Higher bound - 734 0.036 - 20 510 
from micro- to macroalbuminuria 
   Lower bound - 1 836 0.066 - 27 921 
   Higher bound -  3 730 0.131 -28 403 
from macroalbuminuria to ESRD 
   Lower bound - 2 274 0.080 -28 358 
   Higher bound - 3 229 0.112 - 28 727 
Utilities (health states) 
Diabetes (baseline health) 
   Lower bound - 2 719 0.090 - 30 264 
   Higher bound - 2 719 0.100 - 27 194 
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Table 6.4 (continued) 
 Incremental costs Incremental 
QALYs 
Incremental cost- 
effectiveness ratio 
ESRD 
   Lower bound - 2 719 0.142 - 19 081 
   Higher bound - 2 719 0.049 - 55 041 
Disutility of ACE inhibitor treatment 
   Lower bound - 2 719 0.092 - 29 554 
   Higher bound - 2 719 0.095 - 28 647 
Costs 
ACE inhibitor 
   Lower bound - 2 719 0.095 - 28 647 
   Higher bound - 2 569 0.095 -27 062 
ESRD 
   Lower bound - 1 858 0.095 - 19 581 
   Higher bound - 3 579 0.095 - 37 713 
SMR 
   Lower bound - 2 723 0.096 - 28 249 
   Higher bound - 2 715 0.093 - 29 046 
Rate of ARB use 
   Lower bound - 2 419 0.095 - 25 463 
   Higher bound - 2 854 0.095 - 30 042 
Specificity of HPLC (microalbuminuria screening procedure) 
   81% -  1 853 0.039 - 47 513 
Discount rate of costs 
   0% - 9 179 0.095 - 96 710 
   1.5% - 5 708 0.095 - 60 140 
   4% - 2 719 0.095 - 28 647 
   7% - 1 189 0.095 - 12 523 
   10% - 537 0.095 - 5 655 
Discount rate of effects 
   0% - 2 719 0.139 - 19 592 
   1,5% - 2 719 0.095 - 28 647 
   4% - 2 719 0.051 - 52 850 
   7% - 2 719 0.026 - 105 670 
   10% - 2 719 0.014 - 200 909 
QALYs = quality-adjusted life years; ACE = angiotensin-converting enzyme; ESRD = end-stage renal disease; 
SMR = standardized mortality ratio; HPLC = high performance liquid chromatography 
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Figure 6.2 shows the cost-effectiveness acceptability curve, which considers 
uncertainty in cost-effectiveness. The probability of savings of the “treat all” 
strategy compared to screening for microalbuminuria is 70% (see also Figure 
6.3 for the scatterplot). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2 Cost-effectiveness acceptability curve. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3 Cost-effectiveness plane showing 1000 replications from a distribution of cost and quality-
adjusted life year (QALY) differences (angiotensin converting enzyme inhibitor vs 
microalbuminuria screening). 
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Discussion 
This modeling study shows that treating all patients with type 2 diabetes with 
ACE inhibitors (and more expensive ARBs in the event of cough) immediately 
after diagnosis is cost-effective and even reduces health care expenditures in 
the Dutch setting. The results were robust to a variety of different 
assumptions of uncertainty.  
Although a significant number of newly diagnosed type 2 patients may 
receive blood pressure medications, there is no evidence to date that these 
patients are primarily prescribed an ACE inhibitor, which underlines the 
significance of this analysis. Still, our model is far from being perfect, but in 
modeling studies this is rarely the case due to constraints of resources, time, 
and information availability.  
In the present study, savings by treating all diabetic patients with ACE 
inhibitors may even be underestimated for several reasons. First, we did not 
model that ACE inhibitors and ARBs reduce the risk for cardiovascular 
events,57 which would lead to additional savings. Second, Second, we did not 
consider real-world compliance with ACE inhibitor therapy due to a lack of 
data. In the real world some patients discontinue ACE inhibitor therapy and 
thus do not incur any drug cost. On the other hand, the model considered 
trial-based compliance on the effect side, as the rate of compliance is 
implicitly incorporated in clinical trial results, i.e. efficacy data refer both to 
adherers and non-adherers. For this reason the Markov model includes 
patients who discontinue ACE inhibitor treatment in the ACE inhibitor arm. 
Third, the screening costs considered for microalbuminuria screening are 
based on one annual test only. In contrast, considering recommended 
screening procedures from the PREVEND IT study58,59 as a basis would lead to 
a fundamental increase of screening costs as a spot-urine sample (either the 
first-morning void or at the time of the visit to the medical office) was used as 
a pre-screening. Patients whose urine is tested positive should have their 24-h 
urine samples tested repeatedly afterwards.60 
Forth, as this study is based on a cohort simulation it uses data on the 
population mean. In contrast, a patient-level simulation would account for the 
fact that some individuals may stay in more than 2 stages in a year, although 
this is rarely the case. In any case, if patients progressed more rapidly (had 
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higher risk), then ACE inhibitor treatment could lead to an even larger 
absolute risk reduction and therefore larger savings. 
Finally, costs of dialysis treatment will likely continue to rise in the future, thus 
increasing the potential for savings by preventing ESRD. Dialysis costs have 
increased within the last years12 and we expect this trend to continue due to 
stricter regulations concerning dialysis safety, technological advancement of 
dialysis machines, and better-tolerated dialysis solutions. Further limitations 
of the model relate to the data sources.  
First, the model uses some epidemiological data from Western countries 
other than the Netherlands. For example, we used a Finnish study28 as the 
source of the distribution of health states at the time of diagnosis. However, 
changing the initial distribution of health states had little impact on the 
outcome.  
Second, transition rates from macroalbuminuria to ESRD with and without 
ACE inhibitors were not available for patients with type 2 diabetes. Therefore, 
we used a randomized controlled trial in patients with type 1 diabetes as the 
source.15 
Third, the standardized mortality ratio (SMR) we applied to diabetic patients 
without ESRD1 includes patients with ESRD. Excluding these patients would 
lower the SMR to a minor degree as less than 2% of the Dutch diabetic 
population receives renal replacement therapy.35 
Forth, we assumed that the SMR is the same for patients with normo-, micro-, 
and macroalbuminuria as there are no valid data showing that a significant 
difference exists. The slightly higher mortality ratio in microalbuminuric 
patients in the HOPE study (2000)57 was most likely the result of prior 
cardiovascular events. There is no evidence in the literature that mortality 
rates increase only on the basis of the level of albumin in the urine. This is the 
same with the utilities, which are assumed to do not differ between different 
stages of albuminuria. 
Fifth, having microalbuminuria or macroalbuminuria might cause disutility 
due to anxiety. However, standard preference measures such as the SG or the 
TTO method are not able to capture anxiety over future events as both 
evaluation methods assume a constant health state over the remaining 
period of life.  
Finally, it is unclear whether a societal perspective leads to larger or smaller 
savings than a health insurance perspective: on the one hand, ACE inhibitors 
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and ARBs avoid productivity loss and copayments due to renal failure. On the 
other hand, drug copayments lead to additional costs. 
Compared to previous cost-effectiveness models, which were conducted by 
Golan et al. (1999)22 and Rosen et al. (2005)23 based on U. S. data, a much 
broader evidence base for the transition between normo- to 
microalbuminuria and micro- to macroalbuminuria was included in the 
present study. In addition, we considered that patients who are noncompliant 
with ACE inhibitors due to cough may receive more expensive ARBs, as 
similarly done for the German setting.24 The fact that a small proportion of 
patients on ARBs (3.2%) also develop cough17 and thus may discontinue 
treatment was disregarded. The reason for the exclusion is that 
noncompliance with treatment is already incorporated in the relative risk of 
treatment (thus lowering the relative risk), as in RCTs a certain proportion of 
patients discontinued treatment. In contrast to the previous models 
mentioned above we additionally conducted the analysis including an ARB 
for the entire patient population in need of treatment. This was done as some 
studies question that ARBs are not only a more expensive, but also a more 
effective alternative compared to ACE inhibitors. As the breakeven point is 
higher than the annual treatment costs of the ARB therapy this strategy must 
be considered cost-effective. However, we assumed equal effectiveness of all 
ACE inhibitors and ARBs, as meta-analyses do not suggest any independent 
effect of single renin-angiotensin-system agents.30,61 For instance, an ARB as 
an equivalent but more expensive alternative should only be prescribed in 
case of a contraindication (e.g. dry cough associated with ACE inhibitor 
treatment). 
Still, similar to Adarkwah et al. (2010)24 our model shows that treating all 
newly diagnosed type 2 patients with ACE inhibitors saves costs. The 
probability of savings is higher in Germany than in the Netherlands (89% vs. 
70%). Reasons for this difference are not obvious as, e.g. costs of screening, 
ACE inhibitor treatment, and ESRD are quite similar. In contrast to Rosen et al. 
(2005),23 we did not consider the preventive effect of ACE inhibitors on 
cardiovascular outcomes, which would have increased savings. An important 
reason for the large savings potential in the Netherlands is the low price of 
enalapril, which has substantially decreased during the last few years.46,62 The 
most ARBs are still protected by patent. Irbesartan, which we included in our 
study, is protected until March 2012. Assuming that prices of ARBs will decline 
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after expiration of the patent protection would further strengthen our 
conclusion. 
Conclusion and policy considerations 
For patients with diabetic kidney disease treatment with an ACE inhibitor is 
highly cost-effective. Current national guidelines which do not even 
consistently recommend an ACE inhibitor for patients with microalbuminuria 
need to be reconsidered. Still, it is unclear whether a societal perspective 
leads to smaller or larger savings than a health care perspective. For instance, 
ACE inhibitor treatment avoids productivity loss due to renal failure and 
copayments for the treatment of renal failure. But drug copayments lead to 
additional costs.  
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Abstract 
Background 
Treating non-diabetic proteinuric patients with advanced renal disease with an angiotensin-
converting enzyme (ACE) inhibitor is still subject to discussion. This study aims to determine 
the cost-effectiveness of ACE inhibitor therapy in this patient population in the Netherlands.  
 
Methods 
We compared two strategies: first, treating patients with advanced renal disease with an ACE 
inhibitor and no-treatment. A lifetime Markov decision model was developed simulating the 
progression of renal disease and using published data on costs and health outcomes. A health 
care perspective was adopted.  
 
Results  
In the base-case analysis, treatment with ACE inhibitors leads to higher benefits and lower costs 
and dominates the no-treatment strategy. Sensitivity analysis shows that the probability of 
savings is 83%. 
 
Conclusion 
ACE inhibitor treatment for non-diabetic patients with advanced renal disease in the 
Netherlands is highly cost-effective and should therefore be considered. 
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Introduction 
End stage renal disease (ESRD) can be defined by the need for renal 
transplantation or long-term dialysis.1 It is a final outcome of advanced renal 
disease, which is defined as a serum creatinine ≥3.0 mg per deciliter. An 
increasing prevalence of patients in renal replacement therapy in the 
Netherlands is notable within the last 15 years2 as it almost doubled within 
this period. Currently, more than 15 000 patients require renal-replacement 
therapy (RRT) and it is remarkable that the proportion of transplanted patients 
has been continuously increasing and now represents almost 60% of all 
patients requiring RRT.2  
 
ESRD costs represent a significant burden for the health care system, with a 
proportion of the national expenditures in European countries ranging from 
0.7% in the UK to 1.8% in Belgium,3,4, and with a proportion in the Netherlands 
of about 1.3%. To state that prevention of ESRD is important from a medical 
perspective, it becomes clear that this also accounts for an economic 
viewpoint as the costs of ESRD treatment amount to €42 000 per patient per 
year in the Netherlands.3,5,6 
 
Angiotensin-converting enzyme (ACE) inhibitors decelerate the progression 
from mild-to-moderate chronic kidney disease (CKD, with a serum creatinine 
level of 1.5 to 3.0 mg per deciliter) to ESRD in non-diabetic patients with 
hypertension.7-10 ACE inhibitors have also shown to be cost-effective in this 
patient population. In the U. S., e.g., benazepril treatment improves health 
and lowers costs as modelled over a 7-year period.11 The cost-effectiveness of 
ACE inhibitors in mild-to-moderate renal disease has also been shown for the 
Dutch setting.3,12. 
 
In patients with advanced renal disease (serum creatinine levels of 3.0 mg per 
deciliter or more) physicians might be reluctant to use ACE inhibitors because 
of concern that potassium levels or serum creatinine will rise.13,14 Several side 
effects and risks of ACE inhibitor therapy are well described in patients with 
chronic renal disease. Those risks include cough, hyperkalemia, mild 
reduction in glomerular filtration rate in patients with parenchymal renal 
disease, and acute renal failure in patients with bilateral renal artery stenosis 
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or volume depletion.15-18 A placebo-controlled randomized controlled trial 
(RCT) by Hou et al.1 showed that ACE inhibitors can be used safely in this 
patient population: in the 8-week run-in period only 4 out of 281 patients with 
a serum creatinine above 3 mg/ml had to be excluded because of 
hyperkalemia; in the 224 patients who underwent randomization the 
incidence of hyperkalemia was similar among patients who received an ACE 
inhibitor and those who received placebo.  
 
The RCT by Hou et al.1 also showed that ACE inhibitor therapy has a 
renoprotective effect in this patient population, thus confirming the result of 
a small prior RCT.19 Hou et al. demonstrated that the renal protective effect of 
ACE inhibitors in patients with advanced chronic kidney disease is not only 
due to their antihypertensive action as the reduction in the rate of 
progression changed little after correction for blood pressure.1 Although more 
than 90% of patients in this study population suffered from hypertension 
(baseline blood pressure of >150/85 mmHg), these patients did not suffer 
from hypertensive kidney disease as the main cause for their renal failure. In 
about 60% glomerular disease was found to be the main cause.1 
 
A cost-effectiveness model conducted in Germany by Adarkwah et al.20 
suggests that ACE inhibitor treatment in this patient population is cost-
effective, at least in the German setting. Currently, no data are available on 
the cost-effectiveness of ACE inhibitor therapy in non-diabetic patients with 
advanced nephropathy in the Dutch setting. However, results of the German 
study may not be transferable to the Netherlands. Different factors such as 
epidemiology of the disease, demography, the, availability of health care 
resources and differences in reimbursement systems between countries 
hinder transferability of economic evaluation studies between countries, in 
particularly due to variances in absolute and relative costs/prices. Other cost 
effectiveness models on renal disease even in the Dutch setting did include 
patients with less severe stages or renal disease, i.e. a serum creatinine level of 
1.5 to 3.0 mg per decilitre.3,12 This also applies to other European cost-
effectiveness models.21,22 
The goal of this paper was to determine the cost-effectiveness of ACE 
inhibitor therapy in non-diabetic patients with advanced renal disease (serum 
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creatinine above 3.0 mg/dl) and proteinuria in the Netherlands, based on a 
meta-analysis of RCTs by Ihle et al.19 and Hou et al.1 
Materials and methods 
Overview and model design 
A Markov decision model previously developed for the German setting20 was 
adapted and also proven suitable for the prevention of diabetic 
nephropathy23,24 in the Dutch and German setting.  
Based on the results of the RCTs by Ihle et al.19 and Hou et al.1, the progression 
of a cohort of 1000 patients aged 44 years with advanced renal insufficiency 
(serum creatinine: >3.0 mg/dl, glomerular filtration rate (GFR): 
15-26 ml/min/1.73 m²), proteinuria, and hypertension (>150/85 mm Hg), but 
without severe heart failure (New York Heart Association III or IV) was 
simulated.  
In order to simulate costs and effectiveness over lifetime, a Markov model was 
constructed. A Markov model is an iterative process where patients stay in 
one cycle (i.e., a defined health state) for a certain time (here: 1 year) and then 
make a transition to another cycle.  
Markov models are useful when a decision problem involves risk that is 
continuous over time, when the timing of events is important, and when 
important events may happen more than once. A half-cycle correction was 
used to allow for transition events occurring midway through each 12-month 
cycle. A cycle length of one year was chosen because most data were given in 
units per year. The age of 100 was chosen as a cut-off as there are no mortality 
data available beyond this age. Regardless, more than 99% of patients in the 
simulation are dead at this age so that the model represents a lifetime 
horizon. The model was built in Microsoft Excel® 2010.  
Our model contains the following 3 health states (Figure 7.1), which represent 
the occurrence of events after model entry: 
 
1. advanced renal disease (serum creatinine: >3.0 mg/dl, GFR: 
15-26 ml/min/1.73 m², CKD stage 4) 
2.  ESRD and 
3.  death. 
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Figure 7.1 Schematic representation of the Markov decision models. ESRD = end-stage renal 
disease. 
 
 
We performed a cost-utility analysis and health outcomes were measured in 
terms of quality-adjusted life years (QALYs). QALYs are the product of life 
years and a measure of health-related quality of life (preference weight or 
score) and allow comparing cost-effectiveness across diseases. Preference 
weights are anchored on a scale from 0 to 1, where 0 and 1 represent death 
and full health, respectively.25 Economic outcomes were set in relation to 
clinical outcomes by dividing the incremental (i.e., additional) costs of 
providing ACE inhibitors compared to no therapy by the incremental QALYs 
gained. The analysis is conducted from a health care perspective instead of 
choosing a societal perspective in order to increase comparability our 
previous model on this topic.20 
 
Doubling of the serum creatinine level (an outcome in the RCT by Hou1) was 
not included as a separate Markov state, as this is a surrogate for and shortly 
followed by ESRD. After each cycle, a specified proportion of patients move 
from advanced renal insufficiency to ESRD. This transition is delayed by ACE 
inhibitors. Simultaneously, a specified proportion of patients die. During each 
cycle, patients accumulate utilities (measured by QALYs) and costs.  
Combining both states – dialysis and transplant – to ESRD is a common course 
of action when modelling renal disease.26,27 We pooled individual data for 
 
Death 
ESRD 
 
 
Advanced renal disease 
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transplantation and dialysis as well as prevalences according to the national 
register in order to assess valid costs for the stage ESRD. 
Clinical strategies 
Two treatment strategies were considered. In the “ACE inhibitor treatment” 
strategy, patients are treated with benazepril 10 mg twice a day. Patients in 
the control group receive no ACE inhibitor. In addition, both groups receive 
other antihypertensive agents (diuretics, alpha- or beta-blockers, calcium-
channel antagonists, or some combination of these medications), but no 
other renin-angiotensin-system agents.   
Transition probabilities 
In order to identify placebo-controlled RCTs on the effect of ACE inhibitors on 
the progression of advanced renal insufficiency to ESRD we used a literature 
review until July 2001 by Terajima et al.28 as a starting point. This paper found 
one placebo-controlled RCT.19 In order to identify additional placebo-
controlled RCTs published after July 2001 we searched in the PubMed 
database (date: September 05, 2012) using the following search strategy: 
Renal Insufficiency, Chronic AND creatinine AND antihypertensives AND end-
stage renal disease AND angiotensin-converting-enzyme NOT(type-2-diabetes), 
Limits: Randomized Controlled Trial, All Adult: 19+ years. We obtained 43 hits. 
Thereof, 41 papers were excluded because they did not compare ACE 
inhibitors to placebo, did not consider advanced renal insufficiency, or did not 
include ESRD as an outcome. The above mentioned REIN study9,10 including 
amongst other Dutch nephropathy patients was excluded because the overall 
patient population suffered from mild-to-moderate renal disease and 
therefore also did not meet our inclusion criteria. The only 2 studies left were 
by Ihle et al.19 and Hou et al.1 and therefore used as the source of our 
effectiveness data. Both studies7,8 were double-blinded (see Table 7.1 for 
baseline characteristics). To combine effectiveness data from both studies and 
estimate the common odds ratio, we used the Mantel-Haenszel test.29 
 
In order to determine the annual transition probability from advanced renal 
disease to ESRD without ACE inhibitor therapy, we first calculated a total 
probability for each of the two trials, by dividing the number of events (ESRD) 
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during the trial period in the control arm by the number of patients. Second, 
we determined the annual transition probability by assuming a constant 
annual hazard rate over the study time horizon.30 And third, we determined a 
weighted average rate, with the number of individuals included in each study 
as weights. In the study by Hou et al.1 the number of events was obtained by 
directly contacting the authors and does not include death. 
 
Table 7.1 Baseline characteristics of patients with chronic kidney disease. 
Characteristics Hou et al.1 Ihle et al.19 
 ACE inhibitor 
(n=112) 
Placebo 
(n=112) 
ACE inhibitor 
(n=36) 
Placebo 
(n=34) 
Age – years 44 45 41 48 
Male sex – no. (%) 56 (50) 55 (49) 23 (64) 13 (38) 
Blood pressure – mmHg     
   Systolic 153 152 147 154 
   Diastolic   87   85   87   88 
Renal function     
   Serum creatinine – mg/dl   4.0   3.9   5.2   4.4 
   GFR – ml/min/1.73m2 26.3 25.8 14.6 15.8 
   Urine protein excretion – g/day   1.6   1.7   2.3   1.9 
 
 
Transition probabilities with and without an ACE inhibitor therapy are shown 
in Table 7.2. In patients without ESRD mortality was regarded as a function of 
age. Specifically, we used age-specific mortality rates of non-diabetic patients. 
To calculate the latter, age-specific mortality rates of the general population 
were multiplied with a standardized mortality ratio for patients with advanced 
renal disease compared to the general population, which was derived from a 
large community-based cohort study.31 For patients with ESRD we assumed 
that mortality was age-independent.  
Preference weights 
For patients in the health state “advanced renal disease” we considered a 
utility loss according to a survey using the time tradeoff (TTO) method in 
65 patients.32 This population had a mean age of 66 years and a GFR between 
15 and 30 ml/min/1.73 m². Furthermore, we considered an age-dependent 
loss of utility.33 For patients treated with an ACE inhibitor a disutility of 0.05 
from all side effects was considered in a sensitivity analysis.34 The preference 
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weight for ESRD was derived from a systematic review of empirical studies in 
which TTO weights were provided by patients.35 The TTO can be regarded as 
the most commonly used method to derive quality-of-life weights for 
QALYs.36,37  
 
Table 7.2 Data used to determine the cost-effectiveness of angiotensin-converting enzyme 
inhibitor treatment. 
Variable Base-case  
estimate 
Range tested 
in sensitivity 
analysis* 
Reference 
Annual transition probabilities 
   Advanced renal insufficiency to ESRD 
   without ACE inhibitor 
0.14 0.08 – 0.19 1,19 
   Advanced renal insufficiency to death   Age- and gender 
dependent 
0.003 – 0.54 61 
   ESRD to death 0.09 --- 2 
Effectiveness of ACE inhibitor 
   Relative risk of advanced renal insufficiency 
   to ESRD 
0.61 0.39 – 0.95 1,19 
Utilities (health states) 
   General population (age-dependent) 0.83 – 0.94 --- 33 
   Disutility of chronic kidney disease 0.056 -0.045 – 0.156 32 
   Disutility of ACE inhibitor treatment 0.00 0.00 – 0.05 34 
   ESRD 0.62 0.39 – 0.84 35 
Annual costs, € 
   General health care expenditures by age  
   group 
3.140,58 – 23.456,58 --- 39,42,47 
   Per-patient cost of chronic kidney disease  
   compared to non-CKD population  
Age-dependent --- 36,39-42,47 
   ACE inhibitor (20 mg benazepril daily; 5 mg 
   enalapril daily in the SA) 
240,92 28,70 – 240,92 43 
 
   ESRD 42 110 33 688 – 50 
       Transplantation  14 387  
       Dialysis  79 122  
         Home/in-center hemodialysis 83 217  
         CAPD  54 067  
         CCPD  69 546  
2,6 
2,6 
 
   SMR of chronic kidney disease 3.42 2.84 – 4.11 31 
   Discount rate of costs 0.04 0.00 – 0.10 42,47,48 
   Discount rate of benefits 0.015 0.00 – 0.10 42,47,48 
ESRD = end-stage renal disease; ACE = angiotensin-converting enzyme; CKD = chronic kidney 
disease; SA = sensitivity analysis; CAPD = Continuous ambulatory peritoneal dialysis; CCPD = 
Continuous cycling peritoneal dialysis; SMR = standardized mortality ratio. * Based on 95% 
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confidence intervals of the mean except for ESRD (estimate) 
The TTO technique determines the proportion of remaining life years in poor 
health which patients are willing to give up or trade in exchange for perfect 
health.  Based on patient responses utility scores are calculated. Those utility 
measures in economic evaluations are becoming more and more important 
given the fact that decision makers are asked to optimize the allocation of 
scarce health care resources across disease areas and patient groups.38 
Notably, the values are similar to EQ-5D scores (baseline value 0.61) reported 
by de Wit et al.6 We tested a rather broad range of TTO weights in sensitivity 
analysis.  
Costs  
The analysis was conducted from the health care perspective. Therefore, only 
direct health effects– defined as life years gained – and direct costs and were 
considered. Making use of data on the consumer price index, costs were 
inflated to year 2010 euros.39 Costs of health care expenditures unrelated and 
related to CKD as well as costs for ACE inhibitors and treatment of ESRD were 
accounted for. To determine the health care expenditures related and 
unrelated to CKD, we took resource consumption into account, based on 
international guidelines for the treatment of CKD.40,41 The recommendations 
of the Dutch guidelines for pharmacoeconomic research were followed.42  
 
In the base case, the cheapest generic of benazepril 10 mg daily was used 
twice daily.43 We included costs of ACE inhibitor therapy for patients who had 
to be excluded in the 8-week run-in period as these patients would be treated 
in the real world. In a sensitivity analysis we applied the price of the cheapest 
generic of enalapril 5 mg once daily as used in the RCT by Ihle et al..19 This is, 
for instance, the most frequently prescribed ACE inhibitor in the 
Netherlands.44 
 
The costs of benazepril and enalapril were based on 2010 Dutch prices and 
include 6% value-added tax as well as a 3-monthly pharmacists’ prescription 
fee of €7.50.45 
 
The annual costs of patients with ESRD were calculated as a weighted average 
of the costs of renal transplantation as well as different types of dialysis as 
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based on a Dutch study6 and prevalence data available from the national 
register.2 
 
In detail, the following calculations were made (see Table 7.3 for details): 
 
1) cost of dialysis = β1x1 + β2x2 + β3x3 = X, where xn = annual cost of dialysis 
treatment n = 1, 2, 3;  βn = prevalence weight of the dialysis treatment, and 
β1 + β2 + β3 = 1   
2) cost of ESRD = pX + (1-p)Y, where Y = cost of renal transplantation and p = 
proportion of ESRD treated by dialysis treatment. 
 
We assumed a transplant survival of 10 years and a distinction was made 
between the first year of transplantation and the years following.46 Costs were 
inflated to 2010 Dutch prices. 
As our study population is mainly hypertensive (91.5%) and no valid data on 
CKD treatment costs per se are available, we included the costs for 
hypertension treatment as an approximation. Costs were discounted at an 
annual rate of 4% whereas benefits were discounted at an annual rate of 1.5% 
in accordance with the CVZ recommendations.42,47,48 
 
Table 7.3 Parameters used for calculating the cost of end-stage renal disease (see cost 
section under “Methods”). 
Variable Meaning 
1 home/center hemodialysis 
2 continuous ambulatory peritoneal dialysis (CAPD) 
3 continuous cycling peritoneal dialysis (CCPD 
β1 0.82 
β2 0.106 
β3 0.074 
x1 € 83 217 
x2 € 54 067 
x3 € 69 546 
p 0.43 
X € 79 112 
Y € 14 387 
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Sensitivity analysis 
In order to address uncertainty around mean incremental costs and 
effectiveness, we conducted univariate sensitivity analyses, where we varied 
one variable at a time while keeping all other variables constant at their mean 
or base-case value. We ran analyses using the upper and lower bound of the 
95% confidence intervals of the mean whenever possible. For transplantation 
costs we did not have information on the 95% CI and thus varied costs by 20% 
(see Table 7.2 for uncertainty ranges).  
To assess how a simultaneous change of several variables affects the 
incremental cost-effectiveness ratio (ICER), we performed a Monte Carlo 
simulation, a type of multivariate sensitivity analysis. This method runs a large 
number of simulations (here: 1000) by repeatedly drawing samples from 
probability distributions of input variables. Therefore, it provides a probability 
distribution for the output variables (incremental costs, incremental 
effectiveness, and ICERs). Cost data were assumed to follow a gamma 
distribution Gamma(a, b), which reflects the long right tail and restriction to 
positive values. Probabilities were assumed to follow a beta distribution 
Beta(α,β) because they are normally distributed but restricted to take on 
values between 0 and 1. The standard error of a probability or proportion was 
calculated according to the following formula49: 
 
n
ppσ )-(1=  
Where p = probability and n = sample size. Relative risks and odds ratios were 
assumed to follow a lognormal distribution. 
 
Based on the Monte-Carlo simulation we generated a cost-effectiveness 
acceptability curve (CEAC). A CEAC allows a decision-maker to consider 
whether a prevention strategy is cost-effective in relation to the maximum 
amount a decision-maker is willing to pay for a QALY. At each ceiling value for 
the willingness to pay for a QALY, the cost-effectiveness acceptability curve 
shows the probability that the treatment is cost-effective. 
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Results 
Base case 
The base-case analysis, which had a lifetime horizon, shows domination of the 
ACE inhibitor treatment strategy over the no treatment strategy (Table 7.4). 
Treatment was therefore associated with lower costs and larger health 
benefit. Even shorter-term simulations over 3 and 10 years revealed the same 
finding, i.e., lower costs and larger benefits. 
 
Table 7.4 Results of the base-case analysis, based on mean estimates of input variables. 
Strategy Costs  
(€) 
Undiscounted 
LYs 
Discounted 
QALYs 
ICER  
(€/QALY) 
No ACE inhibitor treatment 220 942 13.38 9.32  
ACE inhibitor treatment 183 535 14.66 11.11 Dominates 
ACE = angiotensin-converting enzyme; LYs = life-years; QALY = quality-adjusted life-years; ICER 
= incremental cost-effectiveness ratio 
 
Sensitivity analysis 
Variables with the largest impact on incremental costs and effectiveness in 
the univariate sensitivity analysis are the effectiveness of ACE inhibitor 
treatment, the costs of ESRD, and the discount rates of costs and effects (Table 
7.5). Figure 7.2 shows the cost-effectiveness acceptability curve, considerung 
uncertainty in cost-effectiveness. Replications with lower effectiveness of the 
“ACE inhibitor treatment” strategy compared to the “no treatment” strategy 
(1.6%) were categorized as not cost-effective (regardless of concurrent 
savings). This is because it would be unethical to accept treatment that is less 
effective than no treatment. Hence, the maximum probability of cost-
effectiveness independent of the willingness to pay is 98.4%. The probability 
of savings is 83%. A scatter plot is presented in Figure 7.3. 
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Table 7.5 Univariate sensitivity analyses from a health care perspective: effects of varying 
base-case estimates on the incremental cost-effectiveness ratio of treating all 
patients with advanced renal insufficiency with an ACE inhibitor vs no ACE inhibitor 
treatment (reference strategy). “Lower bound” and “higher bound” refer to the 
limits of the 95% confidence interval or estimate thereof. 
 Incremental costs Incremental 
QALYs 
Incremental cost- 
effectiveness ratio 
Base case - €37 407 1.79 Dominance 
Annual transition probabilities from advanced renal insufficiency to ESRD  
Without ACE inhibitor 
   Lower bound - €36 685 1.76 Dominance 
   Higher bound - €32 842 1.62 Dominance 
Effectiveness of ACE inhibitor 
Relative risk of advanced renal insufficiency to ESRD 
   Lower bound - €72 134 3.39 Dominance 
   Higher bound - €2 673 0.17 Dominance 
Utilities (health states) 
Chronic kidney disease  
   Lower bound - €37 407 1.63 Dominance 
   Higher bound - €37 407 1.86 Dominance 
ESRD 
   Lower bound - €37 407 2.01 Dominance 
   Higher bound - €37 407 1.58 Dominance 
Disutility of ACE inhibitor treatment 
   Lower bound - €37 407 1.79 Dominance 
   Higher bound - €37 407 1.57 Dominance 
Costs 
ACE inhibitor 
   Lower bound - €36 680 1.79 Dominance 
   Higher bound - €37 407 1.79 Dominance 
ESRD 
   Lower bound - €28 400 1.79 Dominance 
   Higher bound -€46 415 1.79 Dominance 
SMR 
   Lower bound - €37 307 1.88 Dominance 
   Higher bound - €37 521 1.69 Dominance 
Discount rate of costs 
   0% - €49 072 1.79 Dominance 
   5% - €35 105 1.79 Dominance 
   7% - €31 066 1.79 Dominance 
   10% - €26 158 1.79 Dominance 
Discount rate of effects 
   0% - €37 407 2.31 Dominance 
   5% - €37 407 1.07 Dominance 
   7% - €37 407 0.84 Dominance 
   10% - €37 407 0.60 Dominance 
QALYs = quality-adjusted life years; ESRD = end-stage renal disease; SMR = standardized 
mortality ratio. 
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Figure 7.2 Cost-effectiveness acceptability curve. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.3 Cost-effectiveness plane showing 1000 replications from a distribution of cost and 
quality-adjusted life year (QALY) differences (angiotensin-converting enzyme 
inhibitor vs no treatment). 
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Discussion 
The study shows that treating non-diabetic patients with advanced renal 
insufficiency in the Netherlands with ACE inhibitors saves both money and 
lives. Despite the considerable costs of dialysis treatment, preventing ESRD 
does not necessarily lead to savings,50 thus necessitating a detailed 
calculation of costs and benefits. This result is consistent with a previous cost-
effectiveness analysis conducted in the German setting.20 Treating patients 
with more advanced renal disease (creatinine ≥3.0 mg per deciliter) with an 
ACE inhibitor to delay disease progression is still subject to discussion and no 
clear guideline statement regarding this aspect is available to date.51-53 
Therefore results could be helpful to adjust current guideline 
recommendations. 
 
Still, our model is subject to some limitations. In modeling studies this is 
usually the case due to constraints of resources, time, and information 
availability. The cost-effectiveness by treating non-diabetic progressed 
chronic kidney disease with ACE inhibitors may be even underestimated for 
several reasons. First, we did not model that ACE inhibitors reduce the risk for 
cardiovascular events,54,55, which leads to additional savings. As our study 
does not consider savings from avoiding cardiovascular events, it does, 
however, consider that patients with chronic kidney disease have a higher risk 
of to die because of cardiovascular reasons. We captured this by the mortality 
ratio for patients with chronic kidney disease compared to the general 
population. Second, effectiveness (and thus savings) of benazepril may have 
been underestimated as ESRD treatment may have been initiated earlier than 
necessary in the ACE inhibitor arms of the RCTs by Hou et al.1 and Ihle et al.19 
due to a drug-induced GFR decrease. Third, we did not consider on the cost 
side that some patients may discontinue ACE inhibitor therapy and therefore 
incur no drug costs. The reason is that information on compliance was 
unavailable in the two RCTs.1,19 Treatment discontinuation was only 
considered on the effect side, as the rate of compliance is implicitly 
incorporated in clinical trial results, i.e., efficacy data refer both to adherers 
and non-adherers. Therefore the Markov model includes patients who 
discontinue ACE inhibitor treatment in the ACE inhibitor arm. And forth, for 
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patients who receive dialysis we were not able to consider health care costs 
unrelated to dialysis due to a lack of available data.  
 
On the other hand, the savings might be smaller than estimated by our 
model. This is because some elderly patients may have a preference against 
replacement therapy and hence do not incur the associated costs. The bias 
seems small, however, given that the percentage of elderly patients requiring 
RRT is small (e.g., less than 3% at the age of 80 years and above) according to 
the register. Further limitations of the model relate to its data sources.  
First, the two trials considered as the source of our effectiveness data used for 
ACE inhibition enalapril and benazepril, respectively. Whether other types of 
ACE inhibitors can achieve the results reported in these studies is not clear. 
ACE inhibitors have potentially important differences in plasma protein 
binding, their affinity for ACE, and pharmacokinetics.56 To date, there is no 
convincing evidence that generic long-acting ACE inhibitors (such as lisinopril 
and enalapril) are inferior to brand-name ACE inhibitors.56,57  
Second, our preference weights for patients with advanced renal disease were 
taken from a U. S. study32 as no similar data for Dutch patients were available.  
Third, the model also uses some epidemiological data from Western countries 
other than the Netherlands. One of the two studies we used as the source of 
our effectiveness data1 was conducted in China. There is a debate on whether 
a significant difference between white and Asian populations exists due to 
ACE gene polymorphism, which might lead to a difference in the efficacy of 
ACE inhibitors. In fact, studies examining the association between differences 
in ACE gene polymorphism and the efficacy of ACE inhibitors have had 
contradictory results.58 In a controlled trial performed among Japanese 
patients with non-diabetic chronic kidney disease whose blood pressure was 
maintained at an average of 126/72 mm Hg with ACE inhibitors, no significant 
correlation was observed between the type ACE gene polymorphism (DD, ID, 
or II) and the efficacy of the intervention or renal outcome.59 On the other 
hand, a controlled trial among 212 whites showed that ACE inhibitor therapy 
was protective against progression to ESRD only in patients with the DD 
genotype.60 But even if this small trial is confirmed, treating whites regardless 
of ACE genotype may not have a smaller impact than treating Asians as 
whites with the DD genotype may have a stronger response than the average 
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Asian patient. Furthermore, the study by Ihle et al.,19 which was conducted in 
Australia, shows a similar result as the study by Hou et al..1 
Forth, quality of life values were derived from non-Dutch populations due to a 
lack of availability. Hence, we tested a broad range of TTO values in sensitivity 
analysis. 
And fifth, longitudinal studies that have examined long-term outcomes of 
ACE inhibitor treatment in patients with advanced chronic kidney disease are 
not available for model validation. This is a common limitation of models on 
the prevention of renal failure. 
In addition, the costs of dialysis treatment will likely continue to rise in the 
future, and therefore increase the potential for savings by preventing ESRD. 
Dialysis costs have significantly increased within the last years.5 We expect this 
trend to continue due to stricter regulations concerning dialysis safety, better-
tolerated dialysis solutions and technological advancement of dialysis 
machines. On the other hand, prices of erythropoietin and reimbursement of 
physicians may drop.  
Conclusion 
For patients with non-diabetic proteinuric advanced renal disease, treatment 
with an ACE inhibitor is highly cost-effective and should therefore be 
considered. A societal perspective will likely lead to even larger savings than a 
health care perspective as ACE inhibitor treatment avoids productivity loss 
due to renal failure. Yet, the transferability of the conclusion of this study to 
other countries is limited given differences in costs, clinical management (eg, 
treatment of ESRD), and epidemiology. 
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Introduction 
As introduced in Chapter 1, the aim of the dissertation is threefold: first, to 
assess whether costs for consumption and leisure activities need to be 
considered in the incremental cost-effectiveness ratio (ICER) in cost-
effectiveness analyses (Part Ia – methodological aspects, utility measurement), 
second, to review evidence and highlight important bias types in trial-based 
as well as in model-based economic evaluations (Part Ib – methodological 
aspects, bias in economic evaluation) and third, to assess the cost-effectiveness 
of angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor 
blockers (ARBs) in diabetic as well as non-diabetic renal disease in different 
countries (Part II – economic evaluation studies).  
In this chapter, we will first summarize the main findings of our research and 
then discuss the implications for clinical practice, research and policy.  
Summary of main findings 
Ia. Methodological work, utility measurement 
Chapter 2 of the thesis presents the results of a randomized study on patients 
with inflammatory bowel disease in Germany (n=104). The purpose of the 
study was to conduct an empirical survey on whether the effects of ill health 
on consumptive activities are spontaneously considered in a health state 
valuation exercise and how much this matters. Patients were randomly 
provided or not provided with explicit instructions regarding the 
consideration of consumption and leisure effects in a time trade-off (TTO) 
exercise. The study showed that explicit instructions to consider non-health-
related utility in TTO exercises did not influence TTO scores. However, 
spontaneous consideration of non-health-related utility in patients without 
explicit instruction (60% of respondents) led to significantly lower TTO scores. 
Based on these findings, we recommend that consumption costs be included 
in the numerator of the ICER, at least for those respondents who 
spontaneously consider non-health-related utility from treatment. However, 
double-counting always has to be avoided. 
To the best of our knowledge, for the effects of ill health on consumptive 
activities, no such empirical evidence has been gathered so far, although this 
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study shows that it plays an important role in the valuation of utilities. Results 
also showed that exercises eliciting health valuations from the general public 
may include a description of the impact of disease on consumptive activities. 
Overall, this research might contribute to a more accurate ICER by providing 
further insights into the TTO understanding of patients. 
1b. Methodological work, bias in economic evaluation 
Chapters 3 and 4 complete the methodological part of the thesis, both dealing 
with bias types and addressing the second aim of the thesis. Chapter 3 aims to 
give an overview of the potential risks of bias in trial-based economic 
evaluations and to identify how key sources for bias can be revealed and 
overcome. In total, eleven biases were identified and assigned to a particular 
trial phase. A distinction was made between pre-trial biases, biases during the 
trial and biases that are relevant after the actual trial. We discussed these bias 
forms in detail and presented strategies to detect and overcome them in a 
systematic way. The biases identified also account for model-based studies. 
Chapter 4 is directly related to Chapter 3. Here, we focused on bias types in 
model-based economic evaluation. It is obvious that bias types relevant for 
trial-based economic evaluation are usually relevant for model-based studies 
as well. So in this chapter, we focused on selected model-specific issues, using 
the Philips checklist as a tool to structure our results.1   
Eleven specific biases for model-based economic evaluations were identified 
and classified related to structure, data and consistency of the model, 
including structural assumptions, model type, time horizon, data selection 
(such as treatment effects), assessment of uncertainty and internal validation. 
In the end, together with biases which account for trial-based as well as for 
model-based studies identified in Chapter 3, a checklist for assessing bias in 
economic evaluations was developed (ECOBIAS). The ECOBIAS checklist 
encompasses a common part for model- and trial-based economic evaluation 
and a model-specific part. Part A of the checklist incorporates eleven biases 
that account for both types of economic evaluation, whereas Part B covers 
eleven model-specific aspects of bias. 
Both studies demonstrated that there are several ways that biases can 
influence the final results of trial-based as well as model-based economic 
evaluations, which could change a result from being cost-effective to not 
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being cost-effective at all. Combining the biases that can occur in trial-based 
with those in model-based economic evaluations identified in a previous 
article by the author group, the ECOBIAS checklist for identifying and 
avoiding bias in economic evaluation is introduced. To our current 
knowledge, we provide the first checklist (ECOBIAS checklist) on biases in trial-
based and model-based economic evaluations. It is important to understand 
that different bias types can be related to each other and that the elimination 
of one can introduce another. The checklist can be used by researchers and 
can be completed with submission of an article, but it can also be used by 
policymakers to check for bias in a systematic way. 
II. Economic evaluation studies 
In Chapter 5, a cost-utility analysis on the cost effectiveness of ACE inhibitors 
in newly diagnosed type 2 diabetes was performed. The aim of this study was 
to assess the most cost-effective time to start an ACE inhibitor in the event of 
cough in patients with type 2 diabetes in Germany. Three strategies were 
compared: treating all patients at the time of diagnosing type 2 diabetes, 
screening for microalbuminuria and screening for macroalbuminuria. A 
lifetime Markov decision model with simulated 50-year-old patients with 
newly diagnosed diabetes mellitus was developed using published data on 
costs and health outcomes and simulating the progression of renal disease. 
We showed that the treat-all strategy is associated with the lowest costs and 
highest benefit and therefore dominates screening both for macro-
albuminuria and microalbuminuria. Our results were robust, even when 
considering a variety of different assumptions of uncertainty. It was 
concluded that patients with type 2 diabetes should be treated with an ACE 
inhibitor immediately after diagnosis if they do not have contraindications. 
Although a significant number of newly diagnosed type 2 patients may 
receive blood pressure medications, it has not been shown that these patients 
are primarily prescribed an ACE inhibitor, which underlines the significance of 
this analysis. Treatment guidelines in Germany and the Netherlands do not 
strictly recommend prescribing an ACE inhibitor in this patient population,2,3 
so our analysis should lead to a correction of current treatment guidelines in a 
way that newly diagnosed type 2 diabetic patients should receive a low dose 
ACE inhibitor, even in the absence of hypertension or heart failure, which are 
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currently the standard indications for this drug class. It is therefore clear that 
an ACE inhibitor should be considered a first-line treatment for hypertensive 
diabetic patients as well. As the topic investigated in Chapter 5 is of great 
importance not only from patient’s perspective but also from an economic 
viewpoint since diabetes is a huge burden for healthcare systems, at least in 
the Western world, Chapter 6 investigated this research question in the Dutch 
setting. The majority of data taken into consideration for the model in Chapter 
5 were country-specific or at least adapted to the German setting. So the 
generalizability of the results is not given. We therefore built a new model for 
examining the cost-effectiveness of ACE inhibitors (or angiotensin II receptor 
blockers (ARBs) if coughing occurs as a side effect) in patients with newly 
diagnosed type 2 diabetes in the Netherlands. We showed a similar trend as in 
the German setting: In the base-case analysis, the treat-all strategy was 
associated with the lowest costs and highest benefit and therefore dominates 
screening both for macroalbuminuria and microalbuminuria. A multivariate 
sensitivity analysis shows that the probability of savings was 70%. It was 
concluded that also in the Netherlands, patients with type 2 diabetes should 
be prescribed an ACE inhibitor immediately after diagnosis if they do not have 
contraindications. An ARB should be considered for patients who develop a 
dry cough when treated with an ACE inhibitor. In addition, accounting for 
both models, the potential for cost savings would be even larger if the 
prevention of cardiovascular events due to the ACE inhibitor treatment were 
considered.   
Although effectiveness was shown in different trials,4-7 cost-effectiveness 
models did not yet exist in this area for the Dutch and German settings. A 
systematic review on ACE inhibitors and ARBs in type 2 diabetic nephropathy 
was published recently.8 Here, 30 articles were evaluated, including Chapters 5 
and 6 of this thesis. Our articles were the only two studies that discussed that 
dry cough, as a possible side effect of ACE inhibitors, could potentially have an 
impact on the cost-effectiveness of the latter. 
With respect to diabetes, diabetic nephropathy, with its final state of end-
stage renal disease (ESRD), is a sequela that causes an enormous economic 
burden for healthcare systems due to high costs for either dialysis or renal 
transplantation. Considering this burden, other causes for ESRD are worth 
investigating in more detail. Diabetes itself accounts for about 40% of patients 
in renal replacement therapy and therefore represents the main cause for 
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ESRD. Contrariwise, about 60% of patients with ESRD suffer from non-diabetic 
renal disease, which is focused on in Chapter 7. There is evidence that ACE 
inhibitors need to be handled with care in this patient population. Therefore, 
national as well as international clinical guidelines do not consistently 
recommend treating non-diabetic proteinuric patients with advanced renal 
disease with an angiotensin-converting enzyme (ACE) inhibitor. This study 
aimed to determine the cost-effectiveness of ACE inhibitor therapy in this 
patient population in the Netherlands by comparing two strategies: treating 
patients with advanced renal disease with an ACE inhibitor versus no 
treatment. A lifetime Markov decision model was developed to simulate the 
progression of renal disease using country-specific published data on costs 
and health outcomes. We found that treatment with ACE inhibitors leads to 
higher benefits and lower costs and dominates the no-treatment strategy. So 
it could be concluded that ACE inhibitor treatment for non-diabetic patients 
in the Netherlands, even those with advanced renal disease, is highly cost-
effective and should therefore be considered. This should have a strong 
impact on current treatment guidelines. Our study was the first cost-
effectiveness study to investigate this patient population with respect to ACE 
inhibitor treatment. 
Assessing cost-effectiveness in diabetic as well as non-diabetic patients with 
renal disease represented the second part of the thesis, addressing the third 
objective as mentioned above. Even though most guidelines recommend 
using a social perspective, where all costs and outcomes are considered 
important regardless of who pays for the costs and who will experience the 
effects, our analyses were performed from a healthcare perspective, which 
was considered more suitable and was stated clearly as well as justified in 
detail. Here, only costs and outcomes relevant to the healthcare system were 
considered. Not stating the perspective correctly or stating a societal view but 
not including all costs and outcomes might induce bias, which was also 
systematically described and investigated in this thesis as mentioned above. 
Implications for clinical practice, research and policy 
This thesis has several implications for clinical practice, further research and 
policy. All implications will be discussed in the following section. 
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Ia. Methodological work, utility measurement 
Looking at the consideration of consumption and leisure activities, we could 
show that explicit instructions to consider non-health-related utility in TTO 
exercises did not influence TTO scores. However, spontaneous consideration 
of non-health-related utility in the group that did not receive explicit 
instructions (60% of respondents of this group) led to significantly lower 
scores. Hence, the first finding could be explained by spontaneous 
consideration of non-health-related utility even without explicit instructions 
(thus offsetting the effect of explicit instructions). Spontaneous consideration 
of non-health-related utility thus leads to a utility gain from treatment 
compared to no spontaneous consideration. This would justify an inclusion of 
consumption costs in the numerator of the ICER, not only for life extending 
but also for quality-of-life enhancing interventions in future research, at least 
for those respondents who spontaneously consider non-health-related utility 
from treatment. Results also suggest that exercises eliciting health valuations 
from the general public for the purpose of conducting economic evaluations 
should be reconsidered. Researchers should include a description of the 
impact of disease on consumptive and leisure activities if those exercises are 
performed from a societal perspective.  
The limitations of this piece of research directly lead to further implications for 
research. For instance, the study population represents a well-defined patient 
population: patients who suffered from an inflammatory bowel disease, i.e. 
either Crohn’s disease or ulcerative colitis. Therefore, other diseases or disease 
groups need to be investigated in future research. Next, the population 
sample included relatively young patients, and while we adjusted for age in 
our analysis, another sample with more elderly patients may provide a 
different result. So studies on elderly patient samples are needed to see if our 
results hold for this age group as well. Last, results may not be transferable 
from country to country as a matter of course. Hence, studies that are 
conducted outside Germany are also needed.  
Given the importance of this question for the conduct of cost-effectiveness 
analysis in healthcare, policymakers should improve the research setting since 
confirmation is urgently needed in additional studies that consider other 
health-state valuation techniques. In a setting where resources are scarce, the 
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reliance on valid data, including valid incremental cost-effectiveness ratios, 
becomes increasingly important.  
1b. Methodological work, bias in economic evaluation 
Investigating bias in economic evaluation explicitly shows that there is a thin 
line between limited methodological quality and biases. A number of 
guidelines have been developed for economic evaluations. However, these 
guidelines are not enough to overcome all biases. Guidelines overall only tell 
you what to do but not how to do it in a sound and transparent way. 
Economic evaluators, like any other researchers, will have to rationalize the 
choices they have made during every phase of each study.9 In order to avoid 
biases in economic evaluations, researchers, readers, reviewers, editors and 
policymakers have to be aware of the possible biases and all stakeholders 
have to examine trial-based economic evaluations in a rigorous and stringent 
manner. Our research can therefore be helpful in this examination for 
researchers as well as for policymakers, as it provides an overview of the 
possible biases that should be taken into account in order to better perform 
an evaluation or to rate an evaluation more adequately. The ECOBIAS 
checklist can be seen as a complementary tool next to existing guidelines and 
checklists.10-26 The establishment of an ISPOR task force on bias or a consensus 
panel meeting could be the next steps forward. Although ECOBIAS already 
covers a large number of items, further research beyond the scope of our 
article is needed to establish all bias-related items relevant to economic 
evaluation studies.  
We might learn from other fields where something comparable does exist, 
e.g. the Cochrane risk of bias instrument27 for systematic reviews of 
interventions which is used to assess the risk of bias in five domains. 
Furthermore, a tool for health behavior change trials was developed 
recently,28 i.e. the risk of bias justification table (RATIONALE). A tool like the 
latter, tailor-made for economic evaluations, could be made obligatory for 
submission of an article.  
Our work on bias gives a good overview of the potential biases in economic 
evaluation, although further research is needed. We recommend that editors 
and reviewers consistently use a checklist, e.g. the ECOBIAS checklist 
presented in Table 8.1. To ensure more transparency, the completed checklist 
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could be made obligatory with submission and afterwards made available 
online to the community with supplementary material.  
 
Table 8.1 The ECOBIAS checklist for bias in economic evaluation. 
 
 
 
Type of bias Issues addressed 
(questions to consider) 
Relevant to 
study 
Yes/ No / Partly / 
Unclear / NA 
How did you deal 
with this bias? 
(description of 
strategy and 
rationale) 
PART A. Overall checklist for bias in economic evaluation 
Narrow perspective 
bias 
Was a societal perspective adopted? If 
not, has a different perspective been 
justified? 
  
Inefficient 
comparator bias* 
Was the best alternative chosen as a 
comparator? Was current practice chosen 
as a comparator? Have all comparators 
been described in sufficient detail?  
  
Cost measurement 
omission bias 
Were all costs relevant to the disease and 
intervention identified and considered? 
  
Intermittent data 
collection bias 
Was the resource use measured 
continuously? 
  
Invalid valuation 
bias 
Is the price calculation presented in a 
detailed manner? Have reference prices 
been used? 
  
Ordinal ICER bias Have cardinal scales for the outcomes 
measure in a CEA been used? 
  
Double-counting 
bias 
Have the variables been adequately 
checked for double-counting? 
  
Inappropriate 
discounting bias 
Have discounting rates from guidelines 
been applied?  
  
Limited sensitivity 
analysis bias§ 
Have the four principles of uncertainty 
(methodological, structural, 
heterogeneity, parameter) been 
considered in sufficient detail? 
  
Sponsor bias Have sponsorships been disclosed? Is the 
study protocol freely accessible? 
  
 
Reporting and 
dissemination bias 
Has the study / trial been listed in a trial 
register? Have all results been reported 
according to the study protocol? 
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Table 8.1 (continued) 
 
 
 
Type of bias Issues addressed 
(questions to consider) 
Relevant to 
study 
Yes/ No / Partly / 
Unclear / NA 
How did you deal 
with this bias? 
(description of 
strategy and 
rationale) 
PART B. Model-specific aspects of bias in economic evaluation 
I Bias related to structure   
Structural 
assumptions bias 
Is the model structure in line with 
coherent theory? Do treatment pathways 
reflect the nature of disease? 
  
No treatment 
comparator bias* 
Is there an adequate comparator, i.e. care 
as usual? 
  
Wrong model bias Is the model chosen adequate regarding 
the decision problem? 
  
 
Limited time horizon 
bias 
Was a lifetime horizon chosen? Were 
shorter time horizons adequately 
justified? 
  
II Bias related to data   
Bias related to data 
identification 
Are the methods of data identification 
transparent? Are all choices justified 
adequately? Do the input parameters 
come from high-quality and well-
designed studies? 
  
Bias related to 
baseline data 
Are probabilities, for example, based on 
natural history data? Is transformation of 
rates into transition probabilities done 
accurately? 
  
Bias related to 
treatment effects 
 
 
 
 
Are relative treatment effects synthesized 
using appropriate meta-analytic 
techniques? Are extrapolations 
documented and well justified? Are 
alternative assumptions explored 
regarding extrapolation? 
  
Bias related to 
quality-of-life 
weights (utilities) 
Are the utilities incorporated appropriate 
for the specific decision problem? 
  
Non-transparent 
data incorporation 
bias 
 
Is the process of data incorporation 
transparent? Are all data and their 
sources described in detail? 
  
 
Limited scope bias§ Have the four principles of uncertainty 
(methodological, structural, 
heterogeneity, parameter) been 
considered? 
  
III Bias related to consistency   
 Bias related to 
internal consistency 
Has internal consistency in terms of its 
mathematical logic been evaluated? 
  
* These biases are overlapping regarding their content.  
§ These biases are overlapping regarding their content. 
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In regard to trustworthiness, transparency is also a big issue. Hence, especially 
when looking at models, policymakers are often insecure because there is a 
high deficit in understanding about what researchers, especially modelers, 
exactly do.29,30 To overcome this problem or at least to minimize it, more 
transparency is needed. Peters et al.31 highlighted the importance of 
introducing a full disclosure policy and showed how even author’s 
reservations can easily be diminished. Peters et al.31 formed some 
recommendations that challenged both authors and editors. Taking those 
recommendations into account might lead to significant benefits. 
Transferring this to model-based economic evaluation would involve 
providing open access to all data and material used in a particular model 
(variables, questionnaires, etc.) or even allowing access to the model itself.  
As the number of studies dealing with biases in economic evaluation is 
limited, additional research is needed to identify biases and to reveal or 
develop appropriate strategies for addressing the risk of bias. 
II. Economic evaluation studies 
With regard to the cost-utility analyses of ACE inhibitors and ARBs in renal 
disease, our findings show the need for a change in the current treatment 
guidelines.2,3,32-34 Consistent treatment with ACEI or ARB in the patient 
populations investigated was the dominant strategy, meaning not only the 
best strategy from patient perspective, but also from a healthcare system 
perspective, as it was associated with the lowest costs. Therefore, clinicians 
should reconsider guidelines by adopting the results and treating all newly 
diagnosed type 2 diabetes patients in the Netherlands and in Germany with 
an ACE inhibitor, independent of elevated blood pressure—the earlier, the 
better. Of course, the monitoring of renal function and potassium should be 
mandatory, but nevertheless, treatment should take place. Second, this drug 
class should strictly and carefully also be considered for patients with non-
diabetic advanced renal disease. Both might lead to better long-term 
outcomes, as they delay advancement towards ESRD, which has a poor 
prognosis and is associated with very low quality of life. Long-term costs and 
outcomes of a very widespread disease would be influenced in a positive way, 
as also a life-prolonging effect was shown. As mentioned above, our research 
shows the need for a change in the current treatment guidelines. As both 
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drug classes investigated, ACE inhibitors as well as ARBs, are no longer patent-
protected, it is not expected that pharmaceutical companies would 
contribute to supporting further indications for the latter. In the light of this 
research and clinical evidence published on this topic,7,35-37 those drugs should 
not be withheld from the patient groups who would – in the majority of cases 
– benefit from early treatment. Further research in this field should be 
performed to confirm our findings, also in other countries as well as in other 
patient populations, e.g. in non-diabetic patients with mild to moderate renal 
failure. 
We are aware of the fact that the development of treatment guidelines is a 
long process. Here, policymakers might interfere and help to create a setting 
where new scientific findings could be turned into practice more rapidly.  
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Valorisation 
This dissertation aimed to contribute to the clarification of methodological 
aspects of economic evaluation in terms of bias and quality of life, as 
measured using the TTO method. It further aimed to assess the cost-
effectiveness of ACE inhibitors and ARBs in renal disease, i.e. nephropathy, in 
various patient populations. All of these studies have clinical, economic and 
societal implications, as they might help to improve treatment and to more 
efficiently allocate scarce healthcare resources.  
This chapter shows how the main findings of this dissertation could be 
applied in practice. In addition, possible dissemination strategies and 
implications for future research and practice are shown.  
With regard to the first part of the thesis about methodological aspects, 
studies on bias in economic evaluations can be helpful for researchers as well 
as for policymakers, as they provide an overview of the possible biases that 
should be taken into account in order to perform a good evaluation or to rate 
an evaluation more adequately. This accounts for trial-based as well as for 
model-based studies. The ECOBIAS checklist that was developed in this thesis 
can be seen as a complementary tool next to existing guidelines and 
checklists to increase the quality of economic evaluations. We discussed the 
ECOBIAS checklist at this year’s annual conference of the Lowland Health 
Economists’ Study Group (LolaHESG). Although a lot of disciplines such as 
epidemiology and psychology have longstanding traditions of discussing 
bias, this tradition is not yet established in the field of health economics. One 
way to do that could be to create an ISPOR taskforce on bias. This could be the 
next step forward in raising further awareness of the importance of a 
systematic approach to bias in economic studies. The checklist could be used 
or recommended by editors and reviewers to assess bias in a systemic way. 
Submitting a checklist like ECOBIAS together with the research article could 
be made a requirement for authors, and journals could adjust their author 
instructions. This would make things more transparent, as literature further 
suggests that barriers to the use of economic evaluations include a lack of 
transparency, a limited understanding and sometimes also a lack of quality.1-3 
Researchers could agree upon an open storage of models, which would allow 
for open access to the model structures and data. This would be a significant 
step towards achieving more transparency. An increased use of economic 
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evaluations will consequently lead to a more efficient way of allocating 
healthcare resources, which society will benefit from.  
Limiting bias is becoming extremely important, as it increases confidence in 
and the usability of economic evaluations. Our research on bias has 
limitations, as discussed in detail in Chapters 2 and 3, and of course further 
research on bias is needed. We hope that our articles will stimulate other 
researchers to work further on bias in economic evaluation, which we would 
consider to be a success. 
Our work on the time trade-off method showed that the inclusion of 
consumption costs in the numerator of the ICER should be considered, not 
only for life-extending but also for quality-of-life enhancing interventions, at 
least for those respondents who spontaneously consider non-health-related 
utility from treatment. Further research should surely be done with other 
patient populations, diseases and countries, but researchers could adapt 
those results to create a valid ICER, at least for the disease population 
investigated. Our results also show that researchers should provide a good 
description of the impact of disease on consumptive and leisure activities 
when doing exercises eliciting health valuations from the general public for 
the purpose of conducting economic evaluations from a societal perspective. 
Currently, this is rarely the case. This is something which clinical researchers as 
well as economists should consider and which can be transferred into practice 
immediately.  
The second part of the thesis, i.e. cost-effectiveness analyses of ACE inhibitors 
and ARBs in renal disease in different patient populations, also has important 
implications. As there has been an increasing incidence and prevalence of 
patients undergoing renal replacement therapy in Western countries in recent 
years, ESRD represents a challenge for healthcare systems. The costs of ESRD 
treatment amount to €42,000 per patient per year in the Netherlands,4,5 and 
up to €45,000 in Germany6 (from a healthcare perspective, respectively), with 
the proportion of the national expenditures devoted to ESRD in European 
countries ranging from 0.7% in the UK to 1.8% in Belgium,4,7 as mentioned 
previously. 
Hence, ESRD is not only a huge burden from the patients’ perspective, as it is 
associated with a reduced quality of life and life expectancy, but also for 
healthcare systems. Thus, prevention of ESRD is not only important from a 
patient and medical viewpoint, but also from a societal viewpoint. Treating 
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patients with ACE inhibitors or ARBs will delay the state of ESRD, which has a 
poor prognosis. Our research was extensively discussed on national and 
international levels, at medical as well as health economic conferences.8-18 It 
has been made available to expert panels and guideline committees and will 
at least be considered in the next update of treatment guidelines of diabetic 
and non-diabetic renal disease. Thus, the results of our studies suggest a 
change of current treatment guidelines. Nevertheless, clinicians should 
already adapt those results and adjust their treatment regimens. Besides 
clinical aspects, the economic aspects of treatment, as investigated in 
Chapters 5 to 7 of the thesis, should be discussed more with clinicians, e.g. at 
clinical conferences. Here, health economic topics are hardly to be found. This 
is most likely due to the fact that HTA does not play a role in medical 
education and that physicians are not familiar with tools and methodologies 
of health economists. An alternative would be to offer post-doctoral courses 
for clinicians to get deeper insights into HTA. Optimally, HTA should be better 
integrated into medical education so that medical students are confronted 
early and more intensely with HTA topics. Hence, a solid background could be 
created which allows physicians in training, and eventually physicians in 
clinical practice, to better understand the drawbacks and opportunities of 
health economic study results. 
All actions mentioned above would have at least two positive effects: first, 
results from HTA would be transferred to practice faster; and second, overall 
acceptance of HTA could be improved and anchored into clinical medicine 
and patient-related treatment decisions.  
Further research in other countries besides Germany and the Netherlands is 
needed to investigate and confirm the transferability of our results from the 
cost-effectiveness analyses of ACE inhibitors and ARBs. Although the drug 
classes under investigation are no longer patent-protected, pharmaceutical 
companies could contribute to the support of research in this field, where 
significant benefits for patients in terms of quality of life and reduced 
morbidity can be achieved. As this also accounts for mortality (a life-
prolonging effect from treatment was shown), long-term costs and outcomes 
of a very widespread disease would be influenced in a positive way. 
In the light of this research and clinical evidence published on this topic, those 
drugs should not be kept back from patient groups that would – in the 
majority of cases – benefit from early treatment. This would lead to better 
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outcomes in these patient populations and consequently to a societal benefit 
due to cost-savings in this disease area. 
Summing up, our research has some important implications for researchers, 
clinicians and policymakers. It might be just a small step, and there are still 
some barriers to overcome, but bringing study results from health economics 
to clinicians is something this dissertation might have contributed to.  
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Summary 
The aim of the dissertation is threefold: first, to assess whether costs for 
consumption and leisure activities need to be considered in the incremental 
cost-effectiveness ratio (ICER) in cost-effectiveness analyses (Part Ia – 
methodological aspects, utility measurement, chapter 2), second, to review 
evidence and highlight important bias types in trial-based as well as in model-
based economic evaluations (Part Ib – methodological aspects, bias in economic 
evaluation, Chapters 3 and 4) and third, to assess the cost-effectiveness of 
angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor 
blockers (ARBs) in diabetic as well as non-diabetic renal disease in different 
countries  (Part II – economic evaluation studies, Chapters 5 to 7).  
 
Chapter 2 of the thesis presents the results of a randomized study on patients 
with inflammatory bowel disease in Germany (n=104). The purpose of the 
study was to conduct an empirical survey on whether the effects of ill health 
on consumptive activities are spontaneously considered in a health state 
valuation exercise and how much this matters. Patients were randomly 
provided or not provided with explicit instructions regarding the 
consideration of consumption and leisure effects in a time trade-off (TTO) 
exercise. The study showed that explicit instructions to consider non-health-
related utility in TTO exercises did not influence TTO scores. However, 
spontaneous consideration of non-health-related utility in patients without 
explicit instruction (60% of respondents) led to significantly lower TTO scores. 
Based on these findings, we recommend that consumption costs be included 
in the numerator of the ICER, at least for those respondents who 
spontaneously consider non-health-related utility from treatment. However, 
double-counting always has to be avoided. 
To the best of our knowledge, for the effects of ill health on consumptive 
activities, no such empirical evidence has been gathered so far, although this 
study shows that it plays an important role in the valuation of utilities. Results 
also showed that exercises eliciting health valuations from the general public 
may include a description of the impact of disease on consumptive activities. 
Overall, this research might contribute to a more accurate ICER by providing 
further insights into the TTO understanding of patients. 
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Chapters 3 and 4 complete the methodological part of the thesis, both dealing 
with bias types and addressing the second aim of the thesis. Chapter 3 aims to 
give an overview of the potential risks of bias in trial-based economic 
evaluations and to identify how key sources for bias can be revealed and 
overcome. In total, eleven biases were identified and assigned to a particular 
trial phase. A distinction was made between pre-trial biases, biases during the 
trial and biases that are relevant after the actual trial. We discussed these bias 
forms in detail and presented strategies to detect and overcome them in a 
systematic way. The biases identified also account for model-based studies. 
Chapter 4 is directly related to Chapter 3. Here, we focused on bias types in 
model-based economic evaluation. It is obvious that bias types relevant for 
trial-based economic evaluation are usually relevant for model-based studies 
as well. So in this chapter, we focused on selected model-specific issues, using 
the Philips checklist as a tool to structure our results.  
Eleven specific biases for model-based economic evaluations were identified 
and classified related to structure, data and consistency of the model, 
including structural assumptions, model type, time horizon, data selection 
(such as treatment effects), assessment of uncertainty and internal validation. 
In the end, together with biases which account for trial-based as well as for 
model-based studies identified in Chapter 3, a checklist for assessing bias in 
economic evaluations was developed (ECOBIAS). The ECOBIAS checklist 
encompasses a common part for model- and trial-based economic evaluation 
and a model-specific part. Part A of the checklist incorporates eleven biases 
that account for both types of economic evaluation, whereas Part B covers 
eleven model-specific aspects of bias. 
Both studies demonstrated that there are several ways that biases can 
influence the final results of trial-based as well as model-based economic 
evaluations, which could change a result from being cost-effective to not 
being cost-effective at all. Combining the biases that can occur in trial-based 
with those in model-based economic evaluations identified in a previous 
article by the author group, the ECOBIAS checklist for identifying and 
avoiding bias in economic evaluation is introduced. To our current 
knowledge, we provide the first checklist (ECOBIAS checklist) on biases in trial-
based and model-based economic evaluations. It is important to understand 
that different bias types can be related to each other and that the elimination 
of one can introduce another. The checklist can be used by researchers and 
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can be completed with submission of an article, but it can also be used by 
policymakers to check for bias in a systematic way. 
In Chapter 5, a cost-utility analysis on the cost effectiveness of ACE inhibitors 
in newly diagnosed type 2 diabetes was performed. The aim of this study was 
to assess the most cost-effective time to start an ACE inhibitor in the event of 
cough in patients with type 2 diabetes in Germany. Three strategies were 
compared: treating all patients at the time of diagnosing type 2 diabetes, 
screening for microalbuminuria and screening for macroalbuminuria. A 
lifetime Markov decision model with simulated 50-year-old patients with 
newly diagnosed diabetes mellitus was developed using published data on 
costs and health outcomes and simulating the progression of renal disease. 
We showed that the treat-all strategy is associated with the lowest costs and 
highest benefit and therefore dominates screening both for macro-
albuminuria and microalbuminuria. Our results were robust, even when 
considering a variety of different assumptions of uncertainty. It was 
concluded that patients with type 2 diabetes should be treated with an ACE 
inhibitor immediately after diagnosis if they do not have contraindications. 
Although a significant number of newly diagnosed type 2 patients may 
receive blood pressure medications, it has not been shown that these patients 
are primarily prescribed an ACE inhibitor, which underlines the significance of 
this analysis. Treatment guidelines in Germany and the Netherlands do not 
strictly recommend prescribing an ACE inhibitor in this patient population, so 
our analysis should lead to a correction of current treatment guidelines in a 
way that newly diagnosed type 2 diabetic patients should receive a low dose 
ACE inhibitor, even in the absence of hypertension or heart failure, which are 
currently the standard indications for this drug class. It is therefore clear that 
an ACE inhibitor should be considered a first-line treatment for hypertensive 
diabetic patients as well. As the topic investigated in Chapter 5 is of great 
importance not only from patient’s perspective but also from an economic 
viewpoint since diabetes is a huge burden for healthcare systems, at least in 
the Western world, Chapter 6 investigated this research question in the Dutch 
setting. The majority of data taken into consideration for the model in Chapter 
5 were country-specific or at least adapted to the German setting. So the 
generalizability of the results is not given. We therefore built a new model for 
examining the cost-effectiveness of ACE inhibitors (or angiotensin II receptor 
blockers (ARBs) if coughing occurs as a side effect) in patients with newly 
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diagnosed type 2 diabetes in the Netherlands. We showed a similar trend as in 
the German setting: In the base-case analysis, the treat-all strategy was 
associated with the lowest costs and highest benefit and therefore dominates 
screening both for macroalbuminuria and microalbuminuria. A multivariate 
sensitivity analysis shows that the probability of savings was 70%. It was 
concluded that also in the Netherlands, patients with type 2 diabetes should 
be prescribed an ACE inhibitor immediately after diagnosis if they do not have 
contraindications. An ARB should be considered for patients who develop a 
dry cough when treated with an ACE inhibitor. In addition, accounting for 
both models, the potential for cost savings would be even larger if the 
prevention of cardiovascular events due to the ACE inhibitor treatment were 
considered.   
Although effectiveness was shown in different trials, cost-effectiveness 
models did not yet exist in this area for the Dutch and German settings. A 
systematic review on ACE inhibitors and ARBs in type 2 diabetic nephropathy 
was published recently. Here, 30 articles were evaluated, including Chapters 5 
and 6 of this thesis. Our articles were the only two studies that discussed that 
dry cough, as a possible side effect of ACE inhibitors, could potentially have an 
impact on the cost-effectiveness of the latter. 
With respect to diabetes, diabetic nephropathy, with its final state of end-
stage renal disease (ESRD), is a sequela that causes an enormous economic 
burden for healthcare systems due to high costs for either dialysis or renal 
transplantation. Considering this burden, other causes for ESRD are worth 
investigating in more detail. Diabetes itself accounts for about 40% of patients 
in renal replacement therapy and therefore represents the main cause for 
ESRD. Contrariwise, about 60% of patients with ESRD suffer from non-diabetic 
renal disease, which is focused on in Chapter 7. There is evidence that ACE 
inhibitors need to be handled with care in this patient population. Therefore, 
national as well as international clinical guidelines do not consistently 
recommend treating non-diabetic proteinuric patients with advanced renal 
disease with an angiotensin-converting enzyme (ACE) inhibitor. This study 
aimed to determine the cost-effectiveness of ACE inhibitor therapy in this 
patient population in the Netherlands by comparing two strategies: treating 
patients with advanced renal disease with an ACE inhibitor versus no 
treatment. A lifetime Markov decision model was developed to simulate the 
progression of renal disease using country-specific published data on costs 
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and health outcomes. We found that treatment with ACE inhibitors leads to 
higher benefits and lower costs and dominates the no-treatment strategy. So 
it could be concluded that ACE inhibitor treatment for non-diabetic patients 
in the Netherlands, even those with advanced renal disease, is highly cost-
effective and should therefore be considered. This should have a strong 
impact on current treatment guidelines. Our study was the first cost-
effectiveness study to investigate this patient population with respect to ACE 
inhibitor treatment. 
Assessing cost-effectiveness in diabetic as well as non-diabetic patients with 
renal disease represented the second part of the thesis, addressing the third 
objective as mentioned above. Even though most guidelines recommend 
using a social perspective, where all costs and outcomes are considered 
important regardless of who pays for the costs and who will experience the 
effects, our analyses were performed from a healthcare perspective, which 
was considered more suitable and was stated clearly as well as justified in 
detail. Here, only costs and outcomes relevant to the healthcare system were 
considered. Not stating the perspective correctly or stating a societal view but 
not including all costs and outcomes might induce bias, which was also 
systematically described and investigated in this thesis as mentioned above. 
The overall findings of this research lead to a number of recommendations for 
clinical practice, policymaking and future research, which are mentioned and 
discussed in detail in the final part of the general discussion (see Chapter 8).  
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